Pr ot oc ol I 8 F- M C- G P G L( b) 
A P hase 3, Ra n d o mize d, O pe n- La bel Trial C o m pari n g Efficac y a n d Safet y of Tirze pati de Vers us 
Se ma gl uti de O nce Wee kl y as A d d- o n T hera p y t o Metf or mi n i n Patie nts Wit h T y pe 2 Dia betes  
( S U R P A S S- 2) 
N C T 0 3 9 8 7 9 1 9 
A p pr o val Date: 2 6-J u n- 2 0 2 0 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e 1
L Y 3 2 9 8 1 7 6 Pr ot o c ol I 8 F -M C -G P G L ( b) 
A P h a s e 3, R a n d o mi z e d, O p e n -L a b el Tri al C o m p ari n g 
Effi c a c y  a n d S af et y  of Tir z e p ati d e v er s u s S e m a gl uti d e 
O n c e W e e kl y  a s A d d -o n T h er a p y  t o M etf or mi n i n 
P ati e nt s wit h T y p e 2 Di a b et e s ( S U R P A S S -2) 
2 0 1 8 -0 0 4 4 2 2 -2 9 
C o nfi d e nti al I nf or m ati o n 
T h e i nf or m ati o n c o nt ai n e d i n t hi s d o c u m e nt i s c o nfi d e nti al a n d i s i nt e n d e d f or t h e u s e of 
cli ni c al i n v e sti g at or s.  It i s t h e pr o p ert y of Eli Lill y a n d C o m p a n y or it s s u b si di ar i e s a n d 
s h o ul d n ot b e c o pi e d b y or di stri b ut e d t o p er s o n s n ot i n v ol v e d i n t h e cli ni c al i n v e sti g ati o n of 
tir z e p ati d e (L Y 3 2 9 8 1 7 6), u nl e s s s u c h p er s o n s ar e b o u n d b y a c o nfi d e nti alit y a gr e e m e nt 
wit h Eli Lill y a n d C o m p a n y or it s s u b si di ari e s .  
N ot e t o R e g ul at or y A ut h oriti e s:   T hi s d o c u m e nt m a y c o nt ai n pr ot e ct e d p er s o n al d at a 
a n d/ or c o m m er ci all y c o nfi d e nti al i nf or m ati o n e x e m pt fr o m p u bli c di s cl o s ur e. Eli Lill y a n d 
C o m p a n y r e q u e st s c o n s ult ati o n r e g ar di n g r el e a s e/r e d a cti o n pri or t o a n y p u bli c r el e a s e. I n 
t h e U nit e d St at e s, t hi s d o c u m e nt i s s u bj e ct t o Fr e e d o m of I nf or m ati o n A ct ( F OI A) 
E x e m pti o n 4 a n d m a y n ot b e r e pr o d u c e d or ot h er wi s e di s s e mi n at e d wit h o ut t h e writt e n 
a p pr o v al of Eli Lill y a n d C o m p a n y or it s s u b si di ari e s. 
Tir z e p ati d e ( L Y 3 2 9 8 1 7 6) 
Eli Lill y a n d C o m p a n y 
I n di a n a p oli s, I n di a n a U S A 4 6 2 8 5 
Pr ot o c ol El e ctr o ni c all y Si g n e d a n d A p pr o v e d b y Lill y : 1 9 -M ar -2 0 1 9 
A m e n d m e nt ( a) El e ctr o ni c all y Si g n e d a n d A p pr o v e d b y Lill y : 2 7 -A pr -2 0 2 0 -2 0 1 9 
A m e n d m e nt ( b) El e ctr o ni c all y Si g n e d a n d A p pr o v e d b y Lill y o n a p pr o v al d at e pr o vi d e d 
b el o w. 
A p pr o v al D at e: 2 6- J u n- 2 0 2 0 G M T 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e 2
L Y 3 2 9 8 1 7 6 T a bl e of C o nt e nt s 
S e cti o n P a g e 
Pr ot oc ol  I 8 F -M C -G P G L( b) A P hase 3, Ra n d o mize d, O pe n -La bel Trial 
C o m pari n g Efficac y  a n d Safet y of  Ti rze pat i de vers us Se ma gl ut i de 
O nce Wee kl y as A d d -o n T hera p y  t o M etf or mi n i n Pati e nts wi t h  T y pe 
2 Dia betes ( S U R P A S S - 2) .................................................................................................... [ADDRESS_141816] u d y  Rati o nale ............................................................................................................ 2 1 
3. 2. Bac k gr o u n d .................................................................................................................. 2 1 
3. 3. Be nefit/ Ris k Assess me nt .............................................................................................. [ADDRESS_141817] u gs ......................................................................................................... 3 9 
7. 4. 2. S peci al Treat m e nt C o nsi derat i o ns ........................................................................ 4 0 
7. 4. 2. 1. Sta n dar ds of Me dical Care .............................................................................. 4 0 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141818] u gs .................................................................................................... 4 1 
7. 4. 2. 5. Ma na ge me nt of Patie nts wit h Gastr oi ntesti nal S y m pt o ms ............................... 4 2 
7. 5. Pre parati o n/ Ha n dli n g/ St ora ge/ Acc o u nta bilit y............................................................... [ADDRESS_141819] ....................................................................... 5 5 
9. 2. 2. 1. H y p o gl yce mia ................................................................................................ 5 5 
9. 2. 2. 2. Se vere, Persiste nt H y per gl yce mia ................................................................... 5 7 
9. 2. 2. 3. Pa ncreat itis ..................................................................................................... 5 7 
9. 2. 2. 4. T h y r oi d Mali g na ncies a n d C -Cell H y per plasia ................................................ 5 8 
9. 2. 2. 5. Maj or A d verse Car di o vasc ular E ve nts ............................................................ 5 8 
9. 2. 2. 6. S u pra ve ntric ular Arr h yt h mias a n d Car diac C o n d ucti o n 
Di s or ders ........................................................................................................ 5 9 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141820] u g A nt i b o dies ............................................................................... 5 9 
9. 2. 2. 8. Di a bet ic Ret i n o pat h y  C o m plicat i o ns ............................................................... 5 9 
9. 2. 2. 9. He pat o biliar y  Dis or ders .................................................................................. 5 9 
9. 2. 2. 1 0. Se vere Gastr oi ntesti nal A d verse E ve nts .......................................................... 6 0 
9. 2. 2. 1 1. Ac ute Re nal E ve nts ........................................................................................ 6 0 
9. 2. 2. 1 2. Meta b o lic Aci d osis, I ncl u di n g Dia betic Ket oaci d osis ..................................... 6 0 
9. 2. 2. 1 3. A m p utati o n/ Peri p heral Re vasc ularizat i o n....................................................... 6 0 
9. 2. 2. 1 4. Maj or De pressi ve Dis or der/ S uici dal I deat i o n.................................................. 6 0 
9. 2. 3. C o m plai nt Ha n dli n g ............................................................................................. 6 0 
9. 3. Treat me nt of O ver d ose ................................................................................................ . 6 0 
9. 4. S af et y........................................................................................................................... 6 1 
9. 4. 1. Electr ocar di o gr a m s.............................................................................................. 6 1 
9. 4. 2. Vi t al  Si g ns........................................................................................................... 6 1 
9. 4. 3. La b orat or y  Tests .................................................................................................. 6 1 
9. 4. 4. I m mu n o ge nici t y  A ssess me nts .............................................................................. 6 2 
9. 4. 5. S af et y M o ni t ori n g ................................................................................................ 6 2 
9. 4. 5. 1. He pati c Safet y M o ni t ori n g .............................................................................. 6 2 
9. 5. P har mac o ki net ics ......................................................................................................... 6 3 
9. 6. P har mac o d y na mics ...................................................................................................... 6 3 
9. 7. P har mac o ge n o mics ...................................................................................................... 6 3 
9. 7. 1. W h o le Bl o o d Sa m ple(s) f or P har mac o ge net ic Researc h ....................................... [ADDRESS_141821] ical C o nsi derat i o ns ........................................................................ 6 8 
1 0. 3. 2. Treat me nt Gr o u p C o m para bilit y........................................................................... 6 9 
1 0. 3. 2. 1. P ati e nt Dis p osi ti o n .......................................................................................... 6 9 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141822] ics .................................................................................... 6 9 
1 0. 3. 2. 3. C o nc o mita nt T hera p y ..................................................................................... 7 0 
1 0. 3. 2. 4. Treat me nt C o m plia nce .................................................................................... 7 0 
1 0. 3. 3. Efficac y A nal yses ................................................................................................ 7 0 
1 0. 3. 3. 1 .Pri mar y A nal yses ........................................................................................... 7 0 
1 0. 3. 3. 2. Sec o n dar y  A nal yses ........................................................................................ 7 1 
1 0. 3. 3. 3. Terti ar y/ E x pl orat or y  A nal yses ........................................................................ 7 2 
1 0. 3. 4. S af et y A nal yses .................................................................................................... 7 2 
1 0. 3. 4. 1. H y p o gl yce mic E ve nts ..................................................................................... 7 2 
1 0. 3. 4. 2. Gastr oi ntesti nal E ve nts ................................................................................... 7 2 
1 0. 3. 4. 3. A d j u dicate d Car di o vasc ular E ve nts ................................................................ 7 2 
1 0. 3. 4. 4. Ce ntral  La b orat or y  Meas ures, Vi t al  Si g ns, a n d 
Electr ocar di o gra ms ......................................................................................... 7 2 
1 0. 3. 5. E val uat i o n of I m m u n o ge nicit y............................................................................. 7 3 
1 0. 3. 6. Ot her A nal yses ..................................................................................................... 7 3 
1 0. 3. 6. 1. Heal t h  Ec o n o mics ........................................................................................... 7 3 
1 0. 3. 6. 2. S u b gr o u p A nal yses ......................................................................................... 7 3 
1 0. 3. 7. I nteri m A nal yses .................................................................................................. 7 3 
1 1. Refere nces ........................................................................................................................ 7 4 
1 2. A p pe n dices ....................................................................................................................... 7 8 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141823] u d y  G P G L .......................................... 4 7 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141824] u d y  desi g n f or Cli nical Pr ot oc ol I 8 F -M C -G P G L. .................. 2 7 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141825] u d y  Pr oce d ures d ue t o t he C O VI D -1 9 Pa n de mic ...................... 9 5 
A p pe n di x 9. Pr ot oc ol  A me n d me nt I 8 F -M C -G P G L( b) 
A P hase 3, Ra n d o mize d, O pe n -La bel Tri al  C o m pari n g Efficac y a n d 
S af et y of  Ti rze pat i de vers us Se ma gl uti de O nce Wee kl y as A d d - o n 
T hera p y  t o M etf or m i n i n Pat ie nt s wi t h  T y pe 2 Di a betes ( S U R P A S S - 2) ......... 9 6 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141826] u d y: 
A P hase 3, Ra n d o mize d, O pe n -La bel Tri al  C o m pari n g Efficac y a n d Safet y of  Ti rze pat i de vers us 
S e m a gl ut i de O nce Wee kl y as A d d -o n T hera p y  t o Metf or mi n i n Pat ie nt s wi t h  T y pe 2 Dia betes 
( S U R P A S S - 2) 
R ati o n ale: 
C urre nt i ncret i n - base d i njecta ble treat me nt o pti o ns f or t y pe 2 dia betes mellit us ( T 2 D M) are 
di recte d at a si n gle i ncreti n m o lec ular tar get ( G L P -1 [ gl uca g o n -li ke pe pti de -1]) .T hese treat me nt 
o pti o ns offer i m pr o ve d gl yce mic c o ntr ol , l o w ri s k of  h y p o gl yce mia ,a n d t h e p ote nti al  f or 
cli nicall y rele va nt wei g ht l oss. H o we ver , a pr o p orti o n of patie nts d o n ot reac h treat me nt tar get s 
des pi[INVESTIGATOR_126143] g h le vel sof  c o m plia nce wi t h  t he treat m e nt re gi me ns.   T her ef o re, t h ere is a n u n met 
nee d f or a d di ti o nal  tr e at m e nt o pti o ns t hat e n ha nce gl yce mic c o ntr ol , pr o m ot e  w ei g ht l oss , a n d 
preser ve a n acce pta ble be nefit/ris k pr ofile (Star k Casa gra n de et al . 2 0 1 3; Zaccar di  et al . 2 0 1 6 ).   
Ti rze pati d e is a [ADDRESS_141827] acti vit y at b ot h t he 
gl uc ose -de pe n de nt i ns uli n otr o pic p ol y pe pti de ( GI P) a n d G L P - [ADDRESS_141828] ure is base d 
o n t he GI P se q ue nce a n d i ncl u des a C 2 0 fatt y  di -aci d m oi et y t h at   
It i s a d mi nistere d o nce wee kl y  ( Q W) b y s u bc uta ne o us ( S C) i nject i o n. 
St u d y  I 8 F -M C -G P G L ( G P G L) i s a P hase 3, ra n d o mize d, o pe n -la bel ,acti ve -c o ntr olle d, parallel 
gr o u p, m ul ti ce nter, m ul ti nat i o nal, 4 -gr o u p tri al t o assess t he safet y  a n d efficac y  of  ti rze pat i de 
5 m g, 1 0 m g, a n d 1 5 m g Q W c o m pare d t o se m a gl uti d e 1 m g Q W  i n patie nts wit h t y pe 2 dia betes 
i na de q uatel y c o ntr olle d wit h ≥ 1 5 0 0 m g/ da y metf or mi n al o ne.  St u d y  G P G L will pr o vi de a 
c o m parat i ve assess me nt of tirze pat i de vers us t h e hi g hest a p pr o ve d d ose of se m a gl ut i de ( 1 m g) 
wi t h  res pect t o gl yce mic c o ntr ol a n d ot her cli nicall y  rele va nt o utc o m es, i ncl u di n g wei g ht c ha n ge, 
h y p o gl yce mia i nci de nce, a n d t olera bilit y pr ofile. C CI 
I8F-MC-GPGL (b) Clinical Protocol Page 10
LY3298176Objectives/Endpoints:
Objectives Endpoints
Primary
To demonstrate that tirzepatide 10 mg 
and/o r 15 mg QW are noninferior to 
semaglutide 1 mg QW forglycemic
control at 40weeksMean change in HbA1c from baseline
Key Secondary (controlled for type 1 error)
Efficacy
To demonstrate that tirzepatide 5 mg 
QW is noninferior to semaglutide 1 mg 
QW forglycemic control at 40weeks 
for:
To demonstrate that tirzepatide 5 mg, 
10mg,and/or15 mg QW is superior to
semaglutide 1 mgQW at 40weeks for:Mean change in HbA1c from baseline
Mean change in body weight from baseline
Mean change in HbA1c from baseline
Proportio n of patients with HbA1c target values of 
<7.0% (53 mmol/mol)
Additional Secondary (not controlled for 
type 1 error)
Efficacy
To compare tirzepatide 5 mg, 10 mg, 
and/or 15mg QW tosemaglutide 1 mg 
QW at 40weeks for:Proportio n of patients achi eving an HbA1c target 
value of ≤6.5% (48 mmol/mol )
Proportio n of patients achi eving an HbA1c target 
value of <5.7% (39 mmol/mol)
Mean change in fasting serum glucose (central 
laborato ry) from baseline 
Mean change in 7 -point SMBG profiles from 
baseline
Proportio n of patients who achieved weight loss of 
>5% , >10%, and >15% from baseline
Patient- reported outcomes:
oDTSQs (baseline only)/ DTSQc (end of 
treatment only)
oIW-SP(baseline and end of treatment)
oAPPADL (baseline and end of treatment)
Safety
To compare the safety of tirzepatide 
5mg, 10 mg, and 15 mg QW to that of 
semaglutide 1 mg QW to the end of 
safety follow -up for:TEAEs
Early  discontinuation of study drug due to AEs
Adjudicated pancreatic AEs
Serum calcitonin 
Incidence of allergic and hypersensitivity reactions
Incidence of treatment -emergent a nti-drug 
antibodies to tirzepatide 
Mean change in systolic and diastolic blood pressure
and heart rate from baseline
Occurrence of hypoglycemic epi[INVESTIGATOR_1841]
Incidence of initiation of rescue therapy for severe ,
persistent hyperglycemia
I8F-MC-GPGL (b) Clinical Protocol Page 11
LY3298176Abbreviations :  AE = adverse event; APPADL = Ability to Perform Physical Activities of Daily Living ;
DTSQc =Diabetes Treatment Satisfaction Questionnaire change ;DTSQs = Diabetes Treatment Satisfaction 
Questionnaire status ;HbA1c = hemoglobin A1c; IW-SP=Impact of Weigh t on Sel f-Perception ;QW = once 
weekly; SMBG = self-monitored blood glucose ; T2DM = type 2 diabetes mellitus; TEAEs = treatment -emergent 
adverse events.
Summary of Study Design:
Study  I8F-MC-GPGL is a Phase 3, 40-week ,randomized, open -label, active -contr olled, parallel 
group, m ulticenter, m ultinational, 4 -group trial to assess the safety  and efficacy  of tirzepat ide 
compared to semaglutide 1 mg in pat ients with type 2 di abetes inadequately  controlled wi th 
≥1500 m g/day metformin alo ne.
Treatment Groups and Duration:
Study  GPGL will consist of 3 sequent ial periods:  
Study  Period I: approximately 3-week screening/lead -in period
Study  Period II: 40-week treatment period ,and 
Study  Period III: 4-week safet y follow-up peri od.
Patients will  be random lyassign ed 1:1:1:1 to 1 of the 4 treatm ents:
Tirzepati de (doses will be double -blinded)
o5 mg
o10 m g 
o15 m g, or
Semaglut ide 1 mg (not blinded) .
Patient randomizat ion will be stratified based on country  and baseline HbA1c ( ≤8.5% or >8.5% 
[69 mmo l/mol]).
Tirzepati de treatm ent will follow a fixed dose escalat ion.It will be
initiated at 2.5 mg QW for 4 weeks, and 
increased by 2.5 mg every 4 weeks (2.5 mg to 5 mg to 7.5 mg to 10 mg to 12.5 mg to 
15mg) until the desired dose is achieved and maintained for the duration of the study.
Semaglut ide treatment will fo llow a fixed dose escal ation. It will be
initiated at 0.25 mg QW for 4 weeks
increased to 0.5 mg QW for 4 weeks, and 
increased to and main tained at 1 m g QW for the durati on of  study .
Number of Patients:
Approximately  1872 pat ientswill be rando mly assigned to treatment groups, with 468 patients in 
each group.
I8F-MC-GPGL (b) Clinical Protocol Page 12
LY3298176Statistical Analysis:
Efficacy Analyses
Efficacy and safet y will be assessed usin g the m odified intent ion-to-treat (mITT) populat ion, 
which consists of al l randomly  assigned pat ientswho are exposed to at least [ADDRESS_141829] in comparing efficacy of t irzepat ide doses with 
semaglutide relat ive to the primary measure of mean change in HbA1 cfrom baseline to the 
40-week visit .  The “efficacy” est imand represents efficacy prior to discontinuat ion of study  drug 
without confounding effects of antihyperglycemic rescue therapy .  The “treatm ent-regimen” 
estimand represents the efficacy  irrespect ive of adherence to invest igational product or 
introducti on of  rescue therapy  for persi stent severe hy perglycemia .  
For the FDA and possibly other regulatory  agencies , the primary  efficacy  assessment will  be 
guided by  [CONTACT_941] “treatm ent-regimen” est imand.  This assessment will analyze change in HbA1c 
values from baseline to the 40-week visit using an analysis of covariance (ANCOVA )with 
terms:  treatm ent, country , and baseline HbA1c as a covariate .  The ANCOVA analysis will be 
conducted using the full analysis set at the 40-week visit, which consists of all available change s
from baseline in HbA1c data at the 40 -week visit, irrespective of whether they were obtained 
while the participants had disco ntinued the study drug or whether the participant had been given 
rescue m edicati on.  Addit ionally, missing HbA1c values at the 40-week visit will be imputed 
based on observed data in the same t reatm ent group from  patients who had the ir efficacy 
assessed af ter early  discontinuat ion of study  drug and/or init iation of rescue antihyperglycemic 
medicat ion.This analysis will be conducted with mult iple imputations, and statistical inference 
over m ultiple imputati ons will  be guided by  [CONTACT_126155] (1987).  
For all other purposes, the primary efficacy  assessment will be guided by  [CONTACT_941] “efficacy” 
estimand.  This assessment will use the efficacy  analysis set that consists of data ob tained before 
the init iation of any  rescue therapy  and before premature treatment discont inuat ion.  The analysis 
model for change from  baseline in HbA1c assessed over time will be a mixed -effects model for 
repeated m easures (MMRM) with terms:  treatm ent, vi sit, treatm ent-by-visit interaction, and 
country  as fixed effects, and baseline HbA1c as a covariate.  An unstructured covariance 
structure will model relat ionship of wit hin-patient errors.  
A 0.3% boundary  will be used for noninferio rity evaluat ions between tirzepat ideand 
semaglutide relative to mean change in HbA1c from baseline.
Since they  are intended for different purposes, each of the [ADDRESS_141830] ical analysis plan (SAP).
I8F-MC-GPGL (b) Clinical Protocol Page [ADDRESS_141831] dose through 
end of saf ety follow-up.  Counts and proportions of patientsexperi encing AEs will be reported 
for each treatm ent group, and Fisher’s exact test will be used to compare the treatment groups.  
For continuous laboratory  analy tes, summary  stati stics will  be provi ded by [CONTACT_765], with statist ical 
comparisons am ong treatm ent at each visit conducted using a nMMRM analysis.  Selected safet y 
analysis (for example, hypoglycemia) may be conducted excluding data after introducing another 
antihyperglycemic therapy .  Addi tional deta ils, including analysis of AEs of special interest, will 
be provided in the SAP.
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141832] o m e c or o na vi r us 2 ( S A R S -C o V -2), t he vir us t hat ca uses t he n o vel 
C or o na vir us Disease 2 0 1 9 ( C O VI D- 1 9), please refer t o A p pe n di x 8f o r a d di ti o nal  i nstr ucti o ns. 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141833] u d y Peri o d 
III 
Scree ni n g/ 
Le a d -i n Tre at me nt Peri o d S afet y F/ U 
Visit [ADDRESS_141834] 
e n d of t x 
All o w a ble 
De vi ati o n ( d a ys) c - ± 3 ± 7 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 7 ± 7 ± [ADDRESS_141835] circ u mfere nce X  X  X  X  X  X  X  X  X  X X
Electr ocar di o gra m X X  X X
Vital si g ns ( 2 sitti n g 
B P a n d H R) g X X  X  X  X  X  X  X  X  X  X X
Dilate d f u n d osc o pic 
e xa mi nati o n h X
A d verse e ve nts X  X  X  X  X  X  X  X  X  X  X  X X
C o nc o mita nt 
me dicati o ns X  X  X  X  X  X  X  X  X  X  X  X X
Re vie w 
h y p o gl yce mic 
e ve nts c ollecte d i n 
t he diar y iX  X  X  X  X  X  X  X  X  X X
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141836] u d y Peri o d 
III 
Scree ni n g/ 
Le a d -i n Tre at me nt Peri o d S afet y F/ U 
Visit [ADDRESS_141837] 
e n d of t x 
All o w a ble 
De vi ati o n ( d a ys) c - ± 3 ± 7 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 7 ± 7 ± 7 
F asti n g Visit dX X X X X X X X X X
P atie nt E d uc ati o n 
Dia betes e d ucati o n i,j X
B G meter, S M B G 
trai ni n g i X
Dis pe nse B G 
meter/s u p plies, as 
nee de d X  X  X  X  X  X  X  X  X  X  X 
St u d y dr u g i njecti o n 
trai ni n g wit h de m o 
de vice iX
Ha n d o ut diar y, 
i nstr uct i n use i X  X X  X 
Re mi n d patie nts 
a b o ut [ADDRESS_141838] u g lX
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141839] u d y Peri o d 
III 
Scree ni n g/ 
Le a d -i n Tre at me nt Peri o d S afet y F/ U 
Visit [ADDRESS_141840] 
e n d of t x 
All o w a ble 
De vi ati o n ( d a ys) c - ± 3 ± 7 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 7 ± 7 ± [ADDRESS_141841] n X X X X
F ollicle -sti m ulati n g 
h or m o ne o X
Estra di ol oX
C he mistr y pa nel XpX X X  X X
Fasti n g g l uc ose X  X  X  X  X  X  X X  X X
Fasti n g ins uli n X X X X X  X X
Fasti n g gl uca g o n X X X X X  X X
Fasti n g C- pe pti de X X X X X  X X
Li pi d pa nel X X X X X  X X
Ur i n ar y 
al b u mi n/creati ni ne 
rati o XpX X  X X
e G F R ( C K D - E PI) qXpX X X  X X
Calcit o ni n XpX X X  X X
He mat ol o g y XpX X X  X X
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141842] u d y Peri o d 
III 
Scree ni n g/ 
Le a d -i n Tre at me nt Peri o d S afet y F/ U 
Visit [ADDRESS_141843] 
e n d of t x 
All o w a ble 
De vi ati o n ( d a ys) c - ± 3 ± 7 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 7 ± 7 ± [ADDRESS_141844] ore d sa m ple 
E D T A plas ma, 
ser u m, P 8 0 0 plas ma X X X X  X X
P atie nt -Re p orte d O utc o mes t
D T S Qs X
D T S Qc X  X 
I W -S P X X  X 
A P P A D L X X  X 
E Q - 5 D- 5 L X X  X 
I W Q O L- Lite- C T X X  X 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e 1 9 
L Y 3 2 9 8 1 7 6 A b bre viati o ns:  A D A = a nti -dr u g a nti b o dies; A P P A D L = A bilit y t o Perf or m P h ysical Acti vities of Dail y Li vi n g; B G = bl o o d gl uc ose; B P = bl o o d press ure; 
C K D -E PI = C hr o nic Ki d ne y Disease -E pi [INVESTIGATOR_32450] o g y; D T S Qc = Dia betes Treat me nt Satisfacti o n Q uesti o n naire c ha n ge; D T S Qs = Dia betes Treat me nt 
Satisfacti o n Q uesti o n naire stat us; E C G = electr ocar di o gra m; e C R F = electr o nic case re p ort f or m; E D T A = et h yle ne dia mi netetraacetic aci d; e G F R = esti mate d 
gl o mer ular filtrati o n rate; E Q - 5 D- 5 L = E ur o pea n Q ualti y of Li fe : 5 di me nsi o ns ,5 le vels ; E T = earl y ter mi nati o n; F/ U = f oll o w -u p; F S H = f ollicle -sti m ulati n g 
h or m o ne; G A D = gl uta mic aci d decar b o x ylase; H b A 1c = he m o gl o bi n A 1c; H R = heart rate; I W Q O L- Lite- C T = I m pact of Wei g ht o n Q ualit y of Life - Lite 
Cli nical Trials Versi o n ; I W -S P = I m pact of Wei g ht o n Self -Perce pti o n; P K = p har mac o ki netics; S M B G = self -m o nit ore d bl o o d gl uc ose; tx = treat me nt. 
aBaseli ne assess me nts m ust be c o m plete d bef ore pr ocessi n g i n t he i nteracti ve we b -res p o nse s y ste m. 
bPatie nts w h o are u na ble or u n willi n g t o c o nti n ue i n t he st u d y f or a n y reas o n will perf or m a n E T visit.  If t he patie nt is disc o nti n ui n g d uri n g a n u ns c h e d ule d 
visit, t hat visit s h o ul d be perf or me d as t he E T visit.  If t he patie nt is disc o nti n ui n g d uri n g a sc he d ule d visit, t hat vis it s h o ul d be perf or me d as a n E T visit.  
Visit 8 0 1 (safet y f oll o w -u p visit) s h o ul d be perf or me d [ADDRESS_141845] he visit date is deter mi ne d i n relati o n t o t he date of t he ra n d o mizati o n visit ( ± t he all o we d visit wi n d o w). 
dF or all t he fasti n g visits ( Visits 3- 9 a n d 1 1 ), E T, a n d at f oll o w -u p, patie nts s h o ul d be re mi n de d t o re p ort t o t he site i n a fasti n g c o n diti o n, after a peri o d of 
a p pr o xi matel y 8 h o urs wit h o ut eati n g, dri n ki n g (e xce pt water), or a n y si g nifica nt p h ysi cal acti vit y  a n d bef ore ta ki n g st u d y dr u g(s) a n d metf or mi n. 
eMe dical hist or y i ncl u des assess me nt of pree xisti n g c o n diti o ns (i ncl u di n g hist or y of gall bla d der disease, car di o vasc ular disea se, a n d me d ullar y t h yr oi d 
carci n o ma) a n d s u bsta nce usa ge (s uc h as alc o h ol a n d t o bacc o). 
fWei g ht meas ure me nts m ust be i n kil o gra ms per i nstr ucti o ns s pecifie d i n A p pe n di x 7 .
gVital si g n meas ure me nts s h o ul d be ta ke n bef ore o btai ni n g a n E C G traci n g a n d bef ore c oll ecti o n of bl o o d sa m ples f or la b orat or y testi n g, at visits w here 
re q uire d.  T he partici pa nt s h o ul d sit q uietl y f or 5 mi n utes bef ore vital si g n meas ure me nts are ta ke n.  F or eac h para meter, 2 meas ure me nts will be ta ke n usi n g 
t he sa me ar m; t he rec or di n gs s h o ul d be ta ke n at least [ADDRESS_141846] be ta ke n wit h a n a ut o mate d bl o o d press ure mac hi ne. 
hDilat e d f u n d osc o pic e xa mi nati o n will be perf or me d b y a n e ye care pr ofessi o nal ( o p ht hal m ol o gist or o pt o metrist) f or all patie nts be t wee n Visit 2 a n d Visit 3 t o 
e xcl u de patie nts wit h pr oliferati ve dia betic reti n o pat h y, dia betic mac ul o pat h y, or n o n pr oliferati ve di a betic reti n o pat h y t hat re q uires ac ute treat me nt.  T he 
res ults fr o m t his e xa mi nati o n will be rec or de d o n a s pecific reti n o pat h y e C R F as a baseli ne meas ure of reti n o pat h y.  F oll o w -u p dilate d f u n d osc o pic 
e xa mi nati o n s h o ul d be perf or me d w he n cli nicall y i n dica te d, a n d t he res ults s h o ul d be rec or de d o n t he reti n o pat h y e C R F. 
iAll trai ni n g s h o ul d be re peate d as nee de d t o e ns ure patie nt c o m plia nce. 
Diaries will be pr o vi de d t o eac h patie nt.  Patie nts will nee d t o fill o ut t heir diar y a n d bri n g it wit h t he m at eac h visit. 
T he f oll o wi n g deli ver y de vices will be use d: asi n gle -d ose pe n f or  tirze pati de a n d a si n gle -patie nt -use pe n f or se ma gl uti de. 
jI ncl u des c o u nseli n g o n diet a n d e xercise, s y m pt o ms a n d ma na ge me nt of h y p o gl yce mia a n d h y per gl yce mia, etc. 
kPat ie nt is re q uire d t o c ollect t w o [ADDRESS_141847] u g at t he e n d of t his visit ( Visit 3) , after all t he ot her st u d y pr oce d ures a n d ra n d o mizati o n.   Pa tie nts will 
t he n c o nti n ue self -a d mi nisteri n g t heir st u d y dr u g Q W, wit h t heir last d ose a d mi nistere d o n Wee k 3 9 ( or wee k of E T visit) .
I8F-MC-GPGL (b) Clinical Protocol Page [ADDRESS_141848] injection of study drug(s) for women of 
childbearing potential only.  Additional pregnancy tests will be performed at Visits 6, 9, and 11.  Pregnan cy tests may alsobe performed at the investigator’s 
discretio n during the study.   If required per local regulations and/or institutional guidelines, pregnancy testing can also occur at other times during the study.
oFSH test will be performed at Visit [ADDRESS_141849] 
had spo ntaneous amenorrhea for more than 6 months and less than 12 months and estradiol levels consistent with a postmenopausal state (FSH ≥40 mIU/mL 
and estradiol <30 pg/mL) .
pScreening visit assessment will serve as baseline. If missed at Visit 1, results should be obtained and reviewed before Visit 3 ( randomization ).
qThe CKD -EPI [INVESTIGATOR_126144]. 
rIn the event of systemic drug hypersensitivity reactions (immediate or nonimmediate), additional blood samples will be collec ted including ADA , PK, and an 
exploratory biomarker sample.
sPK samples for immunogenicity must be taken prior to drug administration.
tAll PROs should be completed before any other study procedures if the patient is not adversely affected by [CONTACT_126156].
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141850] u d y R ati o n al e 
T y pe 2 di a betes m elli t us ( T 2 D M) is a m eta b o lic c o n dit i o n c haracterize d b y i m paire d gl yce mic 
c o ntr ol  ca use d b y  i ncrease d i ns uli n resista nce, pr o gressi ve beta -cell fail ure a n d c o nse q ue ntl y ,
i na de q uate i ns uli n secret i o n.  T 2 D M is ass ociate d wit h c o m or bi dit ies s uc h as i ncrease d wei g ht or 
o besit y,  h y perte nsi o n, d y sli pi [INVESTIGATOR_30192] , a n d a hi g her ris k f or macr o -a n d micr o vasc ular 
c o m plicat i o ns.  T o pre ve nt t h ese c o m p licat i o ns, ti g ht gl yce mic c o ntr ol is rec o m me n de d ( A D A 
2 0 1 9b; Da vies et al. 2 0 1 8). 
I njecta ble i ncreti n -base d treat me nts (f or e xa m ple, gl uca g o n -li ke pe pti de -1 [ G L P -1] rece pt or 
a g o nists) are c o m m o nl y use d i n c o m bi nat i o n wi t h  or al  a nt i h y per gl yce mic m e dicat i o n ( O A Ms) 
a n d basal i ns uli n t o ac hi e ve a n d mai ntai n gl uc ose c o ntr ol  (I nz ucc hi et al. 2 0 1 5; A D A 2 0 1 9b).   
W hile ass ociate d wit h l o wer ris k f or h y p o gl yce mia a n d eit her wei g ht ne utral or wei g ht l oss 
effects, c urre nt pre parati o ns are directe d at a si n gle i ncreti n m o lec ular tar get ( f o r e xa m ple, 
G L P -1 rece pt ors) .  T hese treat m e nt o pti o ns offer i m pr o ve d gl yce mic c o ntr ol , l o w ri s k of 
h y p o gl yce mia, a n d t h ep ote nti al f or cli nicall y  rele va nt wei g ht l oss. H o we ver, a pr o p orti o n of  
patie nts d o n ot reac h treat me nt tar gets des pi[INVESTIGATOR_126143] g h le vel sof  c o m plia nce wi t h  t he treat m e nt 
re gi me ns.   T heref ore, t h ere is a n u nmet nee d f or a d dit i o nal treat me nt o pti o ns t hat e n ha nce 
gl yce mic c o ntr ol , pr o m ot e  w ei g ht l oss , a n d preser ve a n acce pta ble be nefit/ris k pr ofile ( Star k 
Casa gra n de et al . 2 0 1 3; Zaccar di et al . 2 0 1 6). 
T he m eta b o lic effects of G L P -1 rece pt or a g o nists ca n be e n ha nce d b y c o m bi ni n g t he m wit h t he 
acti o ns of  ot her e nter o pa ncreat ic h or m o nes.  Gl uc ose -de pe n de nt i ns uli n otr o pic p ol y pe pti de 
( GI P) sti m ulates i ns uli n secret i o n i n a gl uc ose -de pe n de nt m a n ner a n d ma y  e x ert acti o ns be y o n d 
it s r ol e as a n i ncreti n t hat ma y i m pr o ve t hera pe utic efficac y w he n c o m bi ne d wit h G L P -1 rece pt or 
a g o nists (f or e xa m ple, i m pr o ve d li pi d h o me o stasis a n d w h o le -b o d y  e ner g y  m eta b olis m ) ( As mar 
et al . 2 0 1 6 ; Na uc k a n d Meier 2 0 1 8 ). 
Ti rze pati de ( L Y 3 2 9 8 1 7 6) is a [ADDRESS_141851] ure is base d o n t he GI P se q ue nce a n d i ncl u des a C 2 0 fatt y  
di -aci d m oi et y t h at   It i s 
a d mi nistere d as o nce -wee kl y ( Q W) s u bc uta ne o us ( S C) i nject i o n ( C os k u n et al . 2 0 1 8).   
St u d y  I 8 F -M C -G P G L ( St u d y  G P G L) is a P hase 3, ra n d o mize d, o pe n -la bel , acti ve -c o ntr olle d, 
parallel- gr o u p, m ul ti ce nter, m ul ti nati o nal, 4 -gr o u p tri al  t o assess t he safet y a n d efficac y of 
ti rze pat i de 5 m g, 1 0 m g, a n d 1 5 m g Q W c o m pare d t o se ma gl ut i de 1 m g Q W  i n pat ie nt s wi t h  
t y pe 2 di a betes i na de q uatel y  c o ntr olle d wi t h  ≥ 1 5 0 0 m g/ da y met f o r mi n al o n e.  St u d y  G P G L will 
pr o vi de a c o m parat i ve assess me nt of tirze pat i de vers us t h e hi g hest a p pr o ve d d ose of se ma gl ut i d e 
( 1 m g) wi t h  res pect t o gl yce mic c o ntr ol a n d ot her cli nicall y rele va nt o utc o mes, i ncl u di n g wei g ht 
c ha n ge, h y p o gl yce mia i nci de nce, a n d t olera bilit y pr ofile. 
3. 2. B a c k gr o u n d 
F o ur ti rze pat i de cli nical st u dies ha ve c o m plete d d osi n g a n d a nal ysis:  t w o P hase [ADDRESS_141852] u d y I 8 F -M C -G P G A ( St u d y  G P G A) a n d St u d y  I 8 F -M C -G P G C( St u d y  G P G C) i n Ja pa nese C CI 
I8F-MC-GPGL (b) Clinical Protocol Page 22
LY3298176patients , two Phase 2 studies, Studi es I8F-MC-GPGB (Study  GPGB) and I8F -MC-GPGF (Study  
GPGF) .  
Phase 1 Study  GPGA was a combinat ion of single ascendi ng dose (SAD) and mult iple ascending 
dose study  in healthy subjects followed by  a mul tiple dose proof -of-concept study  in pat ients 
with T2DM.  Study GPGA invest igated safet y, tolerabilit y, pharm acokinet ics (PK), and 
pharmacodynamics (PD) of tirzepat ideadministered as weekly SC inject ions.  A total of 
142subjects (89 healthy subjects and 53 patients wi th T2DM) received at least 1 dose of 
treatm ent.  Doses of tirzepat ide ranged from  0.25 mg to 8mg in the SAD ( with maximum  
tolerated dose achieved at 5 mg) in healt hy subjects; mult iple doses fro m 0.5mg to 4.5 mg QW 
and titrated doses up to 10 mg QW for 4 weeks in healt hy subjects; and mult iple doses ranged 
from 0.5 m g to 5 mg QW and t itrated doses up to 15 mg QW for 4 weeks in pat ients with T2DM.  
The safet y, tolerabilit y, and PK/PD profiles of tirzepati de at doses and escalat ion regimens 
administered in this Phase 1 study  supported further development of tirzepat idefor QW dosing 
in patients with T2DM (Coskun et al. 2018) .
A 26 -week Phase 2 study  (Study  GPGB) assessed the efficacy , tolerabili ty, and safet y of 4 doses 
(1mg, 5 mg, 10 mg, and 15 mg) of tirzepat ideversus placebo and an active comparator 
(dulagluti de 1.5 m g) in 318 pati ents with T2DM wit h inadequate glycemic control on diet and 
exercise alone or on a stable dose of metformin mo notherapy .  The doses of 10 mg and 15 mg 
were a ttained by t itration (Frias et al. 2018).   
Study  GPGB dem onstrated thattirzepat ide 5 -mg, 10 -mg, and 15 -mg doses significant ly lowered 
hemoglo bin A1c (HbA1c) an d body  weight in a dose -dependent manner in pat ients with T2DM 
in comparison to pl acebo.  In addition, reductions in HbA1c in the tirzepat ide5-mg, [ADDRESS_141853] of  the tirzepati deadverse events (AEs) were 
gastrointestinal (GI)related, consist ing mainly  of nausea, vo miting, and diarrhea ,and were 
dose-dependent.  The GI AEs were usually mild to moderate in severi ty.  Seri ous AEs (SAEs) 
were balanced across the treatment groups, and none of the groups in either study  reported severe 
hypoglycemia (Frias etal. 2018 ). 
As it was recognized that the titration scheme emplo yed in Study  GPGB was not optimal , Study  
GPGF was designed to explore alternative t itration schemes (longer time intervals between dose 
escalat ions and different dose increments ) to support evaluat ion of optimized dosing regimen(s) 
in Phase 3. Data from the Phase 1 and Phase 2 studies were used to model the escalat ion scheme 
to be used in the Phase 3 program and to minimize GI -related AEs.
These data support continued development of tirzepati deas a therapy  for T2DM.   
3.3. Benefit/Risk Assessment
Inform ation about the known and expected benefit s, risks, SAEs and reasonably  anticipated AEs 
of tirzepat ide isto be found in the Invest igator’s Brochure (IB).
I8F-MC-GPGL (b) Clinical Protocol Page 23
LY3298176In addit ion, detailed informat ion about the known and expected benefits and risks of semaglut ide 
may be found in the semaglut ide package insert ( Ozempic®USPI [WWW] ; Ozempic®SmPC
[WWW] ).  
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141854] u d y .
T a bl e G P G L . 2. O bj e cti v e s a n d E n d p oi nt s 
O bjecti ves E n d p oi nts 
Pri m ar y 
T o de m o nstrate t hat tirze pati de 1 0 m g a n d/ or 
1 5 m g Q W are n o ni nferi o r t o se ma gl uti de 1 
m g Q W f or gl y ce mic c o ntr ol at 4 0 wee ks Mea n c ha n ge i n H b A 1c fr o m baseli ne 
Ke y Sec o n d ar y (c o ntr olle d f or t y pe 1 err or) 
Efficac y 
T o de m o nstrate t hat tirze pati de 5 m g Q W is 
n o ni nferi o r t o se ma gl uti de 1 m g Q W f or 
gl yce mic c o ntr ol at 4 0 wee ks f or: 
T o de m o nstrate t hat tirze pati de 5 m g, 1 0 m g ,
a n d / o r1 5 m g Q W is s u peri or t o se ma gl uti de 
1m g Q W at 4 0 wee ks f or :Mea n c ha n ge i n H b A 1c fr o m baseli ne 
Mea n c ha n ge i n b o d y wei g ht fr o m baseli ne 
Mea n c ha n ge i n H b A 1c fr o m baseli ne 
Pr o p orti o n of patie nts wit h H b A 1c tar get 
val ues of < 7. 0 % ( 5 3 m m ol/ m ol) 
A d diti o n al Sec o n d ar y ( n ot c o ntr olle d f or t y pe 1 
err or) 
Efficac y 
T o c o m pare tirze pati de 5 m g, 1 0 m g, a n d / or 
1 5 m g Q W t o se ma gl uti de 1 m g Q W at 
4 0 wee ks f or: Pr o p orti o n of patie nts ac hi e vi n g a n H b A 1c 
tar get val ue of ≤ 6. 5 % ( 4 8 m m ol/ m ol )
Pr o p orti o n of patie nts ac hi e vi n g a n H b A 1c 
tar get val ue of <5. 7 % ( 3 9 m m ol/ m ol) 
Mea n c ha n ge i n fasti n g ser u m gl uc ose (ce ntral 
la b orat o r y ) fr o m baseli ne 
Mea n c ha n ge i n 7 -p oi nt S M B G pr ofiles fr o m 
baseli ne 
Pr o p orti o n of patie nts w h o ac hie ve d wei g ht 
l oss of >5 %, >1 0 %, a n d >1 5 % fr o m baseli ne 
Patie nt- re p o rte d o utc o mes: 
oD T S Qs ( baseli ne o nl y )/ D T S Qc (e n d of 
treat me nt o nl y) 
oI W -S P ( baseli ne a n d e n d of treat me nt) 
oA P P A D L ( baseli ne a n d e n d of treat me nt) 
Safet y 
T o c o m pare t he safet y of tirze pati de 5 m g, 
1 0 m g, a n d 1 5 m g Q W t o t hat of se ma gl uti de 
1m g Q W t o t he e n d of safet y f oll o w -u p f or: T E A Es 
Earl y  disc o nti n uati o n of st u d y dr u g d ue t o 
A Es 
A dj u dicate d pa ncreatic A Es 
Ser u m calcit o ni n 
I nci de nce of aller gic a n d h y perse nsiti vit y 
reacti o ns 
I8F-MC-GPGL (b) Clinical Protocol Page 25
LY3298176Objectives Endp oints
Incidence of treatment -emergent anti -drug 
antibodies to tirzepatide 
Mean change in systolic and diastolic blood
pressure and heart rate from baseline
Occurrence of hypoglycemic epi[INVESTIGATOR_1841]
Incidence of initiation of rescue therapy for 
severe persistent hyperglycemia
Exploratory Objective
To compare tirzepati de 5 mg, 10 mg, and 15 mg QW tosemaglutide 1 mg QW at 40weeks for:
Patient- reported outcomes at baseline and end of treatment:
oEQ-5D-5L
oIWQOL -Lite-CT
Change sin fasting glucagon, C -peptide, and insulin level s
Change sin lipi[INVESTIGATOR_805] (total cholesterol, HDL, VLDL, and triglycerides )
Changes from baseline in mean BMI
Mean change in waist circumference 
Biomarkers
Abbreviations :  AE = adverse event; APPADL = Ability to Perform Physical Activities of Daily Living ;
BMI =body mass index; DTSQc = Diabetes Treatment Satisfaction Questionnaire change ;DTSQs = Diabetes 
Treatment Satisfaction Questionnaire status ;EQ-5D-5L = European Qual ity of Life : 5 dimensions ,5 level s;
HbA1c = hemoglobin A1c; HDL = high -density lipoprotein; IW-SP=Impact of Weight on Sel f-Perception ;
IWQOL -Lite-CT = Impact of Weight on Quality of Li fe-Lite Clinical Trials Version; QW = once weekly;
SMBG =self-monito redblood glucose ; T2DM = type 2 diabetes mellitus ; TEAEs = treatment -emergent adverse 
events ; VLDL = very low-density  lipoprotein .
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141855] i ve -c o ntr olle d, parallel -gr o u p, 
m ult ice nter, m ult i nat i o nal, 4 -gr o u p tri al  t o assess t he safet y a n d efficac y of t ir ze pat i de c o m pare d 
t o se m a gl ut i de 1 m g i n pat ie nt s wi t h  t y pe 2 di a betes i na de q uatel y c o ntr olle d wit h ≥ 1 5 0 0 m g / da y 
met f o r mi n al o ne. 
St u d y peri o ds 
St u d y  G P G L will c o nsist of 3 se q ue nt ia l p eri o ds:  
St u d y  P eri o d I: a p pr o xi matel y 3-wee k scree ni n g/lea d -i n peri o d 
St u d y  P eri o d II: 4 0 -wee k treat me nt peri o d ,a n d 
St u d y  P eri o d III: 4-wee k safet y f o ll o w- u p peri o d .  
R a n d o miz ati o n t o st u d y tre at me nt 
P ati e nts will  b e ra n d o m l y assi g ne d 1: 1: 1: 1 t o 1 of 4 Q W treat m e nts: 
Ti rze pati d e ( d oses will be d o u ble -bli n de d) 
o5 m g
o1 0 m g 
o1 5 m g, or 
S e m a gl ut i de 1 m g (n ot bli n de d) .
P ati e nt ra n d o mizat i o n will be stratifie d base d o n c o u ntr y a n d baseli ne H b A 1c ( ≤8. 5 % or >8. 5 % 
[ 6 9 m m o l/ m o l] ). 
St u d y  g o ver na nce c o nsi derati o ns are descri be d i n detail i n A p pe n di x 3 .
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141856] u d y desi g n.   
A b bre viati o n :  Q W = o nce wee kl y. 
aSta ble d oses of metf or mi n ≥ 1 5 0 0 m g/ da y f or at least 3 m o nt hs pri or t o Visit 1 a n d 
d uri n g t he scree ni n g/lea d -i n peri o d. 
bAll tirze pati de d oses will be d o u ble -bli n de d. 
Fi g ur e G P G L .1. Ill u str ati o n of st u d y d e si g n f or Cli ni c al Pr ot o c ol I [ADDRESS_141857] u d y Peri o d I (scree ni n g a n d le a d -i n) 
Scree ni n g ( Visit 1) 
T he p ur p ose of scree ni n g pr oce d ures at Visit 1 is t o esta blis h i nit ial eli gi bilit y a n d t o o btai n 
bl o o d a n d uri ne sa m ples f or l a b orat or y  assess me nts nee de d t o c o nfir m eli gi bilit y at Vi si t 2.  T he 
p ati e nt will si g n t he i nf or me d c o nse nt f or m (I C F) bef ore a n y st u d y  pr oce d ures are perf or me d.  
Pr oce d ures at t his visit will be perf or me d as s h o w n i n t he Sc he d ule of Acti vit ies ( Secti o n 2).
Le a d -i n ( Visit 2 t o Visit 3) 
T he p ur p ose of Visi t [ADDRESS_141858] be c o m plete d 
bet wee n Visit 2 a n d Visit 3. T he p ur p ose of t his e xa mi nat i o n is t o e ns ure t hat patie nts w h o meet 
Excl usi o n Cri t eri o n [1 1 ]are e xcl u de d fr o m t h e st u d y ( S ecti o n 6. 2 ). 
Pati e nts a n d t heir care gi ver(s), if a p plica ble, will recei ve a gl uc o met er a n d trai ni n g o n 
h o w t o perf or m self -m o nit ori n g o f bl o o d gl uc ose ( S M B G). 
oP ati e nts will  b e as ke d t o m o nit or 4- p oi nt S M B G pr ofiles wee kl y a n d 7 -p oi nt 
S M B G pr ofiles t wi c e o n 2 n o nc o nsec ut i ve da ys i n t he 2 - wee k peri o d pri or t o 
Vi si t 3 (ra n d o mizati o n), Visi t 9( Wee k 2 4 ), a n d Visit 1 1 ( Wee k 4 0 ).  
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e 2 8 
L Y 3 2 9 8 1 7 6 P ati e nts will  b e pr o vi de d diaries a n d will be trai ne d as a p pr o priate t o rec or d bl o o d 
gl uc ose ( B G) val ues a n d h y p o gl yce mic e ve nts.  
D uri n g t his peri o d, patie nts will als o be trai ne d o n disease ma na ge me nt (s y m pt o ms of 
h y p o gl yce mia a n d h y per gl yce mia) a n d st u d y  pr oce d ures; t his trai ni n g ca n be re peate d at 
s u bse q ue nt visits as dee me d a p pr o pri ate.   
oP ati e nts s h o ul d m o ni t or B G a n y  ti me a h y p o gl yce mic e ve nt is s us pecte d.  
D uri n g t he l ea d -i n peri o d, patie nts s h o ul d c o nti n ue t heir diet a n d e xercise r o uti ne a n d 
m ust n ot use a n y O A Ms ot her t ha n met f o r mi n, or c ha n ge t heir met f o r mi n d ose or 
f o r m ula ti o n , t o all o w relia ble assess me nt of H b A 1c at baseli ne ( Visit 3).  
St u d y Peri o d II ( 4 0 -wee k tre at me nt peri o d) 
R a n d o miz ati o n ( Visit 3) 
At  Visit 3, pri or t o ra n d o mizat i o n a n d pri or t o ta ki n g t he first d ose of st u d y  dr u g , eli gi ble 
pati e nts will  c o m p lete all re q uire d baseli ne st u d y  pr oce d ures (i ncl u di n g t he c ollecti o n of 
all baseli ne la b orat or y  m eas ures a n d electr ocar di o gra m [ E C G]).  
P ati e nt s h o ul d arri ve t o t he cli nic i n t he fast i n g state t h at s h o ul d ha ve laste d at least 
8h o urs wit h o ut ha vi n g ta ke n a n y d oses of t hei r m etf or mi n d uri n g t hat ti me . 
T he pati e nt -re p orte d o utc o mes q uesti o n naires s h o ul d be c o m plete d bef ore a n y ot her 
st u d y  pr oce d ures if t he patie nt is n ot a d versel y  affecte d b y  t he fast i n g c o n dit i o n or 
c o m plete d after t he patie nt has s ufficie nt l y rec o vere d fr o m  t he prece di n g visit pr oce d ures.  
P ati e nts will  b e i nstr ucte d o n h o w t o use t he ir  deli ver y  de vices:  a si n gle -d ose pe n f o r 
pati e nts ra n d o mize d t o ti rze pat i de a n d a si n gle -pat ie nt -use pe n f or patie nts ra n d o mize d t o 
se ma gl uti de. T he y will i n ject t hei r fi rst d ose of st u d y  dr u g w hile i n t he cli nic f or Visit 3. 
T he date a n d ti me of t he first d ose of st u d y  dr u g s h o ul d be rec or de d o n t he el ectr o nic 
case re p ort f or m ( e C R F). 
F o ll o wi n g ra n d o mizat i o n, pati e nts will  p arti ci pate i n a 4 0 -wee k treat me nt peri o d. 
Tre at me nt peri o d (e n d of Visit 3 t o Visit 1 1 ): 
See t h e Sc he d ule o f Act i vit ies ( Secti o n 2)f o r details a b o ut t he st u d y  pr oce d ures a n d Treat m e nts 
A d mi nistere d ( Secti o n 7. 1 )f o r details a b o ut t he st u d y  dr u g d oses. 
St u d y Peri o d III (s afet y f oll o w - u p peri o d) 
S afety f oll o w -u p ( fi n al tre at me nt visit t o Visit 8 0 1): 
All patie nts w h o c o m plete t he treat me nt peri o d are re q uire d t o c o m plete Visit [ADDRESS_141859] u d y  earl y  a n d perf or mi n g a n earl y ter mi nat i o n ( E T) vi si t will als o be as ke d t o perf or m t he 
safet y f o ll o w- u p visi t, s o t hat t he safet y f o ll o w- u p visit will be t heir fi nal visit.  D uri n g t he safet y  
f o ll o w- u p peri o d, patie nts will n ot recei ve st u d y  dr u g .Patie nts will be treate d w it h a n ot her 
gl uc ose -l o weri n g i nter ve nt i o n deci de d u p o n b y t he i n vest i gat or.   If a n y ne w a nt i h y per gl yce mic 
me dicat i o n is i nit iate d d uri n g t he safet y f o ll o w- u p peri o d, i t will  n ot be classifie d as resc ue 
t h era p y .  Pati e nts are al s o re q ui re d t o ret ur n a n y  r e m ai ni n g st u d y  di aries t o t he st u d y  si te at t he 
e n d of t his peri o d. 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141860] u d y  pr oce d ures liste d i n t he Sc he d ule of Acti vit ies ( Secti o n 2). 
P ati e nts will  c o nt i n ue t o use c o nc o mita nt metf or mi n t hr o u g h o ut t he treat me nt peri o d ; 
di sc o nti n uat i o n or c ha n ges t o t h e d ose or f or m ulat i o n are n ot per mitte d, e xce pt i n t he sit uati o ns 
w here d ose a dj ust me nt  or c o m plete disc o nt i n uat i o n is re q ui re d per c o u ntr y -s pecific la bel or 
w he n all o we d per st u d y  pr ot oc ol  (f or f urt her details ,see Secti o n 7. 7. 1 ). 
P ati e nts will  b e i nstr ucte d t o perf or m 4-p oi nt S M B G meas ure me nts (c o nsisti n g o f fast i n g ,pre -
mi d da y  m e al , pre -e ve ni n g meal , a n d be dti me B G meas ure me nts) o nce wee kl y a n d t o rec or d all 
res ul ts i n di aries . T hese res ults will be use d f or gl uc ose ma na ge me nt o nl y. I n a d dit i o n, a 7 -p oi nt 
S M B G pr of ile ( pri or t o a n d 2 h o urs after t he 3 mai n meals a n d at be dti me) o n [ADDRESS_141861] i vit ies ( Secti o n 2), a n d will be use d f or efficac y a nal y ses. D uri n g t he wee ks 
w he n t he [ADDRESS_141862] i vit ies ( Secti o n 2). If t h e 7-p oi nt S M B G is n ot perf or me d, t he n data fr o m t h e m ost rece nt 
n o nc o nsec ut i ve [ADDRESS_141863] rece nt n o nc o nsec ut i ve pr ofiles s h o ul d be use d. 
P ati e nts w h o de vel o p se vere, persiste nt h y per gl yce mia base d o n pres pecifie d t hres h o l d s (see 
Secti o ns 7. 4. 2. 3 a n d 9. 2. 2. 2 ) will recei ve a ne w gl uc ose -l o weri n g i nter ve nt i o n (“resc ue t hera p y”) 
a n d will als o c o nti n ue t o a d mi nister st u d y  dr u g.  Pati e nts w h o nee d h y per gl yce mic resc ue 
t h era p y  will c o nt i n ue i n t he trial u nt il t he y c o m p lete all st u d y  visi ts .
P ati e nts w h o per m a ne nt l y disc o nt i n ue st u d y  dr u g pri or t o t he safet y f o ll o w- u p p eri o d s h o ul d 
c o nti n ue i n t he trial a n d s h o ul d recei ve a ne w gl uc ose- l o weri n g i nter ve nt i o n ( Secti o n 7. 7. 2 ). 
5. 2. N u m b er of P arti ci p a nt s 
A p pr o xi matel y  [ADDRESS_141864] i vit ies ( Secti o n 2)f o r t he last patie nt .
5. 4. S ci e ntifi c R ati o n al e f or St u d y D e si g n 
St u d y  G P G L will pr o vi de a c o m parati ve assess me nt of tirze pati de vers us se ma gl ut i de [ADDRESS_141865] a p pr o ve d d ose of  
se ma gl uti de f o r patie nts wit h T 2 D Mt h at has s h o w n s u peri orit y i n i m pr o vi n g gl yce mic c o ntr ol 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e 3 0 
L Y 3 2 9 8 1 7 6 a n d re d uci n g b o d y  wei g ht c o m pare d t o 2 ot her G L P - 1 rece pt or a g o nists i n t he class, d ula gl uti de 
a n d e xe nat i de Q W, wit h a si milar safet y pr ofile ( A h ma n n et al. 2 0 1 8 ; Pr atl e y et al . 2 0 1 8 ).  
Metf or mi n was c h ose n as t h e re q ui re d c o nc o mit a nt a nti h y per gl yce mic me dicat i o n beca use it  is 
c o m m o nl y  use d i n cli nical pract ic eas first -li ne t hera p y  a n d w he n use d i n c o m bi nat i o n, t he ris k 
of  h y p o gl yce mia is l o w . T he mi ni m u m d ose (at l east 1 5 0 0 m g/ da y) was c h ose n t o e ns ure 
ma xi mizi n g efficac y of m etf or m i n pri or t o a d di n g a d di ti o nal  t h era p y (Nat ha n et al . 2 0 0 9 ). T o 
mi ni mize t h e p ote nti al  c o nf o u n di n g effect of c ha n ges t o c o nc o mita nt met f o r mi n, patie nts will be 
e x pecte d t o m ai ntai n met f o r mi n t hr o u g h o ut t he treat me nt peri o d u nt il t he last d ose of 
ra n d o mize d treat m e nt, ot her t ha n f or t he sit uati o ns descri be d i n Sect i o n 7. 7. [ADDRESS_141866] u d y treat me nts 
will n ot be all o we d ( Secti o n 7. 7 ). 
T he o pe n -la bel desi g n is use d f o r t his st u d y beca use of t he differe nt de vices use d f or 
a d mi nisteri n g tirze pat i de a n d se ma gl ut i de .T he ti rze pati de d oses will be bl i n de d f or better 
assess me nt of efficac y  a n d safet y o ut c o m es of  i n di vi d ual d oses. 
T he pl a n ne d treat m e nt d urati o n of  4 0 wee ks is c o nsi dere d a p pr o priate t o assess t he f ull effects 
a n d be nefit/ris k of eac h mai nte na nce d ose of tirze pati de o n b ot h gl yce mic c o nt r ol  a n d b o d y  
w ei g ht as re q ueste d b y  t he F D A. 
5. 5. J u stifi c ati o n f or D o s e 
Tirze p ati de D oses 
Ti rze pati d e d oses of  [ADDRESS_141867] u d y . 
T hese d oses a n d ass ociate d escalat i o n sc he mes were selecte d base d o n t h eassess me nt of safet y,  
efficac y  ( gl yce mic a n d wei g ht l oss be nefit), a n d GI t olera bilit y data f o ll o we d b y  e x p os ure -
res p o nse m o deli n g of data i n pati e nts wi t h  T [ADDRESS_141868] u di es. 
T he selecte d d ose a n d escalati o n sc he me w o ul d e na ble f urt her e val uat i o n of be nefit/ris k 
c o nsi derati o ns f or 5 -m g, 1 0 -m g, a n d 1 5 -m g d oses of ti rze pat i de .
I8F-MC-GPGL (b) Clinical Protocol Page [ADDRESS_141869] approved dose 
of semaglut ide (1 mg) for T2D Mwas chosen to be studied. 
Semaglut ide has 2effect ive doses, 0.5 mg QW and 1 mg QW. Whereas the lower dose (0.5 mg) 
is recognized as an effect ive dose for glycemic control ,the 1-mg dose provides so me addit ional 
benefit in glycemic control and weight reduction ,with relatively similar tolerabilit y (Marso et al. 
2016; Ahrén e t al. 2017; Aroda et al . 2017; Sorli  et al . 2017; Pratley  et al . 2018 ; Rodbard et al. 
2018 ).Semaglut ide dose will be escalated to 1 m g as recommended in the prescribing 
inform ation (Ozempic®USPI [WWW] ). 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141870] u d y  o nl y  if t h e y  m eet all  of  t h e f oll o wi n g criteria at 
scree ni n g :
T y pe of P atie nt a n d Dise ase C h ar acteristics 
[ 1] Ha ve bee n dia g n ose d wit h T 2 D M base d o n t he W orl d Healt h Or ga nizat i o n 
cl assificat i o n or ot her l ocall y a p plica ble dia g n ostic sta n dar ds 
P atie nt C h ar acteristics 
[ 2] Ha ve H b A 1c ≥ 7. 0 % ( ≥ 5 3 m m o l/ m o l)  t o ≤ 1 0 . 5 % ( ≤ 9 1 m m o l/ m o l), as deter mi ne d 
b y t h e ce ntral  l a b orat or y  at Visi t 1 
[ 3] Are of sta ble wei g ht ( ± 5 %) ≥3 m o nt hs prece di n g Visit 1 a n d a gree t o n ot i nit iate a 
di et a n d/ or e xerci se pr o gra m  d uri n g t he st u d y  wi t h t he i nte nt of re d uci n g b o d y  
w ei g ht, ot her t ha n t he lifes t y le a n d dietar y  m eas ures f or di a betes treat m e nt 
[ 4] Ha ve b o d y  m ass i n de x ( B MI ) ≥ 2 5 k g/ m 2at Visi t 1 
[ 5] Ha ve bee n o n sta ble dia betes treat me nt wit h met f o r m i n ≥ 1 5 0 0 m g/ da y  d uri n g t he 
3 m o nt hs pri or t o Visit 1 a n d bet wee n Visits 1 a n d 3 
[ 6 ]Are 1 8 y e ars ol dor of a n acce pta ble a ge t o pr o vi de i nf or me d c o nse nt acc or di n g t o 
l o cal re g ulati o ns, w hic he ver is ol der 
Male patie nts ( See A p pe n di x 6 f o r m ore details): 
Male patie nts s h o ul d be willi n g t o use relia ble c o ntrace pti ve met h o ds t hr o u g h o ut 
t h e st u d y  a n d f or at least [ADDRESS_141871] i o n 
Fe male pat ie nt s: 
Fe male pat ie nt s n ot of c hil d beari n g p ote ntial d ue t o s ur gical sterilizat i o n 
( h ysterect o m y or bilateral o o p h orect o m y  or t u bal  li gat i o n), c o n ge nital a n o ma l y 
(t hat i s, M ulleria n a ge nesis), or me n o pa use 
oW o me n wi t h  a n i ntact uter us are dee me d p ost me n o pa usal if t he y are at 
leas t 4 5 years ol d a n d 
ha ve n ot ta ke n h or m o nes or oral c o ntrace pti ves wit hi n t he last y ear 
a n d ha d cessat i o n of me nses f or at least 1 y ear 
O R 
ha ve ha d at least [ADDRESS_141872] i m ulat i n g h or m o ne ( F S H) a n d estra di o l 
le vels c o nsiste nt wit h a p ost me n o pa usal state ( F S H ≥ 4 0 mI U/ m L 
a n d estra di o l < 3 0 p g/ m L). 
I8F-MC-GPGL (b) Clinical Protocol Page 33
LY3298176oFemale pat ients of childbearing potential (not surgically sterilized and 
between m enarche and 1 -year postm enopausal ) must
test negative for pregnancy  at V isit [ADDRESS_141873]
AND
if sexually  active, agree to use [ADDRESS_141874] ive for the durati on of  the tri al 
and for 30 days thereafter ).
not be breastfeeding
[7]In the invest igato r’s opi[INVESTIGATOR_3078] n, are well mot ivated, capable, and willing to
(a) perform  finger -stick BG monitoring, including scheduled BG profiles wit h up to 
7measurements in 1 day
(b) learn how to self- inject study  drugs (tirzepat ide or semaglutide) , as required for this 
protocol  (visually impaired persons who are not able to perform the inject ions must 
have the assistance of a sighted individual trained to inject the study  drug; persons 
with physical limitat ions who are not able to perform the inject ions must have the 
assistance of an individual trained to inject the study  drug) 
(c) inject tirzepatide or sem aglut ideonce weekly
(d) maintain study  diaries, as requi red for this protocol
(e) sufficient lyunderstand one of the provided languages of the country  such that they  
will be able to complete the patient questionnaires
Informed Consent
[8]Have given written informed consent to participate in this study  in accordance 
with local regulat ions and the e thical review board (ERB) governing the study  site
6.2. Exclusion Criteria
Patients will be excluded fro m study  enro llment if they meet any o f the following cri teria at
screening :
Medical Conditions
[9]Have t ype 1 diabetes mellitus (T1DM)
[10]Have a history  of chronic or acute pancreatit is any time pri or to study  entry  
(Visit 1)
[11]Have a history  ofany of the fo llowing:
proliferat ive diabet ic retinopathy,
OR
diabetic maculopathy,
OR
I8F-MC-GPGL (b) Clinical Protocol Page 34
LY3298176nonpro liferat ive diabet ic retinopathy that requires acute treatment (a dilated 
fundoscopic examinat ion performed by [CONTACT_126157] 2 and Visit 3 is required to confirm eligibilit y) 
[12]Have a history  of ketoaci dosis or hy perosm olar state/com a
[13]Have a history  of severe hypoglycemia and /or hy poglycemia unawareness within 
the 6 m onths pri or to Vi sit 1
[14]Have a known clinically significant gastric empt ying abnormalit y (for example, 
severe diabet ic gastroparesis or gastric outlet obstruction), have undergone or plan 
to have during the co urse of the study :  gastri c by[CONTACT_6476] (bariatric) surgery  or 
restri ctive bariatric surgery (for example, Lap -Band®), or chroni cally  take drugs 
that direct ly affect GI motilit y
[15]Have any of the fo llowing cardi ovascular (CV) condit ions within 2 months prior
to Visit 1:  acute my ocardial  infarct ion, cerebrovascular accident (stroke), or 
hospi [INVESTIGATOR_126145] (CHF)
[16]Have a history  of [LOCATION_001] Heart Associat ion Funct ional Classification IV CHF
[17]Have acute or chronic hepat itis, signs and symptoms of any liver disease other 
than nonalcoho lic fatty liver disease (NAFLD), or alanine aminotransferase 
(ALT) l evel >3.0 times the upper limit of normal (ULN) for the reference range, 
as determined by  [CONTACT_126158] .  Patients with NAFLD are 
eligible to participate in this trial if their ALT level is ≤3.[ADDRESS_141875] for the 
reference range
[18]Have an est imated glomerular filtration rate < 45 mL/min/1.73 m2(or lower than 
the country -specific thresho ld for discont inuing metformin therapy  per l ocal 
label) , calculated by  [INVESTIGATOR_82351] -Epi[INVESTIGATOR_126146] 1
[19]Have evidence of a significant, uncontrolled endocrine abnormalit y (for example, 
thyrotoxi cosis or adrenal  crise s), in the opi[INVESTIGATOR_3078] n of the invest igator
[20]Have family or personal history  of medullary thy roid carcino ma (MTC) or 
multiple endocrine neoplasia syndro me type 2 (MEN2)
[21]Have a serum calcitonin level of ≥35 ng/L, as determined by [CONTACT_126159] 1
[22]Have k nown or suspected hy persensit ivity to tri al product(s) or rel ated products
[23]Have evidence of a significant, active autoimmune abnormalit y (for example, 
lupus or rheumatoid arthrit is) that, in the opi[INVESTIGATOR_35272], is likel y to 
requi re concurrent treatment with systemic glucocorticoids in the next 12 months
[24] Have had a transplanted organ (corneal transplants [keratoplasty] allowed) or 
awaiting an organ transplant
I8F-MC-GPGL (b) Clinical Protocol Page 35
LY3298176[25]Have a history  of an act ive or untreated malignancy o r are in remissio n from a 
clinically significant malignancy (other than basal or squamous cell skin cancer, 
in situ carcinom as of  the cervix, or in situ prostate cancer) for less than 5 y ears
[26]Have a history  of any other condit ion (such as known drug, alcoho l abuse, or 
psychiatric disorder) that, in the opi[INVESTIGATOR_1649] o f the investigator, may preclude the 
patient from following and co mpleting the protocol
[27]Have any hematological condit ion that m ay interfere with HbA1c measurement 
(for example, hemo lytic anemias, sickle cell disease)
Prior/Concomitant Therapy
[28]Have been treated with any antihyperglycemic medicat ion (other than met formin) 
within the 3 months pri or to Visit 1.  An except ion is for the use of insulin for 
gestati onal diabetes or short -term use (<14 day s) for acute condit ions such as 
acute illness, hospi[INVESTIGATOR_3094], or elective surgery
[29]Have been treated with prescription drugs that promote weight loss (for example, 
Saxenda [liraglut ide 3.0 mg], Xenical®[orlistat], Meridia®[sibutramine], 
Acutrim®[phenylpropano lamine], Sanorex®[mazindo l], Adipex®[phentermine], 
BELVIQ®[lorcaserin], Qsymia®[phentermine/topi[INVESTIGATOR_82336]], 
Contrave®[naltrexone/bupropi[INVESTIGATOR_2394]], or similar other body  weight l oss medicat ions 
including over -the-counter [OTC] medications [for example, allī®]) wi thin 3 
months prior to Visit 1 and/or between study  entry  (Visit 1) and randomizat ion 
(Visit 3) 
[30]Are receiving chronic (>2 weeks or 14 day s) systemic glucocortico id therapy 
(excluding topi[INVESTIGATOR_2855], intraocular, intranasal, or inhaled preparations) or have 
received such therapy  within 1 m onth of Visit 1 or between Visit s 1 and 3
Prior/Concurrent Clinical Trial Experience
[31] Are current ly enrolled in any other clinical study  involving an invest igational 
product or any  other type of medical research judged not to be scient ifically or 
medically co mpat ible with this study
[32]Have part icipated, within the last [ADDRESS_141876] has a long half -
life, 5 half -lives or 30 days (whichever is longer), should have passed prior to 
screening
[33]Have previously co mpleted or withdrawn fro m this study  or any  other study  
investigat ing tirzepat ide
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e 3 6 
L Y 3 2 9 8 1 7 6 Ot her E xcl usi o ns 
[ 3 4 ]Are i n vest i gat or site pers o n nel directl y affiliate d wit h t his st u d y  a n d/ or t hei r 
i m me diate fa milies.  I m me diate fa mil y is defi ne d as a s p o use, pare nt, c hil d, or 
si bli n g, w het her bi o l o gi c al  or l e gall y a d o pte d 
[ 3 5 ]Are Lill y  e m pl o y ees 
[ 3 6 ]Are u n willi n g or u na ble t o c o m pl y wit h t he use of a data c ollect i o n de vice t o 
di rect l y rec or d data fr o m t he patie nt 
6. 3. Lif e st yl e Re stri cti o n s 
Per t he Sc he d ule of Act i vit ies ( Secti o n 2), q ualifie d m e dical staff will pr o vi de dia betes 
ma na ge me nt c o u nseli n g, w hic h will i ncl u de i nstr ucti o ns o n diet a n d e xercise a n d e d ucat i o n 
a b o ut t he si g ns, s y m pt o ms, a n d treat me nt of h y p o gl yce mia, s h o ul d it occ ur.  
P ati e nts s h o ul d c o nt i n ue t heir us ual e xercise ha bits a n d ge nerall y f o ll o w a heal t h y meal pla n 
( wi t h  c o nsiste nt meal size a n d ti me of da y ) t hr o u g h o ut t he c o urse of t he st u d y .  Dietar y  
c o u nseli n g ma y be re vie we d t hr o u g h o ut t he st u d y , as nee de d.  Per I ncl usi o n Criteri o n [ 3 ] 
( Secti o n 6. 1 ), patie nts s h o ul d n ot i nit iate a n or ga nize d diet a n d/ or e xercise ( wei g ht re d ucti o n) 
pr o gra m d uri n g t he st u d y  ot her t ha n t he lifest yle a n d dietar y meas ures f or dia betes treat me nt .
St u d y  p arti ci pa nts s h o ul d be i nstr ucte d n ot t o d o nate bl o o d or bl o o d pr o d ucts d uri n g t he st u d y .
6. 4. S cr e e n F ail ur e s 
I n di vi d uals w h o d o n ot meet t he criteria f or partici pati o n i n t his st u d y  (scree n fail ure) m ust n ot 
be rescree ne d .
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141877] er e d 
P ati e nts will  b e ra n d o mize d i n a 1: 1: 1: [ADDRESS_141878] u d y treat m e nts: 
Ti rze pati d e ( d oses will be d o u ble -bli n de d) 
o5 m g
o1 0 m g 
o1 5 m g, or 
S e m a gl ut i de 1 m g (n ot bli n de d) .
St u d y  dr u g will be a d mi nistere d Q W as S C i njecti o n i n pat ie nt s wi t h  T 2 D Mi na de q uatel y 
c o ntr olle d wit h ≥ 1 5 0 0 m g/ da y met f o r mi n al o n e. 
Ta ble G P G L . [ADDRESS_141879] u g F or m ul ati o n R o ute o f 
A d mi nistr ati o n 
I n vesti g ati o n al c o m p o u n d 
Tirze pati de a5 m g Q W Si n gle -d ose pe n S C 
1 0 m g Q W Si n gle -d ose pe n S C 
1 5 m g Q W Si n gle -d ose pe n S C 
C o m p ar at or 
Se ma gl uti de b 1 m g Q W Si n gle -patie nt -use pe n S C 
A b bre viati o ns:  S C = s u bc uta ne o us; Q W = o nce wee kl y .
aTirze pati de treat me nt will f oll o w a fi xe d d ose escalati o n .It will be 
i nitiate d at 2. 5 m g Q W f or 4 wee ks, a n d 
i ncrease d b y 2. 5 m g e ver y 4 wee ks ( 2. 5 m g t o 5 m g t o 7. 5 m g t o 1 0 m g t o 1 2. 5 m g t o 1 5 m g ) u ntil t he 
desire d d ose is ac hie ve d a n d mai nt ai ne d f or t he d urati o n of t he st u d y. 
bSe ma gl uti de treat me nt will f oll o w a fi xe d d ose escalati o n. It will be 
i nitiate d at 0. 2 5 m g Q W f or 4 wee ks 
i ncrease d t o 0. 5 m g Q W f or 4 wee ks, a n d 
i ncrease d t o a n d mai ntai ne d at [ADDRESS_141880] u d y. 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141881] i gat or or his/ her desi g nee is res p o nsi ble f or t he f o ll o wi n g: 
e x plai ni n g t he c orrect use of t he st u d y  dr u gs a n d deli ver y  de vices (t hat i s, si n gle -
d ose pe n f or tirze pati de a n d si n gle -pat ie nt -use pe n f or se ma gl ut i de) t o t h e pati e nt 
or pati e nt re pre se ntati ve.   F or si n gle -d ose pe ns , a d e m o nstrati o n de vice will be 
use d 
ex plai ni n g t he c orrect use of c o nc o mit a nt m et f o r mi n t o t he patie nt or patie nt 
re prese ntati ve, i ncl u di n g a n y c o ntrai n dicat i o ns a n d a p pr o priate d osi n g per c o untr y -
s pecific la beli n g 
verif y i n g t hat i nstr ucti o ns are f o ll o we d pr o perl y b y t he patie nt 
mai ntai ni n g acc urate rec or ds of i n vesti gati o nal pr o d uct dis pe nsi n g a n d c o llect i o n
P ati e nts s h o ul d ret ur n all  u n use d st u d y dr u gs t o t he si te acc or di n g t o t he Sc h e d ule of Act i vit ies 
( Secti o n 2).  Patie nts s h o ul d be i nstr ucte d t o discar d all use d deli ver y  de vices i n a cl osea ble, 
p u nct ure -resi sta nt c o ntai ner acc or di n g t o l ocal r e g ul at i o ns. 
7. 1. 1. P a c k a gi n g a n d L a b elli n g 
T he s p o ns or will pr o vi de t ir ze pat i de i n si n gle -d ose pe ns a n d se ma gl ut i de ,i n si n gle -pati e nt -use 
pe ns .  T hese will be dis pe nse d via a n i nteract i ve we b -res p o nse s yste m (I W R S).  Si n gle -d ose 
pe ns a n d si n gle -pat ie nt -use pe ns will  b e pac k a ge d i n cart o ns t o be dis pe nse d.  Cli nical st u d y  
materi als will be la bele d acc or di n g t o t he c o u ntr y ’s re g ul at or y  r e q ui re me nts. 
7. 1. 2. M e di c al D e vi c e s 
T he c o m bi nat i o n pr o d ucts pr o vi de d f o r use i n t he st u d y  are i n vest i gat i o nal prefille d si n gle -d ose 
pe n sf o r ti rze pat i de a n d mar kete d prefille d si n gle -pati e nt -use pe n s f or s e m a gl ut i de .
7. 2. M et h o d of Tr e at m e nt A s si g n m e nt 
P ati e nts w h o m eet all cri t eri a f or e nr oll me nt will be ra n d o m l y assi g ne d t o [ADDRESS_141882] u d y  
treat m e nt gr o u ps at Visit 3 .  Assi g n me nt t o treat me nt gr o u p s will be deter mi ne d b y a 
c o m p uter -ge nerate d ra n d o m se q ue nce usi n g a n I W R S.  Patie nts will be ra n d o ml y assi g ne d i n a 
1: 1: 1: 1 rati o t o recei ve ti rze pat i de 5 m g ,1 0 m g, 1 5 m g, or se m a gl ut i de 1m g .Patie nt 
ra n d o mizat i o n will be stratifie d base d o n c o u ntr y  a n d baseli ne H b A 1c ( ≤8. 5 % or >8. 5 % 
[ 6 9 m m o l/ m o l] ). 
7. 2. 1. S el e cti o n a n d Ti mi n g of D o s e s 
Assi g n me nt t o ti rze pat i de ( 3 d oses) or se ma gl ut i de will occ ur at ra n d o mizat i o n.  
Tirze p ati de 
T here are n o restrict i o ns o n t he ti me of da y  eac h wee kl y d ose of st u d y  dr u g is gi ve n, b ut i t is 
a d visa ble t o a d mi nister t he S C i njecti o ns o n t he sa me da y a n d sa me ti me eac h wee k ,wi t h  or 
wi t h o ut m eals .T he act ual date a n d ti me of all d ose a d mi nistrati o ns will be rec or de d b y t he 
pati e nt i n t he patie nt diar y .  If  a d ose of st u d y  dr u g is misse d, t he patie nt s h o ul d ta ke it as s o o n as 
p ossi ble u nless it is wit hi n 7 2 h o urs of t he ne xt sc he d ule d d ose, i n w hic h case, t hat d ose s h o ul d 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141883] u g S C i n t he a b d o me n or t hi g h; a care gi ver ma y a d mi nister t he 
i nject i o n i n t he patie nt’s u p per ar m. A ne w si n gle -d ose pe n will be use d f or eac h i nject i o n. 
W he n st u d y  dr u g i s al wa ys i njecte d i n t he sa me b o d y  r e gi o n, pati e nts s h o ul d be a d vise d t o use a 
differe nt i nject i o n site eac h wee k. 
Se m a gl uti de 
S e m a gl ut i de s h o ul d be a d mi nistere d Q W o n t he sa me da y  eac h wee k, at a n y  ti me of  t he da y , 
wi t h  or wi t h o ut m eals. T he da y  of  wee kl y a d mi nistrati o n ca n be c ha n ge d if necessar y ,as l o n g as 
t h e ti me bet wee n [ADDRESS_141884] 2 da ys ( > 4 8 h o urs). If a d ose is misse d, se m a gl ut i de s h o ul d 
be a d mi nister e d as s o o n as p ossi ble wit hi n 5 da ys af ter t he misse d d ose. If m o re t ha n 5 da ys 
ha ve passe d, t h e misse d d ose s h o ul d be s ki p pe d a n d t h e ne xt d ose s h o ul d be a d mi nister e d o n t he 
re g ul arl y sc he d ule d da y . I n eac h case, patie nts ca n t he n res u me t heir re g ular Q W d osi n g 
sc he d ule ( Oze m pic ® U S PI [ W W W] ). 
Pati e nts wil li nject se m a gl ut i de S C i n t he a b d o me n or t h i g h usi n g t he si n gle -patie nt -use pe n 
usi n g t he i njecti o n s u p plies pr o vi de d ; a care gi ver ma y a d mi nister t he i nject i o n i n t he patie nt’s 
u p per ar m . W he n st u d y  dr u g is al wa ys i njecte d i n t he sa me b o d y  r e gi o n, pati e nts s h o ul d be 
a d vise d t o use a differe nt i nject i o n site eac h wee k. A si n gle -pat ie nt -use pe n ma y be use d f or 
m ult i ple i nject i o ns. 
7. 3. Bli n di n g 
T his is a n o pe n -la bel st u d y  wi t h  res pect t o assi g n me nt t o se ma gl uti de vers us tirze pat i de.  Wit hi n 
t h e ti rze pati d e ar m s, t he d ose of ti rze pat i de will be d o u ble -bli n de d.   I n vest i gat ors, site staff, 
cli nical m o nit ors, a n d patie nts will re mai n bli n de d t o t he ti rze pat i de d oses u nt il t he st u d y is 
c o m plete.  
If a n i n vest i gat or, site pers o n nel perf or mi n g assess me nts, or patie nt is u n bli n de d t o t he 
ti rze pat i de d ose , t he pati e nt will c o nti n ue o n t he assi g ne d t hera p y  t hr o u g h t he e n d of t he st u d y , if  
me dicall y a p pr o priate.  St u d y  si te pers o n nel a n d t he s p o ns or will d oc u me n t a n y  u n bli n di n g 
e ve nts. 
7. 4. D o s a g e M o difi c ati o n 
7. 4. 1. St u d y Dr u g s 
N o a dj ust me nt  i n st u d y  dr u g d oses will be all o we d u nless f o rsafet y reas o ns .  Details a b o ut d ose 
a d mi nistrati o n of ti rze pat i de a n d se ma gl ut i de d uri n g t he st u d y  are descri be d i n Sect i o ns 7. 2. 1 
a n d 8. 1. 2 .
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141885] i o n pr o vi des g ui da nce o n ma na ge me nt of e pis o des of h y p o gl yce mic e ve nts; se vere, 
persiste nt h y per gl yce mia d uri n g t he treat me nt peri o d; patie nts w h o per ma ne nt l y disc o nt i n ue 
st u d y  dr u g pri or t o Vi si t 1 1 ; a n d pat ie nt s wi t h  GI s y m pt o m s. F or effect i ve i m ple me ntati o n of 
meas ures descri be d here, it is i m p orta nt t hat patie nts, a n d t heir care gi vers, if a p plica ble, be well 
e d ucate d a b o ut t he si g ns a n d s y m pt o ms of h y per gl yce mia (f or e xa m ple, se vere t hirst, dr y  m o ut h, 
fre q ue nt mict urit i o n, or dr y s ki n) a n d h y p o gl yce mia (f or e xa m ple, i nte nse h u n ger, s weati n g, 
tr e m or, restless ness, irrita bilit y, de pressi o n, hea dac hes, dist ur be d slee p, or tra nsie nt ne ur ol o gical 
di s or ders).  Patie nts s h o ul d be i nstr ucte d t o c o ntact t he i n vesti gati ve site i n t he e ve nt of  se vere, 
persiste nt h y per gl yce mia or se vere h y p o gl yce mia bet wee n st u d y  visi ts or i n t he e ve nt w he n a 
pati e nt i nte n ds t o per m a ne nt l y disc o nti n ue st u d y  dr u g. 
7. 4. 2. 1. St a n d ar d s of M e di c al C ar e 
I n vest i gat ors a n d ot her st u d y  t e a m  m e m bers are e x pecte d t o treat patie n ts acc or di n g t o t he 
nat i o nall y esta blis he d sta n dar ds of care f or dia betes ma na ge me nt i n res pect i ve partici pat i n g 
c o u ntri es, e xce pt w here t hat treat me nt w o ul d be i n c o nflict wit h t he pr ot oc ol -pr o vi de d treat m e nt 
re q ui re me nts.  If t here are n o l ocal sta n dar ds of  care f or dia betes, t he i n vest i gat ors s h o ul d f o ll o w 
c urre nt p u blis he d sta n dar ds of care fr o m t he A merica n Dia betes Ass ociati o n a n d t he E ur o pea n 
Ass oci at i o n f o r St u d y  of  Dia betes (Da vies et al. 2 0 1 8) d uri n g t heir patie nts ’part ic i pat i o n i n t his 
st u d y .
7. 4. 2. 2. M a n a g e m e nt of H y p o gl y c e mi a Ri s k 
I n t hi s st u d y , i ncrease d ri s k of  h y p o gl yce mia is defi ne d as ha vi n g a si n gle e pis o de of se vere 
h y p o gl yce mia or ha vi n g m ore t ha n [ADDRESS_141886] e ns ure t hat 
t h e pati e nt has bee n f ull y  c o m plia nt wi t h  t he assi g ne d t hera pe ut ic re gi me n a n d als o t hat t here is 
n o e vi de n ce of ot her p ossi ble ca uses of h y p o gl yce mia (f or e xa m ple, o missi o n of meal, 
u ne x pecte d i ncrease i n e xercise).  T he i n vest i gat or m ust als o c o nfir m t he y ha ve re d uce d or 
di sc o nti n ue d met f o r mi n as descri be d i n Sect i o n 7. 7. [ADDRESS_141887] i gat ors will be trai ne d o n t he a p plicat i o n of cri t eri a f or d e ci di n g w he n a n d h o w t o i nter ve ne 
wi t h  patie nts w h o d o n ot reac h gl yce mic tar gets.  A n a d dit i o n al  t hera pe ut ic i nt er ve nt i o n s h o ul d 
be c o nsi dere d i n pat ie nt s w h o de vel o p se vere, persiste nt h y per gl yce mia after ra n d o mizat i o n. 
Resc ue me dicat i o n will be prescri be d as a d d -o n t o ra n d o mize d treat me nt, a n d patie nts will 
c o nti n ue t o f ol l o w t he pr ot oc ol -s pecifie d visit sc he d ule.   Resc ue treat me nt wit h pra mli nt i d e, 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e 4 1 
L Y 3 2 9 8 1 7 6 di pe pt i d yl pe pt i dase - 4 ( D P P - 4 )i n hi bit ors, or G L P -1 rece pt or a g o nists will n ot be all o we d.   See 
Secti o n 7. 7. 2 f o r details a b o ut t he all o we d a nt i h y per gl yce mic me dicat i o n. 
A d d -o n gl yce mic resc ue t hera p y  will be all o we d f or pati e nts w h o m ee t a n y  o ne of t he f oll o wi n g 
pres pecifie d criteria f or se vere, persiste nt h y per gl yce mia a n d n o i nterc urre nt ca use of t he 
h y per gl yce mia ca n b e i de nt ifie d (i n vest i gat ors s h o ul d first c o nfir m t hat t he patie nt is f ull y 
c o m plia nt  wi t h  t he assi g ne d t hera pe utic re gi me n a n d t hat he or s he d oes n ot ha ve a n ac ute 
c o n di ti o n ca usi n g se vere h y per gl yce mia): 
(a) a vera ge dail y  B G f r o m  t he o nce -wee kl y  4 -p oi nt S M B G pr ofile > 2 7 0 m g/ d L 
( > 1 5. 0 m m o l/ L) o ver at l east a c o nsec ut i ve [ADDRESS_141888] ra n d o mizat i o n; 
O R 
( b) a vera ge dail y  B G f r o m  t he o nce -wee kl y  4 -p oi nt S M B G pr ofile > 2 4 0 m g/ d L 
( > 1 3. 3 m m o l/ L) o ver a c o nsec ut i ve [ADDRESS_141889] 
ra n d o mizat i o n; 
O R 
(c) a vera ge dail y  B G f r o m  t he o nce -wee kl y  4 -p oi nt S M B G pr ofile > 2 0 0 m g/ d L 
( > 1 1. 1 m m o l/ L) o ver a c o nsec ut i ve [ADDRESS_141890] ra n d o mizat i o n; 
O R 
( d) H b A 1c ≥ 8. 5 % at [ADDRESS_141891] 3 m o nt hs ( wee k 1 2 t o wee k 2 4) t hat is < 0. 3 % .
7. 4. 2. 4. M a n a g e m e nt of P ati e nt s P er m a n e ntl y Di s c o nti n ui n g St u d y Dr u g s 
Ci rc u msta nces u n der w hic h pat ie nt s m a y  b e r e q ui re d t o pre m at urel y  disc o nti n ue st u d y  dr u g are 
o utli ne d i n Sect i o n8. [ADDRESS_141892] all pla n ne d efficac y a n d safet y meas ure me nts a n d 
s h o ul d recei ve a n ot her a nti h y per gl yce mic me dicat i o n ( Secti o n 7. 7. 2 ).  T he ne w 
a nt i h y per gl yce mic me dicat i o n will be rec or de d o n t he e C R F s pecifie d f or c ollect i n g s uc h 
me dicat i o ns. 
T o ass ure ti mel y i nit iat i o n of a n ot her a nti h y per gl yce mic me dicat i o n after per ma ne nt 
di sc o nti n uat i o n of st u d y  dr u g, patie nts s h o ul d be a d vise d t o pr o m pt l y n otif y  t he si te w he n t his 
si t u ati o n occ urs.  T he i n vest i gat or s h o ul d e val uate t he nee d f or a d dit i o nal a nt i h y per gl yce mic 
me dicat i o n at t hi s t i me (as o utli ne d i n Sect i o n 7. 7. 2 ) a n d i nit iate t he a d dit i o nal i nt er ve nt i o n 
acc or di n g l y .  A n u nsc he d ule d visit s h o ul d be use d as nee de d f or m ore ti mel y  i ni ti at i o n if 
warra nte d base d o n t he i n vest i gat or ’s cli nical j u d g me nt. 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141893] c o m m o nl y  re p orte d treat me nt -e mer ge nt A Es ( T E A Es) f or 
pati e nts recei vi n g tirze pat i de were na usea, v o mit i n g, a n d di arr hea. 
T he ti rze pat i de d ose escalat i o n sc he me has bee n desi g ne d t o mi ni mize t he de vel o p me nt of GI 
s y m pt o ms.  T he escalat i o n peri o d i s c o nsi dere d t o be [ADDRESS_141894] u g d osa g e. 
T o mit i gate GI s y m pt o ms a n d ma na ge patie nts wit h i nt olera ble GI A Es d uri n g t he escalat i o n 
p eri o d ( Wee k 0 t o 2 4), t he i n vesti gat or s h o ul d 
a d vise patie nts t o eat s maller meals, f or e xa m ple, s plitti n g [ADDRESS_141895] o p eati n g w he n t he y feel f ull. 
prescri be s y m pt o mat ic me dicat i o n (f or e xa m ple, a nt ie met ic or a nti diarr heal me dicat i o n) 
per l o c al  c o u ntr y  a vaila bilit y a n d i n di vi d ual patie nt nee ds.  Use of s y m pt o mat ic 
me dicat i o n s h o ul d be ca pt ure d as c o nc o mita nt me dicat i o ni n t he e C R F. 
bef ore per ma ne nt l y disc o nt i n ui n g ti rze pat i de, c o nsi der a te m p orar y i nterr u pti o n (f o r 
e xa m ple , o mit 1 d ose, t he patie nt will ta ke 3 of 4 d oses at t hat d ose le vel ).  
oAt  a m a xi m u m , 1 d ose ca n be o mitte d per 4 wee ks ( u p t o 6 d oses c o ul d be 
o mitt e d d uri n g t he escalat i o n peri o d ,2 4 wee ks).   
oAfter i nterr u pti o n, t h e i n vest i gat or s h o ul d restart t he d ose, or escalate t he d ose as 
re q ui re d , wi t h  t he pati e nt ta ki n g me dicat i o n t o alle viate t heir GI s y m pt o ms .  
oT he data relate d t o te m p orar y  i nt err u pti o n of st u d y treat m e nt s h o ul d be 
d oc u m e nte d i n s o urce d oc u me nts a n d e ntere d o n t he e C R F.  
If i nt olera ble GI s y m pt o ms or e ve nts persist des pi[INVESTIGATOR_040] t he a b o ve meas ures, t he i n vest i gat or ma y 
deci de t o disc o nt i n ue st u d y  dr u g.  De -escalat i o n of st u d y  dr u g will n ot be al l o we d.  Patie nts w h o 
st o p t he st u d y  dr u g per m a ne nt l y will recei ve a n ot her gl uc ose -l o weri n g i nter ve nti o n 
( Secti o n 7. 7. 2 ) a n d will c o nt i n ue partici pati n g i n t he st u d y  acc or di n g t o t he pr ot oc ol t o c ollect all 
pl a n ne d efficac y  a n d safet y meas ure me nts.  T he ne w gl uc ose- l o weri n g i nter ve nt i o n will be 
rec or de d o n t he e C R F s pecifie d f or c ollecti n g a nt i h y per gl yce mic me dicat i o ns. 
I n t he e ve nt of i nt olera ble persiste nt  GI s y m pt o ms t hat occ ur after t he escalati o n peri o d (after 
Wee k 2 4), t he i n vest i gat or ca n a d vise o n be ha vi oral c ha n ges a n d c o nsi der prescri bi n g 
s y m pt o m at ic me dicat i o nt o kee p t he patie nt o n st u d y  treat m e nt bef ore st o p pi n g t he st u d y  dr u g 
p er m a ne nt l y a n d i nit iat i n g a n ot her gl uc ose- l o weri n g i nter ve nt i o n. 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141896] c o m m o nl y  re p orte d T E A Es were na usea, 
v o mit i n g, a n d diarr hea ( Mars o et al . 2 0 1 6; A hré n et al. 2 0 1 7; Ar o da et al. 2 0 1 7; S orli et al. 2 0 1 7; 
Pr atl e y  et a l.  2 0 1 8; R o d bar d et al. 2 0 1 8). 
T o mit i gate GI s y m pt o ms a n d ma na ge patie nts wit h i nt olera ble GI A Es d uri n g t he escalat i o n 
p eri o d ,wit h a n a d dit i o nal 4 wee ks t o reac h stea d y  state wi t h  1 m g d ose ( Wee k 0 t o 1 2), t he 
i n vesti gat or s h o ul d 
a d vise patie nts t o ea t s m aller m eals (f o r e xa m ple, s plitti n g 3 dail y meals i nt o 4 or m ore 
s maller meals ), a n d t o st o p eati n g w he n t he y  f eel  f ull .
prescri be s y m pt o mat ic me dicat i o n (f or e xa m ple, a nt ie met ic or a nti diarr heal me dicat i o n) 
per l o c al  c o u ntr y  a vaila bilit y a n d i n di vi d ual patie nt nee ds.  Use of s y m pt o mat ic 
me dicat i o n s h o ul d be ca pt ure d as c o nc o mita nt me dicat i o n i n t he e C R F. 
bef ore per ma ne nt l y disc o nt i n ui n g se ma gl ut i de, c o nsi der a te m p orar y i nterr u pti o n (f o r 
e xa m ple , o mit 1 d ose, a n d ha ve t h e pati e nt ta ke 3 of 4 d oses at t hat d ose le vel ).  
oAt  a m a xi m u m , u p t o 3 d oses c o ul d be o mitte d d uri n g t he escalat i o n peri o d 
( 1 2 wee ks). 
oAfter i nterr u pti o n, t h e i n vest i gat or s h o ul d restart t he d ose, or escalate t he d ose as 
re q ui re d , wi t h  t he pati e nt ta ki n g me dicat i o n t o alle vi ate t hei r GI s y m pt o ms .  
oT he data relate d t o te m p orar y  i nt err u pti o n of  st u d y treat m e nt s h o ul d be 
d oc u m e nte d i n s o urce d oc u me nts a n d e ntere d o n t he e C R F. 
If i nt olera ble GI s y m pt o ms or e ve nts persist des pi[INVESTIGATOR_040] t he a b o ve meas ures, t he i n vest i gat or ma y 
deci d e t o disc o nt i n ue st u d y  dr u g.  De -escalat i o n of st u d y  dr u g will n ot be all o we d.  Patie nts w h o 
st o p t he st u d y  dr u g per m a ne nt l y will recei ve a n ot her gl uc ose -l o weri n g i nter ve nti o n 
( Secti o n 7. 7. 2 ) a n d will c o nt i n ue partici pati n g i n t he st u d y acc or di n g t o t he pr ot oc ol t o c ollect all 
pl a n ne d efficac y  a n d safet y meas ure me nts.  T he ne w gl uc ose- l o weri n g i nter ve nt i o n will be 
rec or de d o n t he e C R F s pecifie d f or c ollecti n g a nt i h y per gl yce mic me dicat i o ns. 
I n t he e ve nt of i nt olera ble persiste nt GI s y m pt o ms t hat occ ur after t he escalati o n peri o d (after 
Wee k 1 2 ), t he i n vest i gat or ca n a d vise o n be ha vi oral c ha n ges a n d c o nsi der prescri bi n g 
s y m pt o m at ic me dicat i o nt o kee p t he patie nt o n st u d y  treat m e nt bef ore st o p pi n g t he st u d y  dr u g 
p er m a ne nt l y a n d i nit iat i n g a n ot her gl uc ose- l o weri n g i nter ve nt i o n. 
7. 5. Pr e p ar ati o n/ H a n dli n g/ St or a g e/ A c c o u nt a bilit y 
T he i n vest i gat or or his or her desi g nee is res p o nsi ble f or t he f oll o wi n g: 
co nfi r mi n g a p pr o pri at e t e m perat ure c o n di ti o ns ha ve bee n mai ntai ne d d uri n g 
tra nsi t f or all st u d y  treat m e nt recei ve d a n d a n y discre pa ncies are re p orte d a n d 
res ol ve d bef ore use of t he st u d y  tr e at m e nt. 
I8F-MC-GPGL (b) Clinical Protocol Page 44
LY3298176ensuring that only participants enro lled in the study may r eceive study  treatment 
and only  authori zed si te staff may  supply  study  treatm ent.  All  study  treatm ents 
must be stored in a secure, environmentally controlled, and mo nitored (m anual  or 
autom ated) area in accordance wit h the l abeled storage conditions with access 
limited to the investigator and authorized site staff.
the invest igator, inst itution, or the head of the medical inst itution (where 
applicable) is responsible for study  treatm ent accountabilit y, reconciliat ion, and 
record m aintenance (such as recei pt, reconciliat ion, and final disposit ion records).
The study  site must store the study  drug in a l ocked and secure environment.  Please refer to the 
study  drug l abel for specific storage condit ions.  Pati ents mayreceive insulated bags with 
cooling g el packs for use in transporting the study  drug carton fro m the site to hom e. 
Study  site staff must regul arly assess whether the patient is correctly administering the assigned 
study  drug and storing the study  drug according to the provided instructions.
7.6. Treatment Compliance
Study  drug com pliance will  be determined by  [CONTACT_82374]: 
Study  drug administration data will be recorded by [CONTACT_126160].
The patients will be instructed to return any unused study drug in the original 
carton and/or empt y cartons at the next visit to the study  site for the purpose of 
performing drug accountabilit y.Patients will  be instructed to di scard used pens in 
a closeable, puncture -resistant container a ccording to local regul ations.
In the [ADDRESS_141897] 75% of the required doses of study  drug.  
Similarly, a patient will be consid ered nonco mpliant if he or she is judged by  [CONTACT_126161].  
In addit ion to the assessment of a patient’s co mpliance with the study drug administration, other 
aspect s of compliance wit h the study  procedures will be assessed at each visit based on the 
patient’s adherence to the visit schedule, compliance wi th the requi red concomitant therapy  with 
metformin, com pletion of study  diaries, the resul ts of home BG mo nitoring , and any  other 
param eters the invest igator considers necessary.
Patients consi dered to be poorly  com pliant wi th their medicati on and/or the study  procedures 
will receive addit ional training and instruction, as required, and will be reminded of the 
importa nce of compliance .
7.7. Concomitant Therapy
7.7.1. Background Therapy with Metformin
Patients in thi s study  must be treated wi th metformin for at least 3 m onths pri or to Visit 1; the 
minimum required dose during this t ime will be 1500 mg/day.  Theprescreening dose and 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e 4 5 
L Y 3 2 9 8 1 7 6 f o r m ulat i o n (s h ort -acti n g or l o n g -acti n g) s h o ul d be mai ntai ne d d uri n g t he scree ni n g a n d lea d -i n 
p eri o ds, t hr o u g h ra n d o mizat i o n at Vi si t 3. 
After ra n d o mizat i o n, di sc o nt i n uat i o n of metf or mi n or c ha n ge i n d osa ge a n d f or m ulat i o n is n ot 
per mitte d, e xce pt i n t h e f ol l o wi n g si t u ati o ns: 
1. I n t he e ve nt of a h y p o gl yce mic e pis o de(s) (cli nical s y m pt o ms of h y p o gl yce mia a n d/ or 
B G -c o nfir me d s y m pt o mat ic B G h y p o gl yce mia :gl uc ose c o nce ntrati o n < 3. 0 m m o l/ L [ 5 4 
m g/ d L]):   Patie nts ma y re d uce/ disc o nt i n ue t he d ose of metf or mi n.   
2. I n certai n sit uat i o ns t hat re q uire s h ort -t er m  di sc o nti n uat i o n i n li ne wit h t he pr o d uct(s) 
la beli n g f or eac h res pecti ve c o u ntr y (f or e xa m ple, f or metf or mi n:  se vere de h y drat i o n, 
el ect i ve s ur ger y, or nee d f or ra di o l o gi c e xa mi nat i o n i n v o l vi n g I V i o di nate d c o n trast d y e). 
O nce t he sit uat i o n t hat l e d t o te m p orar y  disc o nt i n uati o n of t he dr u g is res ol ve d, treat me nt 
s h o ul d be restarte d at i n vest i gat or discreti o n. 
3. If a patie nt de vel o ps c o ntrai n dicat i o ns t o met f o r m i n s uc h t hat t he use of t he dr u g is 
c o ntrai n dicate d acc or di n g t o t he c o u ntr y -s pecific la bel .
4. If pat ie nt  m eets t he cri teria f or se vere, persiste nt hy per gl yce mia ( Secti o n 7. 4. 2. 3 ) or 
di sc o nt i n ues st u d y  dr u g, t he n metf or m i n d ose ma y be i ncrease d acc or di n g t o c o u n tr y -
s pecific la bel as l o n g as t hat i s n ot t h e s ol e i nter ve nt i o n ( Ta ble G P G L . 4 ). 
A pat ie nt  will be c o nsi dere d n o nc o m p lia nt wi t h  t he pr ot oc ol ( pr ot oc ol de viat i o n) if he or s he 
c ha n ges t he d ose or disc o nt i n ues metf or mi n f or reas o ns ot her t ha n t h ose descri be d here.  
D ose re d ucti o n/ disc o nt i n uat i o n of metf or mi n d uri n g t he trial s h o ul d be pr o perl y  d oc u me nte d a n d 
rec or de d o n t he a p pr o priate e C R F. 
7. 7. 2. I niti ati o n of N e w A nti h y p er gl y c e mi c M e di c ati o n 
T he i ntr o d ucti o n of ne w a nt i h y per gl yce mic me dicati o n is e x pecte d d uri n g t he st u d y o nl y i n t he 
f o ll o wi n g sit uat i o ns: 
As a n a nt i h y per gl yce mic i nter ve nt i o n f o r se vere, persiste nt h y per gl yce mia ( “resc ue 
t h era p y ”), as defi ne d i n Sect i o n 7. 4. 2. 3 
I n t h ose patie nts w h o re q uire per ma ne nt disc o nt i n uati o n of st u d y  dr u g, b ut re m ai n i n t he 
st u d y  ( Secti o n 8. 1. 1 )
D uri n g t he safet y f o ll o w- u p peri o d ( bet w ee n Visit 1 1 [ Wee k 4 0] or E T a n d Visit 8 0 1) 
If a ne w a nt i h y per gl yce mic me dicat i o n is i nt r o d uce d d uri n g t he treat me nt peri o d (t hat is, pri or t o 
Vi si t 1 1), t he pati e nt s h o ul d be treate d wit h a l ocall y  a p pr o ve d gl uc ose -l o weri n g a ge nt (e xce pt 
ot her G L P -1 rece p t or a g o nists, D P P -4 i n hi bit ors, a n d pra mli nt i de) acc or di n g t o t he f o ll o wi n g 
or der of prefere nce base d o n t he u p date d 2 0 1 8 A D A/ E A S D c o nse ns us state me nt ( Da vies et al. 
2 0 1 8): 
1. S o di u m -gl uc ose c o -tra ns p orter 2 ( S G L T 2) i n hi bit ors are rec o m me n de d first , u nl ess a 
c o ntrai n dicat i o n is prese nt. 
2. If a c o ntrai n dicati o n t o S G L T 2 i n hi bit or is prese nt, t he n a s ulf o n yl urea or 
t hi az o li di ne di o ne ca n be c o nsi dere d. 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e 4 6 
L Y 3 2 9 8 1 7 6 3. If gl yce mic c o ntr ol re mai ns i na de q uate des pi[INVESTIGATOR_040] i ntr o d ucti o n of ne w a nti h y per gl yce mic 
me dicat i o n ( f o r e xa m ple , af t er 3 m o nt hs or wi t hi n a ti mefra me deter mi ne d b y  t h e 
i n vesti gat or), t he n a d dit i o n of basal i ns uli n t hera p y s h o ul d be c o nsi dere d.  If i ns uli n is 
prescri be d as a resc ue t hera p y  f or h y per gl yce mia or as a ne w a nt i h y per gl yce mic 
me dicat i o n i n pat ie nt s re q ui ri n g st u d y  dr u g di sc o nti n uat i o n, i t m ust be differe nt iat e d fr o m 
s h ort -t e r m  us e of  i ns uli n t hera p y  f or m e dical e mer ge ncies w he n re p orte d i n t he e C R F. 
4. I ni ti ati o n of  i ns uli n as t he first resc ue i nter ve nt i o n f or h y per gl yce mia s h o ul d be reser ve d 
f o r p ati e nts wi t h  se vere, persiste nt h y per gl yce mia ( Secti o n 7. 4. 2. 3 ) wit h a n a vera ge 
fast i n g ser u m gl uc ose ≥ 3 0 0 m g/ d L ( ≥ 1 6. 7 m m o l/ L), i n patie nts wit h s y m pt o ms of 
h y per gl y ce mia, or i n ot her cli nical sit uat i o ns w here t he i n vesti gat or belie ves m ore ra pi d 
gl yce mic c o ntr ol is warra nte d. 
7. 7. 3. O t h er C o n c o mit a nt M e di c ati o n s 
P ati e nts will  b e per mitte d t o use c o nc o mita nt me dicati o ns t hat t he y  r e q ui re d uri n g t he st u d y , 
e xce pt certai n me dicat i o ns t hat ma y i nterfere wit h t he assess me nt of efficac y a n d safet y 
c haracterist ic s of t he st u d y  tr e at m e nts (Ta ble G P G L . 4 ). 
I n vest i gat i ve site staff will  i nf or m  pat ie nt s t hat t he y m ust c o ns ult wit h t he i n vesti gat or or a 
desi g nate d site staff me m ber u p o n bei n g prescri be d a n y ne w me dicat i o ns d uri n g t he st u d y .  T hi s 
ma y n ot be p ossi ble w he n i nit iate d f or treat me nt of me dical e mer ge ncies, i n w hic h case, t h e 
pati e nt will i nf or m t he i n vest i gat or or a desi g nate d site staff me m ber as s o o n as p ossi ble.  A n y 
a d di ti o nal  m e dicat i o n i nit iate d d uri n g t he c o urse of t he st u d y  (i ncl u di n g O T C dr u gs, s uc h as 
paraceta m o l or as pi [INVESTIGATOR_27969] n) m ust be d oc u m e nte d, a n d t he na me of t he dr u g a n d t he date(s) of 
a d mi nistrati o n m ust be rec or de d o n t he “ C o nc o mit a nt Me dicat i o ns” sect i o n of t he e C R F. 
A nt i h y per gl yce mic me dicat i o ns ot her t ha n st u d y  dr u gs a n d met f o r mi n are n ot all o we d at a n y  
ti me d uri n g t he st u d y  e xce pt as all o we d f or t h ose patie nt s w h o re q uire per ma ne nt disc o nti n uati o n 
of  st u d y  dr u g, b ut re m ai n i n t he st u d y ; resc ue t hera p y  af ter ra n d o mizati o n d ue t o se vere, 
persiste nt h y per gl yce mia; or d uri n g t he safet y f o ll o w -u p peri o d ( Secti o n 7. 7. 2 ).   S h ort -t e r m  
i ns uli n use f or u p t o 1 4 da ys is all o we d f or certai n cli nical sit uat i o ns (f or e xa m ple, elect i ve 
s ur ger y , d uri n g h os pi [INVESTIGATOR_1314] o n, h y per os m ol ar states) a n d m ust be differe nt iat e d fr o m i ns uli n use 
as resc ue t hera p y  w he n re p orte d i n t he e C R F. 
All n o nst u d y  m e dicati o ns will be rec or de d o n t he e C R F at all visit s. 
N o nst u d y  m e dicat i o ns ta ke n b y  pat ie nt s w h o are scree ne d b ut n ot ra n d o m l y assi g ne d t o 
treat m e nt will n ot be re p orte d t o Lill y u nless a n S A E or A E occ urs t hat t he i n vest i gat or belie ves 
ma y ha v e bee n ca use d b y  a st u d y  pr oce d ure. 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141898] u d y G P G L 
A b bre viati o ns: D P P - 4 = di pe pti d yl pe pti dase -4; G L P -1 R A =gl uca g o n -li ke pe pti de -[ADDRESS_141899]; N =n o; 
N/ A = n ot a p plica ble; S G L T - 2i = s o di u m -gl uc ose c o -tra ns p orter 2 i n hi bit or ; Y =yes. 
aAc ute t hera p y =treat me nt f or u p t o 1 4 da ys. 
bI ncl u des Sa xe n da ® (lira gl uti de 3. 0 m g), Xe nical ®( orlistat), Meri dia ®(si b utra mi ne), Sa n ore x ®( mazi n d ol), 
A pi [INVESTIGATOR_5328] x ®( p he nter mi ne), B E L VI Q ®(l o rcaseri n), Qs y mia ®( p he nter mi ne/t o pi[INVESTIGATOR_77333] c o m bi nati o n), C o ntra ve ®
( naltre x o ne/ b u pr o pri o n), or si milar ot her b o d y wei g ht l oss me dicati o ns i ncl u di n g o ver -t he -c o u nter me dicati o ns 
(f or e xa m ple; allī ®) wit hi n 3 m o nt hs pri or t o Visit 1 or a n y ti me d uri n g t h e trial. 
cFr o m 1 m o nt h pri or t o Visit 1 or bet wee n Visits 1 a n d 3; d oes n ot a p pl y t o t o pi[INVESTIGATOR_2855], i ntra oc ular, i ntra nasal, 
i ntra -artic ular, or i n hale d pre parati o ns. 
dMetf or mi n prescree ni n g d ose a n d f or m ulati o n (s h ort -acti n g or l o n g -acti n g) s h o ul d be mai nta i ne d t hr o u g h o ut t he 
st u d y, e xce pt as s pecifie d i n Secti o n 7. 7. [ADDRESS_141900] i vit ies ( Secti o n 2) f or all  patie nts u ntil n otifie d b y  Lill y t hat 
st u d y  c o m plet i o n has occ urre d. 
Ti rze pati d e will n ot be ma de a vaila ble t o p ati e nts aft er c o ncl usi o n of  t he st u d y .Dr u g Cl ass Use d uri n g 
Scree ni n g/ Le a d -I n C o n diti o ns f or Use after R a n d o miz ati o n 
Ac ute 
T her a p y aResc ue 
T her a p y/ P ost 
St u d y Dr u g 
Disc o nti n u ati o n D uri n g S afet y 
F oll o w -U p Peri o d 
Dr u gs wit h a p pr o ve d wei g ht l oss 
i n dicati o n b E xcl u de d N N/ A Y
S y ste mic gl uc oc ortic oi d t hera p y c E xcl u de d e xce pt 
f or ac ute t hera p y a Y N/ A Y
A nti h y per gl yce mia me dicati o ns 
Ot her G L P -1 R As E xcl u de d N N N
D P P -4 i n hi bit ors E xcl u de d N N N
Pra mli nti de E xcl u de d N N N
S G L T - 2i E xcl u de d N Y Y
I ns uli ns E xcl u de d e xce pt 
f or ac ute t hera p y aY Y Y
Me gliti ni des E xcl u de d N Y Y
Al p ha- gl uc osi dase i n hi bit ors E xcl u de d N Y Y
S ul p h o n yl ureas E xcl u de d N Y Y
T hiaz oli di ne di o nes E xcl u de d N Y Y
Metf or mi n dRe q uire d N/ A YeY
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141901]: 
P atie nt Decisi o n 
oT he patie nt re q uests t o disc o nt i n ue i n vest i gat i o nal pr o d uct. 
Disc o nti n u ati o n d ue t o i ncre ase d ris k of h y p o gl yce mi a 
Pl ease refer t o Secti o n 7. 4. 2. 2 f o r details. 
Disc o nti n u ati o n d ue t o a he p atic e ve nt or li ver test a b n or m alit y 
P ati e nts w h o are di sc o nt i n ue d fr o m i n vest i gat i o nal pr o d uct d ue t o a he pat ic e ve nt or li ver 
test a b n or m ali t y  s h o ul d ha ve a d dit i o nal he pat ic safet y  data c oll ecte d vi a a n e C R F. 
Di sc o nti n uati o n of  t he i n vest i gat i o nal pr o d uct f or a b n or mal li ver tests s h o ul d be 
c o nsi dere d b y t he i n vesti gat or w he n a patie nt meets o ne of t he f o ll o wi n g c o n di ti o ns af t er 
c o ns ultati o n wit h t he Lil l y -desi g nate d m e dical m o ni t or: 
A L T or as partate a mi n otra nsferase ( A S T) > 8 X U L N 
A L T or A S T > 5 X U L N f or m ore t ha n 2 wee ks 
A L T or A S T > 3 X U L N a n d t otal bilir u bi n le vel ( T B L) > 2 X U L N or 
i nt er nat i o nal n or m alize d rati o > 1. 5 
A L T or A S T > 3 X U L N wit h t he a p peara nce of fat i g ue, na usea, v o mit i n g, 
ri g ht u p per q ua dra nt pai n or te n der ness, fe ver, ras h, a n d/ or e osi n o p hilia 
( > 5 %) 
al kali ne p h os p hatase ( A L P) > 3 X U L N 
A L P > 2. 5 X U L N a n d T B L > 2 X U L N 
A L P > 2. 5 X U L N wit h t he a p peara nce of fati g ue, na usea, v o mit i n g, ri g ht 
q ua dra nt pai n or te n der ness, fe ver, ras h, a n d/ or e osi n o p hilia ( > 5 %) 
I n a d dit i o n, pati e nts will  b e per ma ne nt l y disc o nt i n ue d fr o m t h e i n vest i gat i o nal 
pr o d uct i n t he f o ll o wi n g ci rc u msta nces: 
If a patie nt is i na d verte nt l y e nr o lle d a n d it is deter mi ne d t hat c o n ti n ue d treat me nt 
wi t h  st u d y  dr u g w o ul d n ot be m e dicall y  a p pr o pri at e or i s n ot all o we d per l ocal 
la ws or re g ulat i o ns , see Sect i o n 8. 1. 3 
Ac ute or c hr o nic pa ncreat it is 
If a patie nt is dia g n ose d wit h M T C after ra n d o mizati o n or has a p ostra n d o mizat i o n 
cal ci t o ni n val ue ≥ 3 5 ng/ L t h at has i ncrease d at least 5 0 % o ver baseli ne 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e 4 9 
L Y 3 2 9 8 1 7 6 If a patie nt is dia g n ose d wit h a n acti ve or u ntreate d mali g na nc y ( ot her t ha n basal or 
s q u a m o us cell  s ki n ca ncer, i n sit u carci n o mas of t he cer vi x, or i n sit u pr ostate ca ncer) 
af ter ra n d o mizat i o n
A n y si g nifica nt st u d y  dr u g -r el ate d h y perse nsit i vit y reacti o n 
A n y ot her T E A E, S A E, or cli nicall y si g nifica nt la b orat or y  v al ue f or w hic h t he 
i n vesti gat or belie ves t hat per ma ne nt st u d y  dr u g di sc o nti n uat i o n is t he a p pr o priate 
meas ure t o be ta ke n 
If fe male patie nt bec o me s pre g na nt 
If a patie nt is dia g n ose d wit h T [ADDRESS_141902] u g per ma ne nt l y will recei ve a n ot her gl uc ose -l o weri n g i nter ve nt i o n 
(Secti o n 7. 7. 2 ) a n d will c o nt i n ue partici pati n g i n t he trial acc or di n g t o t he pr ot oc ol t o c ollect all 
pl a n ne d efficac y  a n d safet y meas ure me nts.  T he ne w gl uc ose- l o weri n g i nter ve nt i o n will be 
rec or de d o n t he e C R F s pecifie d f or c ollecti n g a nt i h y per gl yce mic me dicat i o ns. 
P ati e nts di sc o nt i n ui n g fr o m t h e i n vest i gat i o nal pr o d uct pre mat urel y f or a n y  reas o n s h o ul d 
c o m plete a d verse e ve nt a n d ot her f o ll o w- u p pr oce d ures per Secti o n 2( Sc he d ule of Act i vit ies), 
Secti o n 9. 2 ( A d verse E ve nts), a n d Secti o n 9. 4 ( Safet y) of t his pr ot oc ol. 
8. 1. 2. T e m p or ar y Di s c o nti n u ati o n fr o m St u d y Tr e at m e nt 
I n certai n sit uat i o ns after ra n d o mizat i o n, t he i n vesti gat or ma y nee d t o te m p ora ril y i nterr u pt st u d y  
dr u g (f or e xa m ple, ac ute ill ness, s ur ger y ,or h os pi[INVESTIGATOR_90730] i o n).  If st u d y dr u g i nterr u pti o n is d ue t o 
a n A E, t he e ve nt is t o be d oc u me nte d a n d f o ll o we d acc or di n g t o t he pr oce d ures i n Secti o n 9. [ADDRESS_141903] u g aft er a n y  t e m p or ar y  i nt err u pti o n, as s o o n as it is safe t o d o s o. 
Tirze p ati de 
If t he n u m ber of c o nsec ut i ve misse d d oses i s ≤ 2, tirze pati de ca n be restarte d at t he 
sa me d ose, if t he dr u g was well t ol erate d pri or t o disc o nti n uat i o n. 
If t he n u m ber of c o nsec ut i ve misse d d oses is ≥ 3, t he n ti rze pati d e s h o ul d be restarte d 
at 5 m g ir res pecti ve of t he d ose t he patie nt was recei vi n g bef ore t he i nterr u pti o n a n d 
s u bse q ue nt l y e scalate d as re q uire d b y pr ot oc ol (see Ta ble G P G L . 3 ). 
T he i n vest i gat or will use t he I W R S t o recei ve t he a p pr o priate st u d y dr u g dis pe nsi n g 
i nf or m at i o n t o preser ve bli n di n g o f t h e ti rze pati de d ose. 
If t he a b o ve sit uati o ns occ ur a gai n d uri n g t he c o urse of t he st u d y ,t h e i n vest i gat or i n 
c o ns ultati o n wit h s p o ns or or desi g nee will  d isc uss t he ne xt treat me nt o pti o n. 
Se m a gl uti de 
If t he n u m ber of c o nsec ut i ve misse d d oses i s ≤ 2, s e m a gl ut i de ca n be restarte d at [ADDRESS_141904] i gat or s h o ul d e val uate eac h case base d o n his/ her cli nical j u d ge me nt a n d 
deci de h o w t o restart se ma gl ut i de. 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e 5 0 
L Y 3 2 9 8 1 7 6 If t he n u m ber of c o nsec ut i ve misse d d oses is 3 or 4, se m a gl uti de treat m e nt s h o ul dbe 
c o nti n ue dwi t h  4 wee ks o n 0. 5 m g Q W bef ore escalat i o n t o t he mai nte na nce d ose of 
1m g Q W .
If t he n u m ber of c o nsec ut i ve misse d d oses is 5 or m ore, a f ull d ose escalat i o n s h o ul d 
be perf or m e d ( 0. 2 5 m g Q W f o r 4 wee ks f oll o we d b y 0. 5 m g Q W f o r 4 wee ks ,a n d 
t h e n escalat i o nt o t he m ai nte na nce d ose of 1 m g ). 
If t he a b o ve sit uati o ns occ ur a gai n d uri n g t he c o urse of t he st u d y ,t h e i n vest i gat or i n 
c o ns ultati o n wit h s p o ns or or desi g nee will  d isc uss t he ne xt treat me nt o pti o n. 
If t he st u d y  dr u g i nterr u pti o n is d ue t o i nt olera ble pe rsiste nt GI A E (f or e xa m ple, na usea, 
v o mit i n g, or diarr hea), t he patie nts s h o ul d be treate d as s u g geste d i n Sect i o n 7. 4. 2. [ADDRESS_141905] i gat or a n d t he s p o ns or cli nical researc h p h ysicia n (C R P )a gree t hat 
it  i s m e dicall y a p pr o priate t o c o nti n ue, t he i n vest i g at or m ust o btai n d oc u me nte d a p pr o val fr o m 
t h e s p o ns or C R P t o all o w t he i na d verte nt l y e nr olle d pati e nt t o c o n ti n ue i n t he st u d y  wi t h  or 
wi t h o ut treat m e nt wi t h  i n vest i gat i o nal pr o d uct. Safet y f o ll o w- u p s h o ul d be perf or me d as 
o utli ne d i n Sect i o n2( Sc he d ule of Act i vit ies), Secti o n9. 2 ( A d verse E ve nts), a n d Secti o n 9. 4 
( Safet y)  of  t he pr ot oc ol .
8. 2. Di s c o nti n u ati o n fr o m t h e St u d y 
To mi ni mize t he a m o u nt of missi n g data a n d t o e na ble assess me nt of st u d y  o bj ecti ves as pla n ne d 
i n t he st u d y  pr ot oc ol , e ver y  att e m pt will be m a de t o kee p patie nts i n t he st u d y  i rres pect i ve of t h e 
f o ll o wi n g: 
a d here nce t o st u d y  dr u g ,
a d here nce t o visit sc he d ule ,
missi n g assess me nts ,
st u d y  dr u g di sc o nt i n uat i o n d ue t o a n A E ,
de vel o p me nt of c o m or bi dit ies , a n d 
de vel o p me nt of cli nical o utc o mes .
T he ci rc u msta nces liste d a b o ve are n ot vali d reas o ns f or disc o nt i n uat i o n fr o m t h e st u d y . 
P ati e nts will be disc o nt i n ue d fr o m t h e st u d y  i n t he f o ll o wi n g circ u msta nces: 
E nr oll me nt i n a n y ot her cli nical st u d y  i n v o l vi n g a n i n vest i gat i o nal pr o d uct or 
e nr o ll me nt i n a n y ot her t y pe o f me d ical researc h j u d ge d n ot t o be 
scie ntificall y or me dicall y c o m pati ble wit h t his st u d y 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e 5 1 
L Y 3 2 9 8 1 7 6 P arti ci p ati o n i n t he st u d y  n ee ds t o be st o p pe d f or me dical, safet y,  re g ul at or y , 
or ot her reas o ns c o nsiste nt wit h a p plica ble la ws, re g ulat i o ns, a n d g o o d cli nical 
practi ce 
If a fe male pat ie nt  bec o mes pre g na nt 
If a patie nt is dia g n ose d wit h T 1 D M 
Pati e nt re q uests t o be wit h dra w n fr o m t he st u d y 
P ati e nts w h o a gree t o pr o vi de i nf or mat i o n rel e va nt t o a n y  st u d y  e n d p oi nt at t he e n d of t he st u d y  
are n ot c o nsi dere d t o ha ve disc o nti n ue d fr o m t he st u d y .
A pat ie nt  w h o wi t h dra ws c o nse nt a n d clearl y i n dicates t hat t here will be n o f urt her c o ntact of a n y 
ki n d wit h t he site will be c o nsi dere d t o ha ve disc o nt i n ue d fr o m t h e st u d y .
Pri or t o earl y  st u d y  di sc o nti n uati o n, t he pati e nt ma y disc o nt i n ue st u d y  dr u g a n d will ha ve 
e n d -of -st u d y  pr oce d ures ( E T vi si t) p erf or m e d as s h o w n i n t he Sc he d ule of Act i vit ies ( Secti o n 2).  
D uri n g t he E T visit, t he patie nt will i nit iate a ne w gl uc ose -l o weri n g t h era p y per t he di scret i o n of 
t h e i n vest i gat or .  Visit 8 0 1 (safet y f o ll o w- u p visi t) s h o ul d be perf or m e d a p pr o xi matel y  [ADDRESS_141906] u d y  pr e m at urel y f or a n y  reas o n s h o ul d c o m plete a d verse e ve nt 
a n d ot her safet y f o ll o w- u p per Secti o n 2( Sc he d ule of Act i vit ies), Secti o n 9. 2 ( A d verse E ve nts), 
a n d Sect i o n9. 4 ( Safet y) of t his pr ot oc ol. 
8. 3. L o st t o F oll o w -U p 
A pat ie nt will be c o nsi dere d l ost t o f o ll o w- u p if he or s he re peate dl y  f ails t o ret ur n f or sc he d ule d 
visit s a n d is u na ble t o be c o n tacte d b y  t he st u d y  si t e .  E ver y  att e m pt will  b e ma de t o mi ni mize 
t h e n u m ber of patie nts c o nsi dere d l ost t o f o ll o w- u p at t he e n d of t he st u d y .  P ati e nts will be 
i nf or m e d a b o ut t he i m p orta nce of c o m plet i n g t he st u d y  a n d pr o vi di n g u p date d c o ntact 
i nf or m at i o n t o t he st u d y  si te w he n necessar y .
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141907] u d y  pr oce d ures a n d t heir ti mi n g (i ncl u di n g 
t ol era nce li mit s f or ti mi n g). 
A p pe n di x [ADDRESS_141908] u d y  Sc he d ule ( Secti o n 2): 
Ke y sec o n d ar y effic ac y assess me nt (c o ntr olle d f or t y pe 1 err or) 
Mea n c ha n ge i n H b A 1c fr o m baseli ne 
Mea n c ha n ge i n b o d y  w ei g ht f r o m  baseli ne 
Pr o p orti o n of  patie nts wi t h  H b A 1c tar get val ues of < 7. 0 % ( 5 3 m m o l/ m o l) 
A d diti o n al sec o n d ar y effic ac y assess me nt ( n ot c o ntr olle d f or t y pe 1 err or) 
Pr o p orti o n of  patie nts ac hie vi n g a n H b A 1c tar get val ue of  ≤ 6. 5 % ( 4 8 m m o l/ m o l) 
Pr o p orti o n of  patie nts ac hie vi n g a n H b A 1c tar get val ue of < 5. 7 % ( 3 9 m m o l/ m o l) 
Mea n c ha n ge i n fast i n g ser u m gl uc ose (ce ntral la b orat or y ) f r o m  baseli ne 
Mea n c ha n ge i n 7 -p oi nt S M B G pr ofiles fr o m baseli ne 
Pr o p orti o n of  patie nts w h o ac hie ve d wei g ht l oss of >5 %, >1 0 %, a n d >1 5 % fr o m 
baseli ne 
P ati e nt -re p orte d o utc o mes: 
oD T S Qs/ D T S Qc 
oI W -S P 
oA P P A D L 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141909] u d y  Sc he d ule (see Sect i o n 2). 
P ati e nt -re p orte d o utc o mes: 
oE Q - 5 D- 5 L 
oI W Q O L -Li t e -C T 
C ha n ges i n f ast i n g gl uca g o n, C -pe pti de, a n d i ns uli n le vel s
C ha n ge si n li pi [INVESTIGATOR_805] (t otal c h o lester ol, H D L, V L D L, a n d tri gl yceri des )
C ha n ges fr o m baseli ne i n mea n B MI 
Mea n c ha n ge i n waist circ u mfere nce 
Bi o m ar kers 
9. 1. 4. B o d y W ei g ht, H ei g ht, a n d B o d y M a s s I n d e x 
B o d y  wei g ht will be m eas ure d at pre s pecifie d t i me p oi nts ( Sc he d ule of Act i vit ies ,Secti o n 2). 
Eac h patie nt’s wei g ht s h o ul d be meas ure d acc or di n g t o a sta n dar dize d pr ot oc ol a n d rec or de d o n 
t h e e C R F t o t he nearest o ne- te nt h k g ( A p pe n di x 7 ). 
B MI will be c o m p ute d fr o m t h e pati e nt’s wei g ht a n d hei g ht. B MI s h o ul d be r o u n de d t o t he 
nearest w h ole n u m ber f or p ur p oses of I ncl usi o n C ri t eri o n [ 4]( Secti o n 6. 1 ). 
9. 1. 5. A p pr o pri at e n e s s of A s s e s s m e nt s 
Efficac y a n d safet y assess me nts i ncl u de d i n t his st u d y  are ge nerall y  re gar de d as relia ble a n d 
acc urate wit h res pect t o t he efficac y a n d safet y assess me nts i n i n di vi d uals a n d p o p ul at i o ns wit h 
T [ADDRESS_141910]. 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141911] u d y  si te pers o n nel  will  rec or d via e C R F t he occ urre nce a n d nat ure of eac h pat ie nt ’s 
pree xist i n g c o n dit i o ns, i ncl u di n g cli nicall y si g nifica nt si g ns a n d s y m pt o ms of t he disease u n der 
treat m e nt i n t he st u d y .  I n a d di ti o n, si te pers o n nel will rec or d a n y  c ha n ge i n t he c o n di ti o n(s) a n d 
a n y ne w c o n dit i o ns as A Es.  F o r eac h A E, t he o nset a n d d urati o n, t he seri o us ness a n d se verit y,  
a n d t he acti o ns ta ke n wit h res pect t o st u d y  tr e at m e nt will be rec or de d. I n vest i gat ors s h o ul d 
rec or d t heir assess me nt of t he p ote ntial relate d ness of eac h A E t o pr ot oc ol pr oce d ure a n d 
i n vesti gat i o nal pr o d uct via a n e C R F. 
Pr oce d ures a n d assess me nts perf or me d pri or t o Visit [ADDRESS_141912] u d y  pr oce d ure, ta ki n g i nt o acc o u nt t he 
di sease, c o nc o mita nt treat me nt , or pat h ol o gies. 
A “reas o na ble p ossi bilit y” mea ns t hat t here is a ca use a n d effect relat i o ns hi p bet wee n t he 
i n vesti gat i o nal pr o d uct, st u d y  de vice a n d/ or st u d y  pr oce d ure ,a n d t he A E. 
T he i n vest i gat or a ns wers yes/ n o w he n ma ki n g t his assess me nt. 
Pl a n ne d s ur geries a n d n o ns ur gical i nter ve nt i o ns s h o ul d n ot be re p orte d as A Es u nless t he 
u n derl yi n g me dical c o n dit i o n has w orse ne d d uri n g t he c o urse of t he st u d y .
If a patie nt ’s i n vesti gati o nal pr o d uct is disc o nti n ue d as a res ult of a n A E, st u d y site pers o n nel 
m us t re p ort t his t o Lill y  or i ts desi g nee via a n e C R F , cl arif yi n g, if p ossi ble, t he circ u msta nces 
lea di n g t o a n y  d osa ge m o dificati o ns or di sc o nt i n uati o ns of treat me nt. 
9. 2. 1. S eri o u s A d v er s e E v e nt s 
A n S A E is a n y  A E f r o m  t his st u d y  t hat res ul ts i n o ne of t he f o ll o wi n g o utc o m es: 
deat h 
i nit ial or pr ol o n ge d i n patie nt h os pi[INVESTIGATOR_90730] i o n
a life -t h reate ni n g e x perie nce (t hat is, i m me diate ris k of d yi n g) 
persiste nt or si g nifica nt disa bilit y/ i nca pacit y
c o n ge nital a n o ma l y/ birt h defect 
i m p orta nt me dical e ve nts t hat ma y n ot be i m me d iatel y life -t h reate ni n g or res ult i n 
deat h or h os pi[INVESTIGATOR_90730] i o n b ut m a y je o par dize t he patie nt or ma y  re q uire i nter ve nt i o n 
t o pre ve nt o ne of t he ot her o utc o mes liste d i n t he defi nit i o n a b o ve.  E xa m ples of 
s uc h m e dical e ve nts i ncl u de aller gic br o nc h os pas m re q uiri n g i nte nsi ve treat me nt 
i n a n e m er ge nc y r o o m  or at h o m e, bl o o d d y scrasias or c o n v ulsi o ns t hat d o n ot 
res ul t i n i n pat ie nt  h os pi [INVESTIGATOR_90730] i o n, or t he de vel o p me nt of dr u g de pe n de nc y  or dr u g 
a b use. 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141913], t h e S A E s h o ul d be re p orte d t o t he s p o ns or as per S A E -
re p orti n g re q uire me nts a n d t i meli nes (see Sect i o n9. 2 ) if it is c o nsi dere d reas o na bl y p ossi bl y 
r el ate d t o st u d y  pr oce d ure. 
St u d y  si te pers o n nel  m ust al ert Lill y or i ts desi g n e e of  a n y S A E wit hi n [ADDRESS_141914] u d y -s pecific S A E f or ms.  T his 
2 4 -h o ur n otificat i o n re q uire me nt refers t o t he i nit ial S A E i nf or mati o n a n d all f o ll o w- u p S A E 
i nf or m at i o n. Patie nts wit h a seri o us he pat ic A E s h o ul d ha ve a d dit i o nal data c ollecte d usi n g t he 
e C R F. 
Pre g na nc y ( d uri n g mater nal or pater nal e x p os ure t o i n vest i gat i o nal pr o d uct) d oes n ot meet t he 
defi nit i o n o f a n A E.  H o we ver, t o f ulfill re g ulat or y re q uire me nts, a n y pre g na nc y s h o ul d be 
re p orte d f o ll o wi n g t he S A E pr ocess t o c ollect data o n t he o utc o me f or b ot h m ot h er a n d fet us. 
I n vest i gat ors are n ot o bli gate d t o acti vel y see k A Es or S A Es i n pat ie nt s o nce t he y  ha ve 
di sc o nti n ue d a n d/ or c o m plete d t he st u d y  (t he pati e nt dis p osit i o n C R F has bee n c o m plete d).  
H o we ver, if t he i n vest i gat or lear ns of a n y S A E, i ncl u di n g a deat h, at a n y  ti me after a pati e nt has 
bee n disc har ge d fr o m t he st u d y  a n d he/s he c o nsi ders t he e ve nt reas o na bl y p ossi bl y  relate d t o t he 
st u d y  tr e at m e nt or st u d y  p arti ci pat i o n, t he i n vest i g at or m ust pr o m ptl y n otif y Lill y .
9. 2. 1. 1. S u s p e ct e d U n e x p e ct e d S eri o u s A d v er s e R e a cti o n s 
S us pecte d u ne x pecte d seri o us a d verse react i o ns ( S U S A Rs) are seri o us e ve nts t hat are n ot liste d 
i n t he I B a n d t hat t he i n vesti gat or i de nt ifies as relate d t o i n vesti gati o nal pr o d uct or pr oce d ure.  
U nite d States [ADDRESS_141915] i ve 2 0 0 1/ 2 0/ E C a n d t he 
ass oci ate d detaile d g ui da nces or nati o nal re g ulat or y  re q uire me nts i n parti ci pat i n g c o u ntries 
re q ui re t he re p orti n g of S U S A Rs. Lill y has pr oce d ures t hat will be f o ll o we d f or t he 
i de nt ificat i o n, rec or di n g a n d e x pe di te d re p orti n g of S U S A Rs t hat are c o nsiste nt wit h gl o bal 
re g ul at i o ns a n d t he ass ociate d detaile d g ui da nces. 
9. 2. 2. A d v er s e E v e nt sof S p e ci al I nt er e st 
9. 2. 2. 1. H y p o gl y c e mi a 
P ati e nts will  c ollect i nf or m at i o n o n e pi s o des of h y p o gl yce mia starti n g fr o m Visit [ADDRESS_141916] u d y  visi t (f ol l o w- u p v isit or E T visit ).  F or t hat p ur p ose, patie nts will be trai ne d a b o ut si g ns a n d 
s y m pt o ms of h y p o gl yce mia, h o w t o treat h y p o gl yce mia, a n d h o w t o c ollect a p pr o priate 
i nf or m at i o n f o r eac h e pis o de of h y p o gl yce mia i n t he st u d y  acc or di n g t o t he Sc he d ule of 
Act i vit ies ( Secti o n 2).  Si te pers o n nel will e nter t his i nf or mat i o n i nt o t he e C R F at eac h visit. 
I n vest i gat ors s h o ul d use t he f o ll o wi n g defi nit i o ns a n d criteria w he n dia g n osi n g a n d cate g orizi n g 
a n e pis o de c o nsi dere d t o be relate d t o h y p o gl yce mia (t he pl as ma gl uc ose [P G ]val ues i n t his 
sect i o n refer t o val ues deter mi ne d b y a la b orat or y  or I nter nati o nal Fe derat i o n of Cli nical 
I8F-MC-GPGL (b) Clinical Protocol Page 56
LY3298176Chemistry  and Laboratory  Medicine plasma -equival ent gl ucose m eters and strips) ( ADA2019a,
2019b):
Glucose alert value (Level 1):
Documented symptomatic hypoglycemia is defined as any time a pat ient feels 
thathe or she is experiencing symptoms and/or signs associated with 
hypoglycemia, and has a PG l evel of ≤70 mg/dL (≤3.9 mmo l/L).
Documented asymptomatic hypoglycemia is defined as any event not 
accompanied by [CONTACT_11017][INVESTIGATOR_10921], but with a measured PG 
≤70mg/dL (≤3.9 mmo l/L).
Documented unspecified hypoglycemia is define d as any  event wi th no 
inform ationabout sym ptoms of hypoglycemia available, but with a measured PG 
≤70 m g/dL (≤3.9 mmo l/L).
Clinically significant h ypoglycemia (Level 2):
Documented symptomatic hypoglycemia is defined as any time a pat ient feels 
thatheor she is experiencing symptoms and/or signs associated with 
hypoglycemia, and has a PG l evel of <54 m g/dL (<3.0 mmo l/L).
Documented asymptomatic hypoglycemia is defined as any event not 
accompanied by [CONTACT_11017][INVESTIGATOR_10921], but with a measured PG 
<54mg/dL (<3.0 mmo l/L).
Documented unspecified hypoglycemia is defined as any  event wi th no 
inform ationabout sym ptoms of hypoglycemia available, but with a measured PG 
<54 m g/dL (<3.0 mmo l/L).
Severe hypoglycemia (Level 3):
Severe hypoglycemia is defined as an epi[INVESTIGATOR_105399], 
glucagon, or other resuscitative act ions.  These epi[INVESTIGATOR_105400]. Blood gl ucose 
measurements may  not be available during such an event, but neurological 
recovery  attributable to the restoration of BG to normal is considered sufficient 
evidence that the event was induced by a low BG concentration.
Other hypoglycemia categories:
Nocturnal hypoglycemia is defined as any hypoglycemic event that occurs 
between bedtime and waking.
If a hypoglycemic event meets the criteria of severe, it needs to be recorded as serious on the AE 
CRF and reported to Lilly as an SAE.
To avoid duplicate reporting, all consecutive BG values ≤70 mg/dL (3.9 mmo l/L) occurring 
within 1- hour perio d may be considered to be a single hypoglycemic event (Weinberg et al.2010 ; 
Danne et al. 2013 ).  
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141917] of t he i nter ve nti o n be assesse d, a n d t he fre q ue nc y of h y p o gl yce mia be 
e val uate d.  T he r ole of dietar y  c ha n ges a n d p h ysic al  e xercise ( or a n y  ot her c o ntri b ut i n g fact or) i n 
t h e de vel o p me nt of a n e ve nt s h o ul d be esta blis he d.  T he patie nt s h o ul d recei ve a d dit i o nal 
e d ucati o n, if dee me d a p pr o priate.  Pl ease refer t o Secti o n 7. 4. 2. [ADDRESS_141918] i n all trials wit h ti rze pat i de i ncl u di n g t his trial.  
Ac ute pa ncreat it is is a n ac ute i nfla m mat or y pr ocess of t he pa ncreas t hat ma y als o i n v o l ve 
p eri pa ncreat ic tiss ues a n d/ or re m ote or ga n s y ste ms ( Ba n ks a n d Free ma n 2 0 0 6 ).  T he di a g n osis of 
ac ute pa ncreatit is re q uires 2 of t he f o ll o wi n g 3 fea t ures: 
a b d o mi nal pai n, c haracterist ic of ac ute pa ncreat itis  ( ge nerall y l ocate d i n t he 
e pi g astri u m a n d ra di ates t o t he bac k i n a p pr o xi matel y half t he cases 
[Ba n ks a n d Free ma n 2 0 0 6 ; K o iz u mi et al . 2 0 0 6 ]; t he pai n is o ft e n ass oc iate d wit h 
na usea a n d v o mit i n g) 
ser u m  a m ylase (t otal a n d/ or pa ncreatic) a n d/ or li pase ≥ 3 X U L N 
c haracterist ic fi n di n gs of ac ute pa ncreat it is o n c o m p ute d t o m o gra p h y  ( C T) sca n or 
ma g net ic res o na nce i ma gi n g ( M RI) 
If ac ute pa ncreat it is is s us pecte d, a p pr o priate la b orat or y  tests (i ncl u di n g le vels of pa ncreat ic 
a m ylase [ p -a m ylase] a n d li pase) s h o ul d be o btai ne d via t he ce ntral la b orat or y  (a n d l ocall y, if 
nee de d).  I m a gi n g st u di es, s uc h as a b d o mi nal C T sca n wit h or wit h o ut c o ntrast, M RI, or 
gall bla d der ultras o u n d, s h o ul d be perf or me d.  If la b orat or y val ues a n d/ or a b d o mi nal i ma gi n g 
s u p p ort t he dia g n osis of ac ute pa ncreat it is, t he patie nt m ust disc o nt i n ue t hera p y wi t h  
i n vesti gat i o nal pr o d uct(s) ,b ut will c o nt i n ue i n t he st u d y  o n a n ot her gl uc ose -l o weri n g re gi me n 
( details o n resc ue i nter ve nt i o n will be pr o vi de d).  T he m ost a p pr o priate dia betes t hera pe utic 
re gi me n will be deci de d b y t he i n vest i gat or, base d o n t he pati e nt’s cli nical stat us.  A re vie w of 
t h e pati e nt’s c o nc o mita nt me dicat i o ns s h o ul d be c o n d ucte d t o assess a n y p ote ntial ca usal 
r el at i o ns hi p wit h pa ncreat it is. 
Eac h case o f a n A E of pa ncreat it is m ust be re p orte d.  If t y pi[INVESTIGATOR_126147] g ns a n d/ or s y m pt o ms of 
pa ncreat it is are prese nt a n d c o nfir me d b y la b orat or y val ues (li pase or a m ylase [t otal a n d/ or 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e 5 8 
L Y 3 2 9 8 1 7 6 pa ncreat ic]) a n d i ma gi n g st u dies, t he e ve nt m ust be re p orte d as a n S A E.  F or a p ote ntial case t hat 
d oes n ot m eet all of t hese criteria, it is u p t o t he i n vesti gat o r t o deter mi ne t he seri o us ness of t he 
case ( A E or S A E) a n d t he relate d ness o f t h e e ve nt t o st u d y  dr u g(s). 
Eac h patie nt will ha ve meas ure me nts of  p -a m ylas e a n d li pase (assesse d at t he ce ntral la b orat or y ) 
as s h o w n o n t he Sc he d ule o f Act i vit ies ( Secti o n 2)t o assess t he effects of  t he i n vesti g ati o n al  
d oses of ti rze pati d e o n pa ncreat ic e nz y me le vels. S eri al  m eas ures of pa ncreat ic e nz y mes ha ve 
li mite d c li nical val ue f or pre dict i n g e pis o des of ac ute pa ncreatit is i n as y m pt o mat ic pat ie nt s 
(Na uc k et al. 2 0 1 7 ; Stei n ber g et al. 2 0 1 7a, 2 0 1 7 b ). T h us, f urt her dia g n ostic f o ll o w- u p of  cases 
of  as y m pt o m atic pa ncreat ic h y pere nz y me mia (li pase a n d/ or p -a m ylase ≥ 3 X U L N) is n ot 
ma n date d b ut ma y be perf or me d base d o n t he i n vesti gat or’s cli nical j u d g me nt a n d assess me nt of 
t h e pati e nt’s o verall cli nical c o n dit i o n. O nl y cases of pa ncreat ic h y pere nz y me mia t hat u n der g o 
a d di ti o nal  di a g n osti c f ol l o w- u p a n d/ or are acc o m pa nie d b y s y m pt o ms s u g gest i ve of pa ncreat it is 
will be s u b mitte d f or a dj u dicat i o n. 
All s us pecte d cases of ac ute or c hr o nic pa ncreat itis  will be a dj u dicate d b y  a n i n de pe n de nt 
cli nical e n d p o i nt  c o m mittee ( C E C).  I n a d dit i o n, A Es of se vere or seri o us a b d o mi nal pai n o f 
u n k n o w n et i ol o g y  will  als o be s u b mitte d t o t he a dj u dicat i o n c o m mit tee t o ass ess f or p ossi ble 
pa ncreat it is or ot her pa ncreatic disease. Rele va nt data fr o m patie nts wit h ac ute or c hr o nic 
pa ncreat it is a n d t h ose wit h se vere or seri o us a b d o mi nal pai n will be e ntere d i nt o a s pecificall y 
desi g ne d e C R F pa ge b y st u d y  si te or Lill y  st aff .T he a dj u dicat i o n c o m mittee re prese ntati ve will 
e nter t he res ults of a dj u dicat i o n i n a c orres p o n di n g e C R F pa ge. 
9. 2. 2. 4. T h yr oi d M ali g n a n ci e s a n d C -C ell H y p er pl a si a 
I n di vi d uals wit h pers o nal or fa mil y hist or y  of  M T C a n d/ or M E N- [ADDRESS_141919] as ms .
Ti rze pati d e s h o ul d be disc o nt i n ue d (after first c o nfir mi n g t he val ue) if p os tra n d o mizat i o n 
cal ci t o ni n val ue is ≥ 3 5 n g/ L a n d has i ncrease d at least 5 0 % o ver baseli ne.  A c o ns ultat i o n wi t h  a 
t h y r oi d s pecialist (if n ot a vaila ble, a n e n d ocri n o l o gist) s h o ul d be o btai ne d.   If t he i ncrease d 
cal ci t o ni n val ue ( ≥ 3 5 ng/ L a n d i ncreases b y ≥ 5 0 % c o m pare d wi t h baseli ne) is o bser ve d i n a 
pati e nt w h o has a d mi nistere d a me dicat i o n t hat i s k n o w n t o i ncrease ser u m calcit o ni n, t his 
me dicat i o n s h o ul d be st o p pe d a n d calcit o ni n le vels s h o ul d b e m eas ure d after a n a p pr o priate 
was h o ut peri o d.  If t he c o nfir me d calcit o ni n v al ue is < 3 5 ng/ L, ti rze pat i de s h o ul d be restarte d 
w he n it i s safe t o d o s o.  
9. 2. 2. 5. M aj or A d v er s e C ar di o v a s c ul ar E v e nt s 
Deat hs a n d n o nfatal C V A Es will be a dj u dicate d b y a c o m mittee of p h ysicia ns e xter nal t o Lill y 
wi t h  car di ol og y  e x pertise.  T he n o nfatal C V A Es t o be a dj u dicate d i ncl u de t he f oll o wi n g:   
m y ocar dial  i nfarct i o n
h os pi [INVESTIGATOR_1314] o n f or u nsta ble a n gi na 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e 5 9 
L Y 3 2 9 8 1 7 6 h os pi [INVESTIGATOR_1314] o n f or heart fail ure 
c or o nar y  i nt er ve nt i o ns (s uc h as c or o nar y  arter y  b y pass graft or perc uta n e o us c or o nar y  
i nt er ve nt i o n) 
cere br o vasc ular e ve nts, i ncl u di n g cere br o vasc ular acci de nt (str o ke ) a n d tra nsie nt 
isc he mic attac k 
9. 2. 2. 6. S u pr a v e ntri c ul ar Arr h yt h mi a s a n d C ar di a c C o n d u cti o n Di s or d er s 
Treat me nt -e mer ge nt car diac c o n d ucti o n dis or ders will be f urt her e val uate d.  Patie nt s w h o 
de vel o p a n y e ve nt fr o m t h is gr o u p of di s or ders s h o ul d u n der g o a n E C G ,w hic h s h o ul d be 
s u b mitte d t o t he ce ntral rea di n g ce nter. A d dit i o nal dia g n ostic tests t o deter mi ne e xact dia g n osis 
s h o ul d be perf or m e d, as nee de d. T he s pecific dia g n osis will be rec or de d as a n A E. E ve nts t hat 
meet criteria f or seri o us c o n diti o ns as descri be d i n Secti o n 9. 2. [ADDRESS_141920] u g(s) vi a a C R F create d f or t his p ur p ose.  A d dit i o nal sa m ples s h o ul d als o be c o llecte d as 
o utli ne d i n Sect i o n 9. 4. [ADDRESS_141921] u g(s) s h o ul d be te m p oraril y i nterr u pte d i n a n y i n di vi d ual 
s us pecte d of ha vi n g a se vere or seri o us aller gic reacti o n t o t h e st u d y  dr u g(s).  St u d y  dr u g(s) m a y 
be restarte d w he n/if it is safe t o d o s o, i n t he o pi [INVESTIGATOR_9384] o n o f t h e i n vest i gat or.  If st u d y dr u g(s) is 
p er m a ne nt l y disc o nt i n ue d, t he patie nt will recei ve a n ot her gl uc ose -l o weri n g treat m e nt, j u d ge d b y 
t h e i n vest i gat or t o be a p pr o priate base d o n t he patie nt’s cli nical stat us, a n d will c o nt i n ue i n t he 
tri al  t o c ollect a ll pla n ne d ef ficac y a n d safet y me as ure m e nts. 
9. 2. 2. 7. 1. I nj e cti o n Sit e R e a cti o n s 
I nject i o n site reacti o ns will be c o llecte d o n t he e C R F se parate fr o m t he h y perse nsit i vit y react i o n 
e C R F.  At t he ti me of A E occ urre nce i n t he tirze pati de gr o u p, sa m ples will be c o llecte d f or 
meas ure me nt of tirze pat i de a nt i- dr u g b o dies ( A D A s) a n d tirze pat i de c o nce ntrati o n. 
9. 2. 2. 7. 2. A nti -Dr u g A nti b o di e s 
T he occ urre nce of A D A f or mat i o n will be assesse d as o utli ne d i n Secti o n 9. 4. 4 .
9. 2. 2. 8. Di a b eti c R eti n o p at h y C o m pli c ati o n s 
Dilate d reti nal f u n d os c o pi [INVESTIGATOR_126148] i o n will be perf or me d b y  a q ualifie d e ye care pr ofessi o nal 
( o p ht hal m o l o gist or o pt o metrist) f or all patie nts bet wee n Visit 2 a n d Visit 3 t o e xcl u de patie nts 
wi t h  pr oliferat i ve ret i n o pat h y  a n d/ or m a c ul o p at h y .  T he res ul ts f r o m  t his e xa mi nat i o n will be 
rec or de d o n a s pecific reti n o pat h y  e C R F as a baseli ne meas ure of reti n o pat h y .  
A f o ll o w- u p dilate d f u n d os c o pi [INVESTIGATOR_126148] i o n s h o ul d be perf o r m e d b y a q ualifie d e y e care 
pr of essi o nal ( o p ht hal m o l o gist or o pt o m etrist) w he n cli nicall y i n dicate d b y a n y A E s us pecte d of 
w orse ni n g reti n o pat h y , a n d t he fi n di n gs s h o ul d be rec or de d o n t he reti n o pat h y  e C R F.  
9. 2. 2. 9. H e p at o bili ar y Di s or d er s 
All e ve nts of T E biliar y  c o lic, c h o lec yst it is, or ot h er s us pecte d e ve nts relate d t o gall bla d der 
di sease s h o ul d be e val uate d a n d a d dit i o nal dia g n ostic tests perf or me d, as nee de d. I n cases of 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141922] i o n 9. 4. 5. 1 a n d 
A p pe n di x 4 .
9. 2. 2. 1 0. S e v er e G a str oi nt e sti n al A d v er s e E v e nt s 
Ti rze pati d e m a y ca use se vere GI A Es, s uc h as na usea, v o mit i n g, a n d diarr hea.  I nf or mat i o n 
a b o ut se vere GI A Es as well as a ntie metic/a nti diarr heal use wil l be c o llecte d i n t he e C R F.  F or 
detaile d i nf or mat i o n c o ncer ni n g t he ma na ge me nt of GI A Es, please refer t o Secti o n 7. 4. 2. [ADDRESS_141923] i ve o f ac ute or w orse ni n g of c hr o nic re nal fail ure .  Gastr oi ntesti nal 
A Es ha ve bee n re p orte d wit h t ir ze pat i de, i ncl u di n g na usea, diarr hea, a n d v o m it i n g.  T hese are 
c o nsiste nt wit h ot her G L P -1 rece pt or a g o nists ( Ar o da a n d Rat ner 2 0 1 1 ).  T he e ve nts ma y lea d t o 
de h y drat i o n, w hic h c o ul d ca use a deteri orati o n i n re nal f u ncti o n, i ncl u di n g ac u te re nal  f ail ure.  
P ati e nts s h o ul d be a d vise d t o n otif y i n vest i gat ors i n case of se vere na usea, fre q ue nt v o mit i n g, or 
s y m pt o ms of de h y drat i o n. 
9. 2. 2. 1 2. M et a b oli c A ci d o si s, In cl u di n g Di a b eti c K et o a ci d o si s 
Ket oaci d osis, a seri o us life -t h reate ni n g c o n dit i o n re q uiri n g ur ge nt h os pi [INVESTIGATOR_90730] i o n, has bee n 
re p orte d rarel y  i n patie nts wi t h  T 2 D M.  Pati e nts w h o prese nt wit h si g ns a n d s y m pt o ms c o nsiste nt 
wi t h  se vere meta b olic aci d osis s h o ul d be assesse d f or ket oaci d osis re gar dless of prese nt i n g B G 
le vels, as ket oaci d osis ma y be p rese nt e ve n if B G le vels are less t ha n 2 5 0 m g/ d L.  Treat me nt of 
ket oaci d osis ma y  re q uire i ns uli n, fl ui d ,a n d car b o h y drate re place me nt.   R o ut i ne bicar b o nate 
assess me nt will be perf or me d d uri n g t he c o urse of t he st u d y .  If  l act ic aci d osis is s us pecte d, 
met f o r mi n s h o ul d be te m p oraril y disc o nt i n ue d u ntil t he res o l ut i o n of t he e ve nt. 
9. 2. 2. 1 3. A m p ut ati o n/ P eri p h er al R e v a s c ul ari z ati o n 
All cases of a m p utati o n a n d peri p heral re vasc ularizati o n s h o ul d be re p orte d as a n A E. 
9. 2. 2. 1 4. M aj or D e pr e s si v e Di s or d er/ S ui ci d al I d e ati o n 
T he pre vale nce of de pressi ve s y m pt o ms a n d dis or ders is i ncrease d i n patie nts wit h T 1 D M or T 2 D M 
( A D A 2 0 1 9a).  A n y A E of maj or de pressi ve dis or der or s uici dal i deati o n s h o ul d be re p orte d. 
9. 2. 3. C o m pl ai nt H a n dli n g 
Lill y c o llects pr o d uct c o m plai nts o n i n vest i gat i o nal pr o d ucts a n d dr u g deli ver y s yste ms use d i n 
cli nical st u dies i n or der t o e ns ure t he safet y of  st u d y  p arti ci pa nts, m o ni t or q uali t y , a n d t o 
facilitate pr ocess a n d pr o d uct i m pr o ve me nts. 
P ati e nts will be i nstr ucte d t o c o ntact t he i n vesti gat or as s o o n as p ossi ble if he o r s he has a 
c o m plai nt or pr o bl e m wi t h  t he i n vest i gat i o nal pr o d uct s o t hat t he sit uati o n ca n be assesse d. 
9. 3. Tr e at m e nt of O v er d o s e 
St u d y  dr u g o ver d ose ( m ore t ha n t he s pecifie d n u m ber of i njecti o ns) will be re p orte d as a n A E.  
I n t he e ve nt of o ver d ose, ref er t o t h e I B f or tirze pati de or t he Pr o d uct La bel f or se ma gl ut i de, as 
a p plica ble (Oze m pic ®U S PI [ W W W] ). 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e 6 1 
L Y 3 2 9 8 1 7 6 9. 4. S af et y 
9. 4. 1. El e ctr o c ar di o gr a m s 
F or eac h patie nt, E C Gs s h o ul d be c o llecte d acc or di n g t o t he Sc he d ule of Acti vit ies ( Secti o n 2). 
E C Gs s h o ul d be p erf or me d af t er vi t al  si g ns are c ollecte d a n d pri or t o t he c o llect i o n of bl o o d 
sa m ples f or la b orat or y  testi n g if t he pat ie nt  is n ot a d versel y affecte d b y  t h e f asti n g c o n di ti o n .
P ati e nts s h o ul d be s u pi [INVESTIGATOR_050] f or a p pr o xi matel y  [ADDRESS_141924] u d y -s pecific rec o m me n dati o ns .  
Electr ocar di o gra ms will i nit iall y  b e i nter prete d b y  a q ualifie d p h ysicia n (t he i n vesti gat or or 
q ualifie d desi g nee) at t he site as s o o n after t he ti me of E C G c ollecti o n as p ossi ble, a n d i deall y  
w hile t he pati e nt i s st ill prese nt, f or i m me diate patie nt ma na ge me nt, s h o ul d a n y cli nicall y 
r el e va nt fi n di n gs be i de ntifie d .  A n y cli nicall y si g nifica nt fi n di n gs fr o m E C Gs t hat res ult i n a 
di a g n osis a n d t hat occ ur after t h e pati e nt recei ves t he first d ose of t he i n vest i gat i o nal treat me nt 
s h o ul d be re p orte d t o Lill y or its desi g nee as a n A E vi a t he e C R F. 
All di gital E C Gs will be o btai ne d usi n g ce ntrall y pr o vi de d E C G mac hi nes a n d will be 
el e ctr o ni call y tra ns mitte d t o a desi g nate d ce ntral E C G la b orat or y .T he ce ntral E C G la b orat or y  
will perf or m a basic q ualit y c o ntr ol  c hec k ( f o r e xa m ple , d e m o gra p hics a n d st u d y  details) a n d 
t h e n st ore t he E C Gs i n a data base. At  a f ut ure ti me, t he st ore d E C G data ma y be o verrea d b y a 
car di ol o gi st at t he ce ntral  E C G l a b orat or y  f or f urt her e val uat i o n of mac hi ne -rea d meas ure me nts 
or t o m eet re g ul at or y  r e q ui re me nt s. T he m ac hi ne -rea d E C G i nter vals a n d heart rate ma y be use d 
f o r data a nal ysis a n d re p ort writ i n g p ur p oses, u nless a car di ol o gist o verrea di n g of t he E C Gs is 
c o n d ucte d pri or t o c o m plet i o n of t he fi nal st u d y  re p ort (i n w hic h case, t he o verrea d data w o ul d 
be use d). 
9. 4. 2. Vit al Si g n s 
Vi t al  si g n m eas ure me nts s h o ul d be ta ke n bef ore o btai ni n g a n E C G traci n g a n d bef ore c ollect i o n 
of  bl o o d s a m pl es f or l a b orat or y  testi n g, at vi si ts w here re q ui re d.  T he parti ci pa nt s h o ul d si t 
q ui et l y f o r [ADDRESS_141925] i vit ie s ( Secti o n 2) a n d 
f o ll o wi n g t he st u d y -s peci fic rec o m me n dati o ns. 
A n y cli nicall y  si g nifica nt fi n di n gs fr o m vital si g n meas ure me nt st h at res ul t i n a dia g n osi s a n d 
t h at occ ur after t h e pati e nt recei ves t he first d ose of st u d y  tr e at m e nt s h o ul d be re p orte d t o Lill y or 
it s desi g nee as a n A E via e C R F. 
9. 4. 3. L a b or at or y T e st s 
F or eac h patie nt, la b orat or y  tests detaile d i n A p pe n di x [ADDRESS_141926] i vit ies ( Secti o n 2). 
U nless ot her wise n ote d i n A p pe n di x [ADDRESS_141927] i gat or wit h t he 
res ul ts of  l a b orat or y  tests a nal yze d b y  a ce ntral  ve n d or if a ce ntral ve n d or is use d f or t he cli nical 
tri al .  
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141928] i vit ies ( Secti o n 2). 
At  t he visit s a n d t i mes s pecifie d i n t he Sc he d ule of Act i vit ie s ( Secti o n 2), ve n o us bl o o d sa m ples 
wi ll be c o llecte d t o deter mi ne a nt i b o d y  pr o d ucti o n a gai nst ti rze pat i de .  T o i nt er pret t he res ults of 
i m m u n o ge nicit y,  a P K sa m ple will be c o llecte d at t he sa me t i me p oi nts as t he i m m u n o ge nicit y 
sa m ple .  All sa m ples f or i m m u n o ge nicit y s h o ul d be ta ke n bef ore d o se w he n a p plica ble a n d 
p ossi ble.  I n t he e ve nt of dr u g h y perse nsi ti vi t y  r e a cti o ns (i m me diate or n o n i m me diate ), 
a d di ti o nal  sa m ples will  b e c ollecte d (i ncl u di n g A D A, P K, a n d e x pl orat or y  i m m u ne safet y 
sa m ple) as cl ose t o t he o nset of t he e ve nt as p ossi ble, at t h e res ol uti o n of  t he e ve nt, a n d [ADDRESS_141929] i o n a n d ha n dli n g of bl o o d sa m ples 
will be pr o vi de d b y t he s p o ns or.  Sa m ple c o llecte d at Visit 8 0 1 will assess i m m u n o ge nicit y at 
was h o ut of ti rze pat i de ( [ADDRESS_141930] e n d of treat me nt). 
Treat me nt -e mer ge nt A D As are defi ne d i n Sect i o n 1 0. 3. 5 .
S a m ples wi t h  ti rze pat i de A D A detecte d will be titere d a n d e val uate d f or t heir a bilit y t o ne utralize 
t h e acti vit y of  assi g ne d treat m e nt ( ti rze pati d e -ne utralizi n g a nt i b o dies).  Sa m ples wi t h  ti rze pat i de 
A D A detecte d will als o be teste d f or cr oss -reacti ve bi n di n g t o nati ve GI P a n d G L P -1, a n d, if 
s uc h i s detecte d, t he n f o r ne utralizi n g a nt i b o dies a gai nst nati ve GI P a n d G L P - 1. 
S a m ples will  b e retai ne d f or a m a xi m u m  of  [ADDRESS_141931] u d y  p ati e nt e x perie nces ele vate d A L T ≥ 3 X U L N, A L P ≥ 2 X U L N, or ele vate d T B L ≥ 2 X 
U L N, li ver testi n g ( A p pe n di x 4 ) s h o ul d be re peate d wi t hi n [ADDRESS_141932] i gat or a n d i n 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141933] u d y  m e dical m o nit or.  M o ni t ori n g of  A L T, A S T, T B L, a n d A L P s h o ul d 
c o nti n ue u ntil le vels n or malize or ret ur n t o a p pr o xi mate baseli ne le vels. 
He p atic S afet y D at a C ollecti o n 
A d dit i o nal safet y data s h o ul d be c o llecte d via t he e C R F if 1 or m ore of t he f o ll o wi n g c o n di ti o ns 
occ ur: 
Ele vat i o n o f ser u m  A L T t o ≥ 5 X U L N o n 2 or m ore c o nsec uti ve bl o o d tests 
Ele vat i o n of ser u m T B L t o ≥ 2 X U L N (e xce pt f or cases of k n o w n Gil bert’s 
s y n dr o me) 
Ele vat i o n of ser u m A L P t o ≥ 2 X U L N o n 2 or m ore c o nsec uti ve bl o o d tests 
P ati e nt disc o nt i n uat i o n fr o m treat me nt d ue t o a he patic e ve nt or a b n or malit y 
of  l i ver tests 
He pati c e ve nt c o nsi dere d t o be a n S A E 
9. 5. P h ar m a c o ki n eti c s 
A P K sa m ple will be c ollecte d at t he sa me ti me p oi nts as t he i m m u n o ge nicit y sa m ple per t he 
St u d y  Sc he d ule o f Act i vit ies ( Sect i o n2). All sa m ples f or P K assess me nt s h o ul d be ta ke n 
pre d ose. 
C o nce ntrati o ns of tirze pat i de will be assa ye d usi n g a vali date d li q ui d c hr o mat o gra p h y  m ass 
s pectr o metr y  m et h o d. 
Bi oa nal y ti c al  sa m ples c ollecte d t o m eas ure ti rze pati de c o nce ntrati o ns will be retai ne d f or a 
ma xi m u m o f [ADDRESS_141934] e ( s) f or P h ar m a c o g e n eti c R e s e ar c h 
A w h o le bl o o d sa m ple will be c o llecte d f or p har mac o ge net ic a nal ysis as s pecifie d i n t he 
Sc he d ule of Act i vit ies ( Secti o n 2) w here l o c al  re g ulat i o ns all o w.   
S a m ples will  n ot be use d t o c o n d uct u ns pecifie d disease or p o p ulat i o n ge net ic researc h eit her 
n o w or i n t he f ut ure.  Sa m ples will be use d t o i n vesti gate varia b le res p o nse t o tirze pat i de a n d t o 
i n vesti gate ge net ic varia nts t h o u g h t t o pl a y a r ol e i n T [ADDRESS_141935] u d y  or f or a s h orter peri o d if l o cal  re g ulat i o ns a n d/ or 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e 6 4 
L Y 3 2 9 8 1 7 6 E R Bs/I R Bs i m p ose s h orter ti me li mits.  T his rete nti o n peri o d e na bles use of ne w tec h n o l o gi es, 
res p o nse t o re g ulat or y  q uest i o ns, a n d i n vest i gat i o n of varia ble res p o nse t hat ma y n ot be o bser ve d 
u nt il later i n t he de vel o p me nt  of tirze pat i de or after tirze pat i de bec o me(s) c o m merciall y 
a vaila ble. 
M olec ular tec h n o l o gi es are e x pecte d t o i m pr o ve d uri n g t he [ADDRESS_141936] i o n, varia bilit y of  p ati e nt res p o nse (i ncl u di n g safet y ), a n d 
cli nical o utc o me.  Sa m ple c o llect i o n is i nc or p orate d i nt o cli nical st u dies t o e na ble e xa mi nat i o n of 
t h ese q uest i o ns t hr o u g h meas ure me n t of  bi o m ol e c ul es ,i ncl u di n g D N A, R N A, pr otei ns, li pi [INVESTIGATOR_805], 
a n d ot her cell ular ele me nts. 
S er u m  a n d plas ma sa m ples f or bi o mar ker researc h will be c o llecte d at t he ti mes s pecifie d i n t he 
Sc he d ule of Act i vit ies ( Secti o n 2)w here l ocal re g ulat i o ns all o w. 
S a m ples will  b e use d f or researc h o n t he dr u g tar get, disease pr ocess, varia ble res p o nse t o 
ti rze pati de, pat h wa ys ass ociate d wit h T 2 D M, mec ha nis m o f acti o n of  ti rze pat i de, a n d/ or researc h 
met h o d or i n vali dat i n g dia g n ost ic t o ols or assa y(s) relate d t o T [ADDRESS_141937] i o n naires will be c o m plete d b y t he patie nts at s pecific cli nic visit s acc or di n g 
t o t he Sc he d ule of E ve nts ( Secti o n 2). At t hese visits, t he q uesti o n naires s h o ul d be c o m p lete d 
bef ore t he patie nt has disc usse d t heir me dical c o n dit i o n or pr o gress i n t h e st u d y  wi t h  t he 
i n vesti gat or a n d/ or site staff a n d bef ore a n y ot her st u d y  pr oce d ures if t he pat ie nt  is n ot a d versel y 
affecte d b y  t heir fast i n g c o n dit i o n. 
9. 9. 1. Di a b et e s Tr e at m e nt S ati sf a cti o n Q u e sti o n n air e 
T he stat us (s) a n d c ha n ge (c) versi o ns of t he D T S Q will be use d d uri n g t he st u d y  t o assess t he 
pati e nt ’s sat isfacti o n wit h t heir dia betes treat me nt a n d t he percei ve d fre q ue nc y o f h y per gl yce mia 
a n d h y p o gl yce mia.  T he q uesti o n naire c o ntai ns 8 ite ms ( Bra dle y 1 9 9 4).  Eac h ite m is rate d o n a 
7-p oi nt Li kert scale.  Si x it e m s ( 1 a n d 4 t hr o u g h 8) are s u m me d t o pr o d uce a meas ure of 
I8F-MC-GPGL (b) Clinical Protocol Page [ADDRESS_141938] ion ranging fro m 0 “very  dissat isfied” to 6 “very sat isfied.”  The remaining 
2items (2 and 3) are treated individually .  Item  2 measures the perceived frequency  of 
hypergl ycemia on a scale ranging fro m 0 “none of the time” to 6 “most of the time,” and Item [ADDRESS_141939] ion (3 “much more satisfied now” to - 3 “much less 
satisfied now”) .
9.9.2. Impact of Weight on Self -Perception Questionnaire
The IW -SP questi onnaire contains 3 items that assess how often the patients’ body  weight affects 
how happy  they are wi th their appearance and how often they  feel self -conscious when out in 
public (Hayes and DeLozier 2015 ).  Each i tem is rated on a 5 -point scale ranging fro m “always” 
to “never.”  Total scores for the IW -SP are derived by  [CONTACT_10621] i tem scores and dividing by  
[CONTACT_63312].  The score can also be transformed to a range fro m 0to100.  Higher IW -SP 
scores correspond to better self -percept ion (Hay es and DeLozi er 2015 ).
9.9.3. Ability to Perform Physical Activities of Daily Living
The APPADL quest ionnaire conta ins [ADDRESS_141940] ivities considered to be integral to normal daily life, such as walking, standing, and 
climbing stairs (Hay es et al . 2012 ).  Item s are scored on a 5 -point numeric rating scale, where 
5 =“not at all difficult” and 1 =“unable to do.”  A raw overall score is calculated by [CONTACT_126162] 7 i tems, and a transformed overall score is obtained by [CONTACT_126163] a 0 to 100 scale.  A higher raw overall score and a higher 
transformed overall score are indicat ive of better abilit y to perform  activities o f daily living.  
9.9.4. European Quality of Life 
Generic healt h-related quali ty of life will be assessed using the EQ -5D- 5L 
(EuroQoL Group 2015).  The EQ -5D- 5L is a standardized 5 -item instrument for use as a 
measure of health outcome.  It provides a simple descript ive profile and a single index value for 
healt h status that can be used in the clinical and economic evaluat ion of health care as well as 
popul ation health surveys.  The EQ -5D- 5L com prises 5 dimensions of healt h (mobilit y, self -care, 
usual act ivities, pain /discomfort, and anxiet y/depressi on).  The 5L versio n, introduced in 2005, 
scores each dimensio n at 5 levels (no problems, slight problems, moderate problems, severe 
probl ems, and unable to perform/extreme problems), for a total of 3125 possible healt h states.  In 
addition to the health profile, a single healt h state i ndex value can be derived based on a formula 
that attaches weights to each of the levels in each dimensio n. This index value ranges between 
less than 0 (where 0 is a healt h state equivalent to death; negat ive values are valued as worse 
than dead) and 1 (perfect health).   In addition, the EQ Visual Analog Scale records the 
respondent’s self -rated heal th status on a verti cal graduated (0 to 100) visual analog scale.  In 
conjunction with the heal th state data, it provides a composite pi[INVESTIGATOR_10905]’s healt h 
status.
I8F-MC-GPGL (b) Clinical Protocol Page 66
LY3298176The EQ -5D- 5L is used worldwide and is available in more than 130different languages.  Details 
on the instrument, and scoring, organizing, and presenting the data collected c an be found in the 
EQ-5D- 5L User Guide (EuroQoL Group 2015).
9.9.5. Impact of Weight on Quality of Life -LiteClinical Trials Version
The IWQOL -Lite-CT is a 20 -item, obesi ty-specific patient -reported outcome (PRO) instrument 
developed for use in obesit y clinical tri als. It assesses 2 primary  dom ains of obesit y-related 
healt h-related qualit y of life :  physical (7 items), and psychosocial (13 items). A 5-item subset of 
the physical do main –the physical funct ion composite is also supported. Items in the physical 
funct ion composite describe physical impacts related to general and specific physical act ivities. 
All items are rated on ei ther a 5 -point fre quency ( “never ”to “always ”) scale or a 5 -point truth 
(“not at all true” to “completely true ”) scal e (Ko lotkin et al. 2017 , 2018).
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141941] e Si z e D et er mi n ati o n 
A p pr o xi mat el y 1 8 7 2 pat ie nt s( 4 6 8 per gr o u p) will be ra n d o m l y assi g ne d i n a 1: 1: 1: 1 rati o t o 
ti rze pat i de 5 m g, 1 0 m g, 1 5 m g Q W , or se m a gl ut i d e1 m gQ W .  Patie nt ra n d o mizati o n will be 
stratifie d base d o n c o u ntr y  a n d baseli ne H b A 1c ( ≤8. 5 % or >8. 5 % [ 6 9 m m o l/ m o l]) . 
T he tri al  i s p o were d t o assess n o ni nferi orit y of  ti rze pati de 1 0 m g a n d/ or tirze pat i de 1 5 m g Q W t o 
se ma gl uti de 1 m g Q W , r el at i ve t o t he pri mar y e n d p oi nt:  mea n c ha n ge i n H b A 1c fr o m baseli ne 
t o 4 0 wee ks .  
The p o wer i s assesse d base d o n t he f o ll o wi n g ass u m pt i o ns:  
eac h of t he [ADDRESS_141942] se m a gl uti d e 1 m g Q W at 2 -si d e d 0. 0 2 5 si g nifica nce le vel 
use of [ADDRESS_141943] utilizi n g H b A 1c data c ollecte d bef ore i nit iati o n o f a n y resc ue 
me dicat i o n or pre mat ure treat me nt disc o nti n uati o n wit h n o m ore t ha n 2 8 % of  patie nts 
i nit iat i n g a n y resc ue me dicat i o n or pre mat ure treat me nt disc o nt i n uat i o n i n eac h treat me nt 
gr o u p 
n o differe nce bet wee n tirze pati de d oses a n d se ma gl ut i de 1 m g relat i ve t o t he pri mar y 
e n d p oi nt 
a n o ni nferi orit y mar gi n o f 0. 3 % ,a n d 
a c o m m o n sta n dar d de viat i o n ( S D) of 1. 1 %.  
O n t he basis of t hese ass u m pt i o ns, ra n d o ml y assi g ni n g a p pr o xi matel y 1 8 7 2 patie nts t o t he 
4treat m e nts usi n g a 1: 1: 1: [ADDRESS_141944] 9 0 % p o wer t o de m o nstrate n o ni nferi orit y  
of  ti rze pat i de 1 0 m g a n d/ or 1 5 m g Q W  d oses t o se ma gl ut i de 1 m g Q W , rel at i ve t o t he pri mar y 
e n d p o i nt f o r t he “efficac y ”est i ma n d .  F urt her m ore, t hi s sa m ple size will e ns ure 9 0 % p o wer t o 
d e m o nstrate n o ni nferi ori t y  f o r t he “treat m e nt -re gi me n ”est i ma n d c o n d ucte d usi n g a n a nal ysis of 
c o vari a nce ( A N C O V A) utilizi n g all a vaila ble H b A 1c data at 4 0 wee ks . M issi n g data will be 
i m p ute d wit h a c o nser vat i ve m ult i ple i m p utati o n met h o d (as descri be d i n Sect i o n 1 0. 3. 3 ) if S D 
were t o i ncrease u p t o 1. 3 %d ue t o t he i ncl usi o n of data o n resc ue me dicat i o ns, i ncl usi o n of data 
af ter pre m at ure treat m e nt disc o nt i n uat i o n, a n d i m p utati o n of t h e missi n g data.  
I8F-MC-GPGL (b) Clinical Protocol Page 68
LY329817610.2. Populations for Analyses
For purposes of the analys es, the fo llowing popul ations are defined:
Populati on Description
Screened patients All participants who sign informed consent
Random lyassigned patients All patients who are randomly assigned to a treatment group
Modified intent -to-treat (mITT) 
populatio nAll randomly assigned patients who are exposed to at least 1 dose of study 
drug.  In the event of a treatment error, patients will be analyzed according to 
the treatment they were random lyassigned to .
Efficacy analysis set (EAS) Data obtained during Study Period II from the mITT popu lation, excluding 
data after initiating rescue antihyperglycemic medication or stoppi[INVESTIGATOR_126149].
Full analysis set (FAS) Data obtained during Study Period II from the mITT population, regardless of 
adherence to study drug or initiation of rescue antihy pergly cemic medication .
Safety analy sis set (SS) Data obtained during Study Period II or III from the mITT population, 
regardless of adherence to study drug or initiation of rescue antihyperglycemic 
medication.
10.3. Statistical Analyses
10.3.1. General Statistical Considerations
Statistical analysis o f this study  will be the responsibilit y ofLilly o r its desi gnee.   Any change to 
the data analysis methods described in the protocol will require an amendment ONLY if it 
changes a principal feature of the protocol.  Any other change to the data analysis methods 
described in the protocol, and the just ificat ion for making the change, will be described in the
statist ical analysis plan (SAP) or the clinical study  report .  Addit ional exploratory  analyses o f the 
data maybe co nducted as deemed appropriate.
Unless otherwise noted, all tests of treatment effects will be conducted at a 2 -sided alpha level o f 
0.05, and the confidence interval (CI) will be calculated at 95%, [ADDRESS_141945] estimand, “efficacy ,” represents efficacy  prior to di scont inuat ion of study  
drug wi thout confounding effect s of antihyperglycemic rescue therapy .  The s econd est imand, 
“treatm ent-regimen ,” represents the efficacy irrespective of adherence to study  drug or i nitiation 
of rescue ant idiabeti c drugs.
The primary  efficacy  assessment for change fro m baseline in HbA1c, guided by  [CONTACT_941] “efficacy” 
estimand, will be conducted using the efficacy analysis set (EAS).  The primary efficacy 
assessment, guided by  [CONTACT_941] “treatm ent-regimen” estimand, will be conducted using the full 
analysis set (FAS) .  As they  are intended for differ ent purposes, no mult iplicity adjust ments will 
be made for conducting 2 primary efficacy assessments relat ive to the “efficacy ”and “treatm ent-
regimen ”estimands.
Unless specified otherwise, safet y assessments will be guided by  [CONTACT_126164] 
I8F-MC-GPGL (b) Clinical Protocol Page 69
LY3298176antihyperglycemic rescue therapy.  Thus, safety analysis will be conducted using the safet y 
analysis set (SS).   Selected safet y analyses may  be conducted after excluding data on rescue 
therapy  or data after starting another antihyperglycemic medicat ion.
Summary  statistics for continuous m easures will  include sample size, mean, SD, median, 
minimum, and maximum.  The analysis model to make co mpar isons amo ng treatme nt groups 
relative to continuous measurements assessed over time will be a mixed -effect smodel for 
repeated m easures (MMRM) with terms for: 
treatm ent 
visit
treatm ent-by-visit interaction 
country  
baseline HbA1c category (≤8.5% or >8.5% [69 m mol/mol]), and
baseline measurement as a covariate.  
For analyses wit h HbA1c, the baseline HbA1c category  will not be incl uded in the m odel.  An 
unstructured covariance structure will model the relat ionship of wit hin-patient errors.
The Kaplan -Meier m ethod will be u sed for estimatio n of cumulative event -free survival rates 
over time, and Cox proporti onal hazards regressio n analysis will be used to compare hazard rates 
among treatm ents.
Summary  statistics for categorical measures (including categorized continuous meas ures) will 
include sample size, frequency, and percentages.  Fisher’s exact test will be used to examine the 
treatm ent difference in categorical outcomes.  Logistic regression may  be used to examine the 
treatm ent difference in binary  efficacy  outcomes.  Th e negative bino mial regressio n model will 
be used for the treatment comparison of discrete count measures if deemed appropriate.
Other stati stical methods may be used, as appropriate, and details will be documented in the 
SAP.
10.3.2. Treatment Group Comparability
[IP_ADDRESS]. Patient Disposition
Frequency counts and percentages of all pat ients screened, rando mly assigned , and receiving at 
least [ADDRESS_141946] ing of rando mlyassigned 
patients not receiving study  drug will  be provi ded.  Of the patients in the mITTset, frequency, 
counts, and percentages of patients complet ing the study; prematurely discont inuing the study 
including the reason for premature discont inuat ion; and prem aturely  discontinuing study  drug 
including the reason for premature discont inuat ion of study  drug will be presented by [CONTACT_98540].  A Kaplan -Meier analyses o f time fro m rando mizat ion to prem ature di scont inuat ion from 
study  and prem ature di scont inuat ion from study  drug by  [CONTACT_126165]. 
[IP_ADDRESS]. Patient Characteristics
Dem ographics, medical history , and conco mitant illness will be summarized by [CONTACT_126166].
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141947] 7 5 % of re q uire d 
i nject i o ns o f st u d y  dr u gs.  O verall treat me nt c o m plia nce f or eac h pat ie nt  will be c o m p ute d b y t he 
n u m ber of i njecti o ns di vi de d b y  t he t otal  pl a n ne d n u m ber of i njecti o ns t he patie nt s h o ul d ta ke 
d uri n g t he st u d y .  Fre q ue nc y c o u nts a n d perce nta ges of patie nts c o m plia nt t o st u d y dr u g wil l be 
s u m marize d b y  tr e at m e nt gr o u ps usi n g t he mI T T p o p ulat i o n. 
1 0. 3. 3. Effi c a c y A n al y s e s 
1 0. 3. 3. 1. Pri m ar y A n al y s e s 
As i n dicate d i n Secti o n 1 0. 3. 1 , t here will be 2 pri mar y efficac y a nal yses c o n d ucte d t o esta blis h 
n o ni nferi orit yof  ti rze pat i de 1 0 m g a n d/ or 1 5 m g Q W  t o se m a gl uti d e 1 m g Q W relati ve t o m ea n 
c ha n ge i n H b A 1c val ues fr o m baseli ne t o t he 4 0 -wee k visit. 
F or t he F D A a n d p ossi bl y ot her re g ulat or y  a ge ncies, t he pri mar y  efficac y  a nal ysis will  b e g ui de d 
b y t he “treat me nt -re gi me n” est i ma n d defi ne d i n Secti o n 1 0. 3. 1 usi n g t h e F A S dataset .  T his 
assess me nt will a nal yze c ha n ge i n H b A 1c val ues fr o m baseli ne o btai ne d at t he 4 0 -wee k visit 
usi n g a n a nal ysis o f c o vari a nce ( A N C O V A) wi t h  t er m sf o r:  
treat m e nt 
c o u ntr y , a n d 
baseli ne H b A 1c as a c o vari at e .  
As i nit ial ste p, a 2-si d e d 9 7. 5 % CI f or t he differe nce i n mea n c ha n ge i n H b A 1c fr o m baseli ne t o 
t h e 4 0 -wee k visit bet wee n 1 0 m g t ir ze pati de Q W a n d se ma gl ut i de 1 m g Q W, as well as bet wee n 
1 5 m g t ir ze pat i de Q W a n d se ma gl ut i de 1 m g Q W, will be c o nstr ucte d.  If t he u p per li mit of t he 
CI is bel o w 0. 3 %, t he tirze pati de d ose will be declare d n o ni nferi or t o se ma gl ut i de. A gra p hical 
testi n g a p pr oac h ( Bretz et al . 2 0 1 1) will be e m pl o ye d t o c o ntr ol t he fa mil y -wise t y pe 1 err or at 
5 % l e vel f or t he pri mar y  a n d ke y  sec o n dar y  e n d p oi nts. Details will be descri be d i n t he S A P. 
Missi n g H b A 1c val ues at t he [ADDRESS_141948] u g a n d/ or i nit iat i o n of resc ue a nti h y per gl yce mic me dicat i o n.  T hi s a nal ysis will be 
c o n d ucte d wit h m ult i ple i m p utati o ns, a n d statist ical i nfere nce o ver m ult i ple i m p utati o ns will be 
g ui de d b y  t he met h o d pr o p ose d b y  R u bi n ( 1 9 8 7). 
F or all ot her p ur p oses, t he pri mar y efficac y  a nal ysis will  b e g ui de d b y t he “efficac y” est i ma n d 
defi ne d i n Sect i o n [ADDRESS_141949] baseli ne 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141950] i o n, a n d c o u ntr y as fi xe d effects, a n d base li ne H b A 1c as a c o variate. 
Si nce t he y  are i nte n de d f or differe nt p ur p oses, eac h of t he 2 pri mar y  efficac y assess me nts 
r el at i ve t o t h e “ efficac y ”a n d “tr e at m e nt -re gi me n ”esti ma n ds will be c o n d ucte d at a fa mil y -wise 
t y pe [ADDRESS_141951] t o t y pe 1 err or rate c o ntr ol are as f oll o ws: 
N o ni nferi ori t y  of  ti rze pat i de 5m g Q W t o se ma gl uti de 1 m g Q W r el at i ve t o mea n c ha n ge 
i n H b A 1c fr o m baseli ne t o t he 4 0 -wee k visit 
S u peri ori t y  of ti rze pati d e 5m g, 1 0 m g, a n d/ or 1 5 m g Q W  t o se m a gl ut i de 1 m g r el at i ve 
t o :
omea n c ha n ge i n b o d y  wei g ht fr o m  b aseli ne t o t h e 4 0 -wee k visit 
omea n c ha n ge i n H b A 1c fr o m baseli ne t o t h e 4 0 -wee k visit 
opr o p orti o n of  pat ie nt s ac hie vi n g t he tar get val ue of H b A 1c < 7 % ( < 5 3 m m o l/ m o l)  
at t he 4 0 - w ee k visit .
T he t y pe 1 err or -c o nt r olle d strate g y f or t he pri mar y a n d sec o n dar y e n d p oi nts will be descri be d i n 
t h e S A P.  All t y pe 1err or -c o nt r olle d sec o n dar y efficac y a nal yses will be c o n d ucte d se paratel y 
f o r b ot h esti ma n ds, t he “efficac y” est i ma n d a n d t he “t reat m e nt -re gi me n” est i ma n d. 
A nal ysis of c ha n ge fr o m baseli ne i n b o d y  wei g ht at t he 4 0 -wee k visit will be c o n d ucte d i n a 
ma n ner si milar t o t he pri mar y efficac y a nal yses wit h baseli ne H b A 1 c cate g or y  ( ≤ 8. 5 % or >8. 5 % 
[6 9 m m o l/ m o l] ) a d de d i n t he m o d el , a n d baseli ne of t he c orres p o n di n g varia ble as a c o variate.  
T he M M R M a nal yses are descri be d i n Sect i o n 1 0. 3. 1 . 
C o m paris o ns a m o n g tr e at m e nts relati ve t o t he pr o p orti o n of patie nts ac hie vi n g t he H b A 1c tar get 
val ue of < 7. 0 % ( < 5 3 m m o l/ m o l)  at t he [ADDRESS_141952] ic 
re gressi o n a nal ysis wit h ter ms f o r: treat me nt, c o u ntr y , a n d baseli ne H b A 1c as a c o variate. I n t he 
a nal ysis of pat ie nt s ac hie vi n g t he H b A 1c tar get val ue relati ve t o t he “efficac y” est i ma n d, patie nts 
wi t h  m issi n g val ues at t he 4 0 -wee k visit will be e xcl u de d.  I n t he a nal ysis o f pati e nts ac hie vi n g 
t h e H b A 1c tar get val ue relat i ve t o t he “treat me nt -re gi me n” est i ma n d, missi n g val ues at t he 
[ADDRESS_141953] u g 
a n d/ or i nit iat i o n of resc ue me dicat i o n.  T he a nal ysis will be c o n d ucte d wit h m ult i ple i m p utati o ns 
a n d statist ic al  i nfere nce o ver m ul ti ple i m p utati o ns will be g ui de d b y  t he met h o d pr o p ose d b y  
R u bi n ( 1 9 8 7). 
I8F-MC-GPGL (b) Clinical Protocol Page 72
LY329817610.3.3.3. Tertiary/Exploratory Analyses
All exploratory  efficacy analyses will be guid ed by [CONTACT_941] “efficacy” estimand and will be 
conducted using the EAS.  Details will be provided in the SAP.
10.3.4. Safety Analyses
Unless specified otherwise, safet y assessments will be guided by  [CONTACT_126167] .  Thus, safet y analyses will be conducted using the SS.  Selected safety analyses 
may be conducted after excluding data on rescue therapy or data after starting another 
antihyperglycemic medicat ion.
AEs will be coded fro m the actual  term  using the Medical Dict ionary for Regulatory  Activities 
(MedDRA) and reported with preferred terms and system organ class.  Selected notable AEs of 
interest m ay be reported using high -level term s or Standar dized MedDRA Queries.  Summary  
statist ics will be provided for incidence of TEAEs, SAEs, and study  discont inuat ion due to AEs, 
study  drug di scont inuat ion due to AEs ,or deaths from the time of first dose through end of safet y 
follow-up .  Counts and proport ions of pat ients experi encing AEs will be reported for each 
treatm ent group, and Fisher’s exact test will be used to compare the treatment groups.
[IP_ADDRESS]. Hypoglycemic Events
Incidence of documented symptomat ic hypoglycemia events and severe hypoglycemia will be 
summarized and co mpared between tirzepat ide doses and semagl utide.  Rate of hypoglycemic 
epi[INVESTIGATOR_126150] a generalized linear mixed -effects m odel assuming negative 
binomial distribut ion for hypoglycemic epi[INVESTIGATOR_126151]. Some a nalys es may be 
conducted excluding data after introducing another antihyperglycemic therapy.
[IP_ADDRESS]. Gastrointestinal Events
Summaries and analyses for incidence and severit y of nausea, vo miting, and diarrhea will be 
provi ded by [CONTACT_91014].
[IP_ADDRESS]. Adjudicated Cardiovascular Events
Listings of deaths, myo cardi al infarct ions, strokes, and hospi[INVESTIGATOR_126152].  The event, first dose and last dose of study 
drug, and time fro m rando mizat ion to the even t will  be listed.
[IP_ADDRESS]. Central Laboratory Measures, Vital Signs, and Electrocardiograms
Values and change from baseline to postbaseline values of central laboratory  measures, vital 
signs, and selected ECG parameters will be summarized at each scheduled visit.  The analysis 
model to m ake co mpar isons amo ng treatment groups relat ive to continuous change fro m baseline 
values assessed over time will be an MMRM similar to the primary  efficacy  analysis and wit h 
baseline measurement as a covariate.  An unstructured cova riance structure will model the 
relationship of wit hin-patient errors.
The percentages of pat ients with TE abnormal, high, or low laboratory  measures at any  time will 
be summarized and compared between treatment groups using Fisher’s exact test.  A TE 
abno rmal value i s defined as a change from normal value at baseline to a value greater than the 
I 8 F -M C -G P G L ( b ) Cli ni c al Pr ot o c ol P a g e [ADDRESS_141954] i n g A D A, wit h T E A D A, a n d wit h 
ne utralizi n g T E A D A t o ti rze pat i de will be ta b ulate d b y  ti rze pat i de d ose . Treat me nt -e m er ge nt 
A D As are defi ne d as t h ose wit h a titer 2 -f o l d ( 1 dil uti o n) greater t ha n t he mi ni m u m re q uire d 
dil ut i o n if n o A D As were detecte d at baseli ne (treat me nt -i n d uce d A D A) or t h ose wi t h  a 4 -f o l d 
( 2 dil ut i o ns) i ncrease i n t it er c o m pare d t o baseli ne if A D As were detecte d at baseli ne 
(treat me nt -b o oste d A D A).  The mi ni m u m re q uire d dil ut i o n of t he A D A assa y is 1: 1 0. F or t he 
pati e nts wi t h  T E A D A , t h e di stri b uti o n of  m a xi m u m  ti ters will  b e d escri be d.  The fre q ue nc y o f 
ne utralizi n g a nt i b o dies t o ti rze pati de a n d/ or cr oss -reacti ve a n d ne utralizi n g a nt i b o dies t o 
e n d o ge n o us c o u nter parts will be ta b ulate d i n pat ie nt s wi t h  T E A D A .
The relat i o ns hi p bet wee n t he prese nce of a nt i b o dies a n d ti rze pati d e P K a n d P D res p o nse 
i ncl u di n g safet y a n d efficac y t o ti rze pati d e ma ybe assesse d. 
[ADDRESS_141955] ors t hat ma y be c o nsi dere d rele va nt.  
T hese varia bles will be s pecifie d i n t he S A P. 
1 0. 3. 6. 2. S u b gr o u p A n al y s e s 
S u b gr o u p a nal yses of mea n c ha n ge i n H b A 1c val ues fr o m baseli ne t o Visit 1 1will be pr o vi de d 
b y 
a ge 
race 
et h nicit y 
ge n der 
d urati o n of  di a betes, a n d 
baseli ne H b A 1c ( ≤8. 5 % a n d >8. 5 % [6 9 m m o l/ m o l] ). 
[ADDRESS_141956] or, or desi g nee, will be c o ns ulte d t o deter mi ne 
w het her i t i s necessar y  t o a m e n d t he pr ot oc ol .
I8F-MC-GPGL (b) Clinical Protocol Page 74
LY329817611. References
[ADA] American Diabetes Associat ion. Com prehensive medical evaluat ion and assessment of 
comorbidi ties: standards of medical care in diabetes —2019 . Diabetes Care. 2019a;42(suppl  
1):S34-S45.
[ADA] American Diabetes Associat ion. Glycemic targets : standards of medical care in 
diabetes —2019. Diabetes Care . 201 9b;42(suppl  1):S 61-S70 .
Ahmann AJ, Capehorn M, Charpent ier G, Dotta F, Henkel E, Lingvay I, Holst AG, Annett MP, 
Aroda VR. Efficacy and safet y of once -weekly  semagluti de versus exenat ide ER in subjects 
with type 2 d iabetes (SUSTAIN 3): a 56 -week, open -label, r ando mized clinical t rial.Diabetes 
Care . 2018;41(2):258 -266.
Ahrén B, Masmiquel L, Kumar H, Sargin M, Karsbøl JD, Jacobsen SH, Chow F.Efficacy and 
safet y of once -weekly semaglut ide versus once -daily  sitagliptin as an add -on to m etformin, 
thiazolidinedio nes, or both, in pat ients with type 2 di abetes (SUSTAIN 2): a 56 -week, double -
blind, phase 3a, randomised trial . Lancet Diabetes Endoc rinol .2017;5(5):341 -354.
Albert i KG, Zimmet PZ. Definit ion, diagnosis and cl assificat ion of diabetes mellitus and its 
complicat ions. Part 1: diagnosis and classificat ion of diabetes mellitus provisio nal report of a 
WHO consultation. Diabet Med. 1998;15(7):539 -553.
Aroda VR, Bain SC, Cariou B, Pi[INVESTIGATOR_17972]č M, Rose L, Axelsen M, Rowe E, DeVries JH. Efficacy 
and safet y of once -weekly semaglut ide versus once -daily  insulin glargine as add- on to 
metformin (with or without sulfo nylureas) in insulin- naive pa tients wi th type 2 di abetes 
(SUSTAIN 4): a randomised, open -label, parallel -group, m ulticentre, m ultinational, phase 3a 
trial.Lancet Diabetes Endocrinol .2017;5( 5):355 -366.
Aroda VR, Ratner R. The safet y and tol erabilit y of GLP -1 receptor agonists in the treatment of 
type 2 di abetes: a review. Diabetes Metab Res Rev .2011 ;27(6):528- 542.
Asmar M, Simo nsen L, Asmar A, Holst JJ, Dela F, Bulow J. Insulin plays a permissive role for 
the vasoactive effect of GIP regulating adipose tissue metabo lism in humans. J Clin 
Endocrinol Metab .2016;101 (8):3155 -3162.
Banks PA, Freeman ML. Practice guidelines in acute pancreatit is. Am J Gastroenterol.
2006;101(10):[ADDRESS_141957] ion questionnaire: DTSQ. In: Bradley C, editor.
Handbook o f Psychology and Diabetes: a guide to psychological measurement in diabetes 
research and practice. Chur, Switzerland: Harwood Academic Publishers; 1994.
Bretz F, Posch M, Glimm E, Klinglmueller F, Maurer W, Rohmeyer K. Graphical approaches for 
multiple com parison procedures using weighted Bonferroni, Simes, or parametric tests. Biom 
J. 2011;53(6):[ADDRESS_141958], Gimeno R E, D’Alessio DA, 
Haupt A. LY3298176, a novel dual GIP and GLP -[ADDRESS_141959] for th e treatm ent of ty pe 2 
diabetes m ellitus: from discovery  to clinical  proof  of concept. Mol Metab . 2018 ;18:3 -14.
I8F-MC-GPGL (b) Clinical Protocol Page 75
LY3298176Danne T, Philotheou A, Goldman D, Guo X, Pi[INVESTIGATOR_007] L, Cali A, J ohnston P. A randomized trial 
comparing the rate of hypoglycemia – assessed using continuous glucose monitoring – in 125 
preschool children with ty pe 1 diabetes treated with insulin glargine or NPH insulin (the
PRESCHOOL study ). Pediatr Diabetes . 2013;14(8):593 -601. 
Davies MJ, D ’Alessio DA, Fradkin J, Kernan WN, Mathi eu C, Mingrone G, Rossing P, Tsapas 
A, Wexler DJ, Buse JB. Management of hyperglycemia in type 2 diabetes, 2018. A consensus 
report by  [CONTACT_126168] (ADA) and the European Associ ation for the 
Study  of Diabetes (EASD). Diabetes Care . 2018 ;41(12):[ADDRESS_141960], in pat ients with type 2 di abetes: a randomised, pl acebo -controlled and act ive 
comparator -controlled phase 2 trial. Lancet. 2018;392([ZIP_CODE]):2180- 2193.
EuroQoL Group. EQ -5D- 5L User guide: basic info rmation on how to use the EQ -5D- 5L 
instrum ent. Versi on 2.1. Available at: https://euroqol.org/wp -content/uploads/2016/09/EQ -5D-
5L_UserGuide_2015.pdf. Published April 2015. Accessed August [ADDRESS_141961] of  Weight on 
Self-Percept ions Questionnaire (IW -SP) in individuals with ty pe 2 diabetes and obesit y. 
Diabetes Technol Ther . 2015;17(3):[ADDRESS_141962] ionnaire in 
individuals wit h type 2 di abetes and obesit y. Diabetes Technol Ther . 2012;14(12):1118- 1125.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas 
A, Wender R, Matthews DR. Management of hyperglycemia in t ype 2 diabetes, 2015: a 
patient-centered approach: update to a posit ion statem ent of  the Ameri can Diabetes 
Associ ation and the European Associat ion for the Study  of Diabetes. Diabetes Care.
2015;38(1):140 -149.
Koizumi M,Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M, Sekimoto M, Hirota M, 
Kimura Y, [COMPANY_005] K, Isaji S, Otsuki M, Matsuno S; JPN. JPN Guidelines for the management 
of acute pancreatit is: diagnostic criteria for acute pancreat itis. J Hepatobiliary Pancreat Surg .
2006;13(1):[ADDRESS_141963] of Weight on Qualit y of Life -Lite questi onnaire (IWQOL -Lite Clinical  
Trials Versi on): resul ts from two qualitative st udies. Clin Obes . 2017;7(5):290 -299.
Kolotkin RL, Williams V, Ervin, CM, Meincke HH, Qin S, Smit h LvH, Fehnel SE. Validat ion of 
a new measure of qualit y of life in obesit y trials: IWQOL –Lite Clinical Tri als Versio n. Poster 
presented at: Obesit yWeek 2018; November 13, 2018; Nashville, TN
Marso SP, Bain SC, Conso li A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, 
Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN -[ADDRESS_141964] igators. Semaglut ideand cardi ovascular outcom es in p atients with type 2 d iabetes. N 
Engl J Med . 2016;375(19):1834-1844.
I8F-MC-GPGL (b) Clinical Protocol Page 76
LY3298176Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; 
American Diabetes Associat ion; European Association for Study  of Diabetes. M edical 
management of hyperglycemia in t ype 2 diabetes: a consensus algorithm for the init iation and 
adjustm ent of  therapy : a consensus statement of the American Diabetes Associat ion and the 
European Associat ion for the Study  of Diabetes. Diabetes Care . 200 9;32(1):193-203.
Nauck MA, Meier JJ. Incret in hormones: their role in healt h and disease. Diabetes Obes Metab.
2018:20(suppl 1):5-21.
Nauck MA, Meier JJ, Schmidt WE. Incretin -based glucose -lowering medications and the risk o f 
acute pancreatit is and/or panc reatic cancer: reassuring data from cardio -vascular outcome 
trials. Diabetes Obes Metab . 2017;19(9):1327- 1328.
Ozem pic® [EMA summary of product characteristics (SmPC)]. Bagsvaerd, Denmark: Novo 
Nordi sk. Available at https://www.ema.europa.eu/documents/prod uct-informat ion/ozem pic-
epar-product -informat ion_en.pdf . Last accessed January  23, 2019.
Ozem pic® [US package insert (USPI) ]. Bagsvaerd, Denmark: Novo Nordisk. Available at 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf . Last accessed 
January  23, 2019.
Pratl ey RE, Aroda VR, Lingvay I, Lüdemann J, Andreassen C, Navarria A, Viljoen A; 
SUSTAIN 7 investigators. Semaglutide versus dulaglut ide once weekly in pat ients with type 2 
diabetes (SUSTAIN 7): a randomised, open -label, phase 3 b trial.Lancet Diabetes Endocrinol . 
2018;6( 4):[ADDRESS_141965], 
Wijayasinghe N, Norwood P. Semaglutide added to basal insulin in t ype 2 diabetes 
(SUSTAIN 5): a randomized, controlled trial.J Clin Endocrinol Metab . 2018;103 (6):2291 -
2301.
Rubin DB. Mult iple imputati on for nonresponse in surveys. [LOCATION_001]: John Wiley & Sons Inc.; 
1987.
Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, Bain SC. Efficacy and 
safet y of once -weekly semagl utidemonotherapy  versus pl acebo in pat ients with type 2 
diabetes (SUSTAIN 1): a double -blind, randomised, placebo -controlled, parallel -group, 
multinational, mult icentre phase 3a trial. Lancet Diabetes Endocrinol . 2017;5(4):[ADDRESS_141966] KF, Cowie CC. The prevalence of meet ing
A1c, blood pressure, and LDL goals amo ng people with diabetes, 1988 -2010. Diabetes Care .
2013;36(8):2271 -2279.
Steinberg WM, Buse JB, Ghorbani MLM, Ør sted DD, Nauck MA; LEADER Steering 
Committee; LEADER Tri al Invest igators. Amylase, lipase, and acute pancreat itis in people 
with type 2 diabetes treated with liraglut ide: result s from the LEADER rando mized trial. 
Diabetes Care. 2017a;40(7):[ADDRESS_141967] of 
liraglutide on amylase, lipase, and acute pancreat itis in part icipants wi th overwei ght/obesi ty 
and normoglycemia, prediabetes, or ty pe 2 di abetes: secondary  analyses of pool ed dat a from 
the SCALE clinical development program. Diabetes Care. 2017b;40(7):839 -848.
I8F-MC-GPGL (b) Clinical Protocol Page 77
LY3298176Weinberg ME, Bacchetti P, Rushakoff RJ. Frequent lyrepeated gl ucose m easurements 
overestimate the incidence of inpatient hy poglycemia and severe hyperglycemia. J Diabetes 
Sci Technol . 2010;4(3):[ADDRESS_141968] treatm ents: a sy stematic review and network meta -
analysis. Ann Intern Med. 2016;164 (2):102-113.
I8F-MC-GPGL (b) Clinical Protocol Page 78
LY329817612. Appendices
I8F-MC-GPGL (b) Clinical Protocol Page 79
LY3298176Appendix 1. Abbreviations and Definitions
Term Definition
ADA anti-drugantibody
AE adverse event :  Any untoward medical occurrence in a patient or clinical investigation 
patient administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally  associated with the use of a medicinal (investigational) product, whe ther o r 
not related to the medicinal (investigational) product.
ALP alkaline phosphatase
ALT alanine aminotransferase
ANCOVA analy sis of covariance
APPADL Ability to Perform Physical Activities of Daily Living
AST aspartate aminotransferase
BG blood glucose
blinding In the context of this study, double -blind means that the patient, the investigator/site 
staff, and sponsor staff are blinded .  
BMI body mass index
CEC clinical endpoint committee
CHF congestive heart failure
CI confidence interval
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all study -related good clinical practice (GCP) and applicable regulatory 
requirements.
COVID -19 Coronavirus Disease 2019
CRP clinical research physician: Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician or other medical officer.
CT computed tomography
I8F-MC-GPGL (b) Clinical Protocol Page [ADDRESS_141969] been assigned to a treatment.
EQ-5D-5L European Quality of Life : [ADDRESS_141970]
ET early  termination
FAS full analy sis set
FSH follicle -stimulating hormone
GI gastrointestinal
GIP glucose -dependent insulinotropic polypeptide
GLP-1 glucagon -like peptide -1
HbA1c hemoglobin A1c
HDL high-density lipoprotein
IB Investigator’s Brochure
ICF informed consent form
Informed consent A process by [CONTACT_9444] a patient voluntarily confirms his or her willingness to participate 
in a particular study, after having been informed of all aspects of the study that are 
relevant to the patient’s decision to participate.  Informed consent is documented by 
[CONTACT_3553] a written, signed, and dated informed consent form.
investigational 
produ ctA pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
I8F-MC-GPGL (b) Clinical Protocol Page 81
LY3298176ITT intent to treat:  The principle that asserts that the effect of a treatment policy can be best 
assessed by [CONTACT_126169] a patient (that is, the planned 
treatment regimen) rather than the actual treatment given.  It has the conse quence that 
patients allocated to a treatment group should be followed up, assessed, and analyzed as 
members of that group irrespective of their compliance to the planned course of 
treatment.
IWQO L-Lite- CT Impact of Weight on Quality of Life -Lite Clinical Trials Version
IWRS interactive web -response sy stem
IW-SP Impact of Weight on Self -Perception
MedDRA Medical Dictionary for Regulatory Activities
MEN2 multiple endocrine neoplasia type 2
mITT modified intent -to-treat
MMRM mixed-effects model for repeated measures
MRI magnetic resonance imaging
MTC medullary thyroid carcinoma
NAFLD nonalcoholic fatty liver disease
OAM oral antihy pergly cemic medications 
OTC over the counter
p-amylase pancreatic amylase
PG plasma glucose
PK/PD pharmacokinetics/pharmacodynamics
PRO/ePRO patient -reported outcomes/electronic patient -reported outcomes
QW once weekly
SAD single ascending dose
SAE serious adverse event
SAP statistical analysis plan
SARS -CoV-[ADDRESS_141971] of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
I8F-MC-GPGL (b) Clinical Protocol Page [ADDRESS_141972] deviation
SGLT2 sodium -glucose co -transporter 2
SMBG self-monitored blood glucose
SS safety analysis set
S[LOCATION_003]Rs suspected unexpected serious adverse reactions
T1DM type 1 diabetes mellitus
T2DM type 2 diabetes mellitus
TBL total bilirubin level
TEAE Treatment -emergent adverse event:  An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal relationship 
with this treatment.
ULN upper limit of normal
VLDL very low-density  lipoprotein
I8F-MC-GPGL (b) Clinical Protocol Page 83
LY3298176Appendix 2. Clinical Laboratory  Tests
Clinical Laboratory Testsa
Hematology Chemistry Panel
Hemoglobin Sodium
Hematocrit Potassium
Erythrocy te count (RBC) Bicarbonate
Mean cell volume Total bilirubin
Mean cell hemoglobin concentration Direct bilirubin
Leukocytes (WBC) Alkaline phosphatase
Neutrophils, segmented Alanine aminotransferase (ALT)
Lymphocy tes Aspartate aminotransferase (AST)
Monocytes Blood urea nitrogen (BUN)
Eosinophils Creatinine
Basophils Uric acid
Platelets Calcium
Glucose (Fasting )
Urine Chemist ries
Microalbumin
Creatinine
Urine microa lbumin/ creatinine ratiodPregnancy t est(serum and urine ;females only) b
Follicle -stimulating hormone (FSH)c
Estradiolc
HbA1c
Endocrine eGFR (calculated by [CONTACT_9289] -EPI [INVESTIGATOR_10908])d
Glucagon (fasting )
Insulin (fasting )
Calcitonin
C-peptide (fasting )
Immunogenicity
Tirzepatide anti -drug antibody
PK sample for immunogenicityPancreas (Exocrine) Panel
Pancreatic amylase
Lipase
Anti -GAD Antibodies Lipid Panel (F asting)
Total cholesterol
LDL
HDL
VLDL
TriglyceridesPharmacogenetic Stored Sample
Nonpharmacogenetic Stored Samples
EDTA plasma
Serum
P800 plasma
I8F-MC-GPGL (b) Clinical Protocol Page 84
LY3298176Abbreviations :  CKD -EPI =Chronic Kidney Disease -Epi[INVESTIGATOR_623]; EDTA =ethylenediaminetetraacetic acid; 
eGFR =estimated glomerular filtration rate; FSH = follicle -stimulating ho rmone; GAD = glutamic acid 
decarboxylase ;HbA1c =hemoglobin A1c; HDL =high-density lipoprotein; LDL =low-density  lipoprotein;
RBC =red blood cells; VLDL =very low -density  lipoprotein; WBC =white blood cells.
aAll tests will be performed by a Lilly -designated central laboratory, unless otherwise noted .
bSerum pregnancy test will be performed by [CONTACT_82408] [ADDRESS_141973] 
injection of study drug(s) for women of childbearing potential only.  Additional pregnancy tests will be 
performed at Visits 6, 9, and 11.  Pregnancy  tests may be performed at the investigator’s discretion during the 
study.  If required per local regulations and/or institutional guidelines, pregnancy testing can also occur a t other 
times during the study treatment period .
cFSH test performed at Visit [ADDRESS_141974] had spontaneous amenorrhea for more than 6 months and less than 1 2 months 
and estradiol levels consistent with a postmenopausal state (FSH ≥40 mIU/mL and estradiol <30 pg/mL).
dUrine micro albumin/creatinine ratio and estimated glomerular filtration rate will be calculated by [CONTACT_126170].
I8F-MC-GPGL (b) Clinical Protocol Page 85
LY3298176Appendix 3. Study  Governance Considerations
I8F-MC-GPGL (b) Clinical Protocol Page [ADDRESS_141975] igator is responsible for
ensuring that the patient understands the nature of the study , the potential risks 
and benefits of participat ing in the study , and that their participat ion is 
voluntary.
ensuring that informed consent is given by [CONTACT_57996].  
This includes obtaining the appropriate s ignatures and dates on the informed 
consent form (ICF) prior to the performance of any  protocol  procedures and 
prior to the administration o f investigational product.
answering any quest ions the pati ent m ay have throughout the study  and 
sharing in a t imely manner any  new informat ion that m ay be relevant to the 
patient’s willingness to continue his or her participation in the study .
ensuring that a copy  of the ICF is provi ded to the participant or the 
participant’s l egal representative and is kept on file.
ensuring that the medical record includes a statement that written informed 
consent was obtained before the participant was enrolled in the study  and the 
date the written consent was obtained.  The authorized person obtaining the 
inform ed consent m ust al so sign the ICF.
Appendix 3.1.[ADDRESS_141976] igator (or an appropriate local representative) must give assurance that the ethical 
review board (ERB) was properly  consti tuted and convened as required by [CONTACT_126171] (ICH) guidelines and other applicable laws and regulations.
Docum entati on of  ERB approval  of the protocol and the ICF must be provided to Lilly  before the 
study  may begin at the investi gative si te(s).  Lilly  or its representatives must approve the ICF, 
including any  changes made by [CONTACT_41429], before it is used at the inv estigative site(s).  All ICFs 
must be compliant with the ICH guideline on Good Clinical Pract ice (GCP).
The study  site’s ERB(s) shoul d be provided wi th the f ollowing:
the protocol and related amendments and addenda, current Invest igator 
Brochure (IB), and updates during the course of the study
inform ed consent form  
other rel evant docum ents (for example, curricula vitae, advertisements)
I8F-MC-GPGL (b) Clinical Protocol Page 87
LY3298176Appendix 3.1.4. Regulatory Considerations
This study  will be conducted in accordance wit h the protocol and with the
consen sus ethi cs principles derived from internat ional ethics guidelines, 
including the Declarat ion of Helsinki and Council forInternational
Organizat ionsofMedical Sciences (CIOMS ) Internat ional Ethi cal Guidelines
applicable ICH GCP guidelines
applicable laws and regulations
Some of the obligat ions of the sponsor will be assigned to a third party.
Appendix 3.1 .5.Investigator Information
Physicians with a specialt y indiabetes/endocrinology , internal  medicine, family  medicine, 
general medicine , or any  other sp ecialty physician who ha veexperience treating T2DM and 
clinical research in T2DM will participate as investigators in this clinical study .
Appendix 3.1. 6. Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the pl anned design and conduct of the 
study .
After reading the protocol, each principal invest igator will sign the protocol signature [CONTACT_25327] a copy  of the signed page to a Lilly representative.
Appendix 3.1. 7. Final Report Signature
[CONTACT_100359] C linical Study Report (CSR) coordinat ing investigator will sign the final CSR for this study, 
indicat ing agreement that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study .
A qualified invest igator will serve as the CSR coordina ting invest igator.  If this invest igator is 
unable to fulfill this funct ion, another invest igator will be chosen by [CONTACT_126172].
The sponsor’s responsible medical o fficer and statistician will approve the final CSR f or thi s 
study , confirming that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study .
Appendix 3.2. Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives wi lldo the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate
provi de sponsor start -up training to instruct the investigators and study  
coordinators.  This training will give instruction on the protocol, the 
completion of the CRFs, and study  procedures.
I8F-MC-GPGL (b) Clinical Protocol Page 88
LY3298176make periodic visit s to the study  site
be available for consultation and stay  in contact [CONTACT_17092], tel ephone, and/or fax
review and verify  data reported to detect potential errors 
In addit ion, Lilly or its representatives will periodically check a sample of the patient data
recorded against source documents at the study  site.  The study  may be audi ted by  [CONTACT_47551] i ts 
representatives and/or regulatory  agencies at any  time.  Invest igators will be given notice before 
an audit occurs.
The invest igator will keep records of all original source data.  This might include laboratory 
tests, m edical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicabl e regulatory  agencies, and applicable ERBs with direct access to original source 
docum ents.
Appendix 3.2.1. Data Capture System
The invest igator is responsible for ensuring the accuracy, completeness, legibilit y, and timeliness 
of the data reported to the sponsor.
An electronic data capture sy stem  (EDC) will be used in this study  for the collect ion of CRF 
data.  The investigator maintains a separate source for the data entered by  [CONTACT_32864] -provided EDC system.  The inves tigator is responsible for the 
ident ificat ion of any data to be considered source and for the confirmat ion that data reported are 
accurate and complete by  [CONTACT_11003] .
Addit ionally , clinical  outcom e assessment data (scales, self -reported di ary data) will be collected 
by [CONTACT_102]/investigator site personnel, via a paper source document, and will be transcribed 
by [CONTACT_126173].
Data collected via the sponsor- provided data capture system (s) will be stored at thir d parti es. 
The invest igator will have cont inuous access to the data during the study and unt il 
decommissio ning of the data capture sy stems.  Pri or to decommissio ning, the invest igator will 
receive an archival copy  of pertinent data for retention.
Data m anaged by  a central  vendor, such as laboratory  test data, will be stored electronically  in 
the central  vendor’s database system ,and electronic transfers will be provided t o the invest igator 
for review and retent ion.  Data will subsequently be transferred fr om the central  vendor to the 
Lilly data warehouse.
Data from co mplaint forms submitted to Lilly will be encoded and stored in the global product 
complaint m anagement sy stem .
I8F-MC-GPGL (b) Clinical Protocol Page [ADDRESS_141977] igator, or the ERB 
of the study  sitejudges it necessary for medical , safet y, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
Appendix 3.3.2. Discontinuation of the Study
The study  will be di scontinued if Lilly or i ts desi gnee judges it necessary  for m edical, safet y, 
regul atory , or other reasons consistent with applicable laws, regulat ions, and GCP.
Appendix 3.4. Publication Policy
The publicat ion policy for Study  I8F-MC-GPGL is described in the Clinical Trial Agreement.
I8F-MC-GPGL (b) Clinical Protocol Page [ADDRESS_141978]
GGT Alkaline phosphatase isoenzymes a
CPK
Anti -smooth muscle antibody (or anti -actin antibody) a
Abbreviations:  ALT = alanine aminotransferase; AST = aspi[INVESTIGATOR_82355]; CPK = creatinine 
phosphokinase; GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = international normali zed 
ratio; RBC = red blood cells; WBC = white blood cells
aAssay ed by [CONTACT_11007] -designated or local laboratory
bReflex/confirmation dependent on regulatory requirements and/or testing availability
I8F-MC-GPGL (b) Clinical Protocol Page 91
LY3298176Appendix 5. World Health Organization Classification 
of Diabetes and Diagnostic Criteria
Type 1 Diabetes:   Type 1 di abetes is j udged to be present when the classical symptoms of 
diabetes (thi rst, polyuri a, wast ing and stupor, or coma) are associated with readily detectable 
concentrations of glucose and ketone bodies in the blood and urine.  Insul in treatment is 
necessary  not only to control  hyperglycemia but also to prevent spontaneous ketosis and death.
Type 2 Diabetes:   Type 2 di abetes, al though often asymptomat ic, may also present with 
classical hyperglycemic symptoms (thirst, polyuria, weight loss), but despi[INVESTIGATOR_126153], 
ketone bodi es are present in only low concentrations in the blood and urine.  Coma is rare in 
type2 diabetes ,but m ay resul t from extrem e hyperglycemia and hyperosmolarit y; lactic acidosis 
or ketoacidosis can also occur i n fulminat ing illness (for example, severe infect ion or mesenteric 
artery  throm bosis) due to an acute increase in insulin requirements, but spontaneous ketosis does 
not occur.  Some patients with t ype 2 diabetes later progress to a state of abso lute insuli n 
deficiency ( Albert i and Zimmet 1998 ). 
I8F-MC-GPGL (b) Clinical Protocol Page 92
LY3298176Appendix 6. Classification of Contraceptive Methods
Highly Effective Methods of Contraception:
Combined oral contraceptive pi[INVESTIGATOR_10917]
NuvaRing
Implantable contraceptives
Injectable contraceptives (such as Depo -Provera®)
Intrauterine device (such as Mirena®and ParaGard®)
Contraceptive patch –ONLY women <198 pounds or 90 kg
Total  abstinence (if this is their preferred and usual lifestyle) or in a same -sex rel ationship 
with no sexual  relati onship wi th males (as part of t heir preferred and usual lifest yle).  
Note:  periodic abst inence ( for example , calendar, ovul ation, symptothermal, 
postovulat ion methods), declarat ion of abst inence just for the duration of a trial, and 
withdrawal  are not acceptabl e methods of contraceptio n
Vasectomy  –for men in clinical studies
Effective Methods of Contraception (must use combination of 2 methods):
Male condom wit h spermicide
Female condo m with spermicide
Diaphragm  with spermicide
Cervical sponge
Cervical cap wit h spermicide
Men, regardless of their fertilit y status, with nonpregnant women of childbearing potential 
partners must agree to either remain abstinent (if this is their preferred and usual lifest yle) or use 
condoms plus 1additional highly  effect ive (less than 1% fail ure rate) m ethod of contraception 
(such as co mbinat ion oral  contraceptives, implanted contraceptives, or intrauterine device) or 
effect ive method of contraception (such as diaphragms wit h spermicide or cervical sponge) for 
the duration of the study  and for at least [ADDRESS_141979] imated relevant potential exposure in women of childbearing potential. 
Men who are in exclusively same sex relat ionships (as their preferred and usual lifest yle) are not 
requi red to use contraception. 
I8F-MC-GPGL (b) Clinical Protocol Page [ADDRESS_141980] 
Circumference
The fo llowing inform ation has been adapted from standardized physical measurement protocols 
for the World Healt h Organization’s STEPwise approach to Surveillance (STEPS) (WHO 2017 ) 
(Available at:
https://www.who.int/ncds/surveillance/steps/Sect ion%204%20Step%202%20Physical%20Measu
rements.pdf ).Last a ccessed February  8, 2019 .
Measuring Height
Step 1. Ask the pati ent to rem ove their footwear and any headgear (light headgear worn for 
religious reasons can remain, but this should be worn by [CONTACT_126174] m easured).
Step 2. Ask the pati ent to stand on the calibrated height measuring board (stadio meter) or against 
a wall wit h their feet together and their knees straight with their heels against the backboard, the 
stadiometer or the wall .
Step 3. Ask the pati ent to look strai ght ahead wi thout til ting their head up.
Step 4. Ask the pati ent to breathe in and stand tall.  If using a stadiometer or fixed measuring 
device, move the device’s measurement arm gently down onto the top of the patient’s head.  
Record the pat ient’s height in cent imeters (cm).
Measuring Weight
Body  weight m easurements shoul d be done in a consistent manner using a calibrated 
electroni c scale capable of measuring weight in kilograms.
All weights for a given patient should be measured using the sa me scale, whenever possible, 
at approximately the same time in the morning after evacuat ion of bladder contents .  
Patients shoul d be light ly clothed but not wearing shoes while their weight is measured.
Step 1 .Ask the pati ent to rem ove their footwear, ou terwear (coat, jacket, etc), and any headgear 
(light headgear worn for religious reasons can remain, but this should be worn by [CONTACT_126175]).
Step 2 .Make sure the scale is placed on a firm, flat, even surface (not on carpet, on a slopi[INVESTIGATOR_126154], or a rough, uneven surface).
Step [ADDRESS_141981] weight in kilograms (kg) 
to the nearest one-tenth kg.
I8F-MC-GPGL (b) Clinical Protocol Page [ADDRESS_141982] Circumference
Waist circumference should be measured at midpoint, between lower margin o f least 
palpable rib and top o f iliac crest (~1 inch [2.54 cm] above the navel).
Patients shoul d be light ly clothed.
Step 1.   Ask the patient to stand with their feet close together, and arms at their side with their 
body  weight evenly distributed.
Step 2.   Ask patient to relax
Step 3.   Measurements should be recorded at the end of a normal expi[INVESTIGATOR_57774].
I8F-MC-GPGL (b) Clinical Protocol Page 95
LY3298176Appendix 8. Changes to Study  Procedures due to the 
COVID -19 Pandemic
Severe acute respi[INVESTIGATOR_19960] 2 ( SARS -CoV -2), the virus that causes the novel
COVID -[ADDRESS_141983] a 
patient’s abilit y and/or willingness to attend their onsite study  visit as ori ginally  scheduled.  In 
such a situation, please fo llow the gui dance below:
1)Patients shoul d com e for the primary  endpointvisit (Visit 11) at the ori ginally planned 
40-week (±7 days) schedule whenever possible and safe to do so, at the invest igator's 
discreti on.  However, in order to maximize the abilit y for onsi te visi ts for Vi sit 11, 
minimize missing data ,and preserve the intended conduct of the study , the visi t window 
for Visit 11may be brought forward no sooner than 14 days (Week 38) or extended up to 
28days (Week 44).  The subsequent safet y follow-up visit (Visit 801) should take place 
4weeks ±7 day s after Vi sit 11.  
2)For pati ents requi ring an extensio n for Visit 11 up to Week 44, addit ional study  drug will 
be provided to allow pat ients to rem ain on study  drug uninterrupted during the extended 
treatm ent peri od, to ensure patient safet y,and to maintain the overall integrity of the tri al. 
3)Addit ional consent fro m the pati ent per l ocal regulati ons will  be obtained for those 
patients who will be dispensed addit ional study  drug during the extended treatment 
period.
4)The sites will need to ident ify and document the detail s of how all pat ients and visits 
were affected by [CONTACT_4113] -[ADDRESS_141984] ions.
5)Mobile (in-home) healthcare visits: 
Mobile visits may be performed at participants’ homes when participants cannot 
travel  to the si te due to extenuating circumstances. These will be perform ed by  a 
qualified ho me nursing service provider fo llowing sponsor approval, if permitted by  
[CONTACT_4159]. Procedures performed may include, but are not limited to, taking 
blood sam ples, conduct ing physical assessments, administering PR Os, and co llecting 
healt h informat ion. Please note that requirements related to the reporting of SAEs 
remain unchanged. Every  effort shoul d be made for the participant to return to onsite 
visits as soon as reasonably  possible, while ensuring the safety  of the participant and 
investigat ional site staff. 
Addit ional consent fro m the parti cipant will  be obtained for those who participate in 
home healt h services.
I8F-MC-GPGL (b) Clinical Protocol Page 96
LY3298176Appendix 9. Protocol A mendment I8F-MC-GPGL( b)
A Phase 3, Randomized, Open -Label Trial Comparing 
Efficacy  and Safety  of Tirzepatide versus Semaglutide 
Once Weekly  as A dd-on Therapy  to Metformin in 
Patients with Ty pe 2 Diabetes (SURPA SS-2)
Overview
Protocol  I8F-MC-GPGL ti tled “A Phase 3, Randomized, Open -Label Trial Co mpar ing Efficacy  
and Safety  of Tirzepati de versus Sem aglut ide Once Weekly as Add- on Therapy  to Metf ormin in 
Patients wi th Type 2 Di abetes (SURPASS -2)” has been amended.  The new protocol is indicated 
by [CONTACT_61504] ( b) and will be used to conduct the study in place of any preceding versio n of the 
protocol .
The overall changes and rationale for the changes made to this protocol are described in the 
following table.
I8F-MC-GPGL (b) Clinical Protocol Page 97
LY3298176Amendment Summary for Protocol I8F -MC-GPGL Amendment ( b)
Sectio n # and 
NameDescription of Change Brief Rationale
Appendix 8,
Changes to Study 
Procedures due to 
the COVID -19 
PandemicAdded language about the mobile (in-
home )healthcare visits.This provides an option to conduct a clinical 
trial visit and all the applicable procedures in a 
mobile healthcare facility or at the home of a 
patient when the patient is not able or not 
willing to go to the site due to COVID -19 
restrictions.
L e o  D o c u m e n t  I D  =  5 7 c 3 b 8 7 9 - 7 4 b 5 - 4 b 5 6 - 9 3 b 2 - a f 1 d 0 6 a 5 7 c 7 0 
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  2 6 - J u n - 2 0 2 0  1 8 : 3 6 : 3 2  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d 
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  2 6 - J u n - 2 0 2 0  1 8 : 5 0 : 0 2  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d P P D 
P P D 